BAX activators and use thereof

Novel BAX activators, such as compounds of formula (A-I), selectively activate BAX to overcome cancer cell resistance to apoptosis, providing a therapeutic option for treating cancers by inducing cell death in cancer cells and leukemic stem cells.

WO2024249284A2PCT designated stage expired Publication Date: 2024-12-05IPSEN PHARMA SAS +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/030943
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-26
Filing Date
2024-05-24
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Cancer cells often resist apoptosis due to overexpression of anti-apoptotic BCL-2 proteins, which neutralize the pro-apoptotic protein BAX, making it challenging to induce cell death and counteract cancer therapies effectively.

Method used

Development of novel BAX activators, specifically compounds of formula (A-I) and their pharmaceutically acceptable salts, which can selectively activate BAX to promote apoptosis in cancer cells, potentially used in combination with inhibitors of anti-apoptotic proteins like BCL-2 and MCL-1.

Benefits of technology

The BAX activators effectively induce apoptosis in cancer cells and leukemic stem cells, offering a therapeutic approach to treat various cancers, including those resistant to conventional therapies, while minimizing harm to healthy tissues.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000002_0001
    Figure IMGF000002_0001
  • Figure IMGF000003_0001
    Figure IMGF000003_0001
  • Figure IMGF000003_0002
    Figure IMGF000003_0002
Patent Text Reader

Abstract

Disclosed herein are small molecule activators of the B-cell lymphoma-2-associated X protein (BAX). Also disclosed are compositions containing one or more BAX activators and uses thereof in the treatment of cancer.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] BAX ACTIVATORS AND USE THEREOF

[0002] BACKGROUND

[0003] Programmed cell death, or apoptosis, is a vital component for important processes such as normal cell turnover, the development and functioning of the immune system, hormone-dependent atrophy, and embryonic development (Elmore, Toxicol Pathol. 2007; 35(4); 495-516). The commitment of a cell to apoptosis via the mitochondrial pathway is regulated by a complex interaction network of proteins of the B-cell lymphoma-2 (BCL-2), which include proteins that are pro-apoptosis (e.g., BCL-2-associated X-protein (BAX) and BCL-2 homologous Antagonist Killer (BAK)) and those that are anti-apoptosis (e.g., BCL-2, B-cell lymphoma-extra large protein (BCL-XL), B cell lymphoma 2-like protein (BCL-w), and myeloid cell leukemia 1 (MCL-1). Importantly, the dysregulation of apoptosis is implicated in a number of human pathologies, including cancer (Elmore, 2007).

[0004] Cancer cells are known to reprogram the interaction between BCL-2 proteins to ensure their growth, maintenance, and resistance to cancer therapies (Hata et al., Cancer Discov. 2015; 5(5) 475-87; Llambi et al., Curr Opin Genet Dev. 2011 ; 21 (1): 12-20). For example, cancer cells are frequently found to overexpress BCL-2, BCL-XL, and MCL-1 , which bind to and neutralize the BH3 death domains of the activated pro-apoptotic BCL-2 members BAX, BAK and the BH3-only proteins such as BCL-2-like protein 11 (BIM) and BH3-interacting domain death agonist (BID) and therefore impede cell apoptosis (Letai, Nat Rev Cancer. 2008; 8(2): 121-32; Youle et al., Nat Rev Mol Cell Biol. 2008; 9(1): 47-59). It has also been found that the vast majority of cancer cells contain functional BAX in an inactive conformation or suppressed by anti-apoptotic proteins (Gao et al., Sci Signal. 2013; 6(269): pl1). The direct activation of BAX with targeted therapeutics can therefore be used to counteract the effects of anti-apoptotic BCL-2 proteins or otherwise promote apoptosis in cancer cells.

[0005] Thus, there is a need to provide BAX activators for the treatment of cancers, particularly apoptosis-resistant cancers.

[0006] SUMMARY

[0007] The present disclosure provides novel compounds for treating cancers and methods of using the same.

[0008] In one aspect, the disclosure features compounds of formula (A-l): or a pharmaceutically acceptable salts thereof, wherein

[0009] G is CH or N;

[0010] R1is optionally substituted aryl or optionally substituted heteroaryl;

[0011] X is an optionally substituted C1-C3 alkyl group or a C1-C3 heteroalkyl group R2is selected from optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted heterobicycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl, R3ais selected from optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroalkyl, optionally substituted heterocycloalkyl, or CHR4(CR5aR5b)0-4R6; wherein R4, R5a, and R5bare independently selected from H, optionally substituted C1-C4alkyl, and R6is selected from CONR7R8, SO2NR7R8, NR7COR7, NR7SO2R8; wherein R7and R8are independently selected from H, optionally substituted alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or R7and R8together with the atoms to which they are attached form a optionally substituted C3-C7cycloalkyl, optionally substituted C3-C7heterocycloalkyl, or optionally substituted C3-C7heterobicycloalkyl; R3bis optionally substituted alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl; Y is selected from O, NR9, S, (CHR9)1-4, CO, or SO2; each R9is independently selected from H or optionally substituted C1-C4 alkyl; p is 0 or 1; and q is 0 or 1. In some embodiments, G is N. In some embodiments, p is 1 and X is -CH2-. In some embodiments, R2is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, q is 0. In some embodiments, R1is: wherein R1aand R1bare independently selected from H, optionally substituted C1-5 alkyl, or optionally substituted C3-5 cycloalkyl. In some embodiments, R1aand R1bare independently -CH3, -CH2CH3, -CH(CH3)2, -C(CH3)3, cyclopropyl, or -CF3. In some embodiments, R1aand R1bare both methyl. In some embodiments, R2-(X)p- forms a moiety selected from: In some embodiments, R3ais an optionally substituted heterocycloalkyl, acyl, amido, sulfonyl, C1- C6 alkyl, or heterobicycloalkyl. In some embodiments, R3ais an optionally substituted heterocycloalkyl. In some embodiments, R3ais optionally substituted pyrrolidonyl, optionally substituted pyrrolidenonyl, optionally substituted pyrrolinyl, optionally substituted piperidinyl, optionally substituted 2-sultamyl, optionally substituted piperidonyl, optionally substituted pyrazolinonyl, or optionally substituted tetrahydrofuranyl. In some embodiments, R3ais acyl, amido, or sulfonyl. In some embodiments, R3ais C1-6 alkyl. In some embodiments, R3ais methyl, ethyl, or isopropyl. In some embodiments, R3ais C3-8cycloalkyl. In some embodiments, R3ais optionally substituted cyclopropanyl, optionally substituted cyclobutanyl, or optionally substituted cyclohexyl. In some embodiments, R3ais a heterobicycloalkyl. In some embodiments, R3ais optionally substituted spiro[4,5]decanyl, optionally substituted spiro[5,5]undecanyl, optionally substituted spiro[3,3]heptanyl, optionally substituted azaspiro[3,3]heptane, optionally substituted azaspiro[4,5]decane. In some embodiments, R3bis optionally substituted heterocycloalkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl. In some embodiments, R3bis optionally substituted aryl. In some embodiments, R3bis R10a, R10b, R10c, R10c, R10d, and R10eare independently H, halo, sulfonyl, carboxyl, optionally substituted C1-C4 alkyl, hydroxy, or C1-C4 alkoxy. In some embodiments, R3a-(Y)q-R3bform a moiety selected from: NH N O N O O F N N N SOF,O,O O , F F F N N F N N O ,OF,O,O O S S N O O N O OH O,O,O,

[0012]

[0013] In a particular embodiment, the compound is a compound from Table 1 , or a pharmaceutically acceptable salt thereof

[0014] Table 1 157 158 In some embodiments, the disclosure features for a pharmaceutical composition including any compound disclosed herein, and a pharmaceutically acceptable excipient In a further aspect, the disclosure features A method of treating cancer, comprising administering to a subject in need thereof an effective amount of a compound disclosed herein or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is administered in combination with is an inhibitor of B cell lymphoma 2 (BCL-2), B-cell lymphoma-extra large protein (BCL-XL), B cell lymphoma 2-like protein (BCL-w), BCL-2-related protein A1 (BFL-1), myeloid cell leukemia 1 (MCL-1), or a combination thereof. In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is breast cancer, skin cancer, central nervous system cancer, head and neck cancer, bladder cancer, kidney cancer, cancer of the gastrointestinal tract, lung cancer, eye cancer, genitourinary cancer, gynecologic cancer, endocrine cancer, soft tissue sarcoma, hematopoietic cancer, or neuroendocrine cancer. In some embodiments, the cancer is hematopoietic cancer. In some embodiments, the cancer is leukemia. In some embodiments, the cancer is acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, or chronic myeloid leukemia. In some embodiments, the cancer is lymphoma. In a further aspect, the disclosure features method of treating a disorder associated with cancer, comprising administering to a subject in need thereof an effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, wherein the disorder is malignant hypercalcemia or cervical hyperplasia. In a further aspect, the disclosure features a method of inducing apoptosis in a cancer cell in a subject, comprising contacting the cancer cell with an effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the cancer cell is a leukemia cell. In some embodiments, the cancer cell is selected from acute lymphoblastic leukemia cells, acute myeloid leukemia cells, chronic lymphocytic leukemia cells, or chronic myeloid leukemia cells. In some embodiments, the cancer cell is a solid tumor cell. In a further aspect, the disclosure features a method of inducing apoptosis in a leukemic stem cell in a subject, comprising contacting the leukemic stem cell with an effective amount of a compound disclosed herein or a pharmaceutically acceptable salt thereof. In some embodiments, the method does not induce apoptosis in healthy tissue. In some embodiments, the subject is a human. Definitions To facilitate the understanding of this invention, a number of terms are defined below. Terms defined herein have meanings as commonly understood by a person of ordinary skill in the areas relevant to the invention. Terms such as “a”, “an,” and “the” are not intended to refer to only a singular entity, but include the general class of which a specific example may be used for illustration. The terminology herein is used to describe specific embodiments of the invention, but their usage does not limit the invention, except as outlined in the claims. As used herein, the term “about” refers to a value that is within 10% above or below the value being described. Furthermore, as used herein, any values provided in a range of values include both the upper and lower bounds, and any values contained within the upper and lower bounds. As used herein, the term “pharmaceutically acceptable salt” represents those salts of the compounds described that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, allergic response and the like and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in: Berge et al., J. Pharmaceutical Sciences 66:1-19, 1977 and in Handbook of Pharmaceutical Salts: Properties, Selection, and Use, (Eds. P.H. Stahl and C.G. Wermuth), Wiley-VCH, 2008. These salts may be acid addition salts involving inorganic or organic acids. The salts can be prepared in situ during the final isolation and purification of the compounds described herein or separately by reacting the free base group with a suitable acid. As used herein, the term “effective amount” refers to an amount sufficient to effect beneficial or desired results, such as clinical results, and, as such, a “therapeutically effective amount” depends upon the context in which it is being applied. For example, in the context of administering a compound disclosed herein (e.g., a compound of formula (A-I), any of formulas (I-V) or a compound of any of Tables 1-4) to treat cancer, a therapeutically effective amount of a compound is, for example, an amount sufficient to induce apoptosis in cancer cells and / or leukemic stem cells. As used herein, and as well understood in the art, “to treat” a condition or “treatment” of various diseases and disorders is an approach for obtaining beneficial or desired results, such as clinical results. Beneficial or desired results can include, but are not limited to, alleviation of one or more symptoms or conditions; diminishment of extent of disease, disorder, or condition; stabilizing (i.e., not worsening) state of disease, disorder, or condition; delay or slowing the progress of the disease, disorder, or condition; amelioration or palliation of the disease, disorder, or condition; and remission (whether partial or total), whether detectable or undetectable. “Palliating” a disease, disorder, or condition means that the extent and / or undesirable clinical manifestations of the disease, disorder, or condition are lessened and / or time course of the progression is slowed or lengthened, as compared to the extent or time course in the absence of treatment. In the context of cancer, the term “treating” may refer to reducing the growth of the cancer in a subject, reducing the spread of cancer in the subject, or reducing the severity of a symptom of the cancer in the subject. In the context of a method of treating a tumor, “treating” may refer to reducing the size of the tumor, stabilizing the size of the tumor or otherwise reducing the further growth of the tumor. In some embodiments, “treating” may refer to inducing apoptosis in cancer cells and / or leukemic stem cells. The term “subject,” as used herein, can be a human, non-human primate, or other mammal, such as but not limited to dog, cat, horse, cow, pig, goat, monkey, rat, mouse, and sheep. In preferred embodiments, the subject is a human. As used herein, the term “pharmaceutical composition” refers to an active compound, formulated together with one or more pharmaceutically acceptable excipients. In some embodiments, a compound of the invention is present in unit dose amount appropriate for administration in a therapeutic regimen that shows a statistically significant probability of achieving a predetermined therapeutic effect when administered to a relevant population. In certain embodiments, pharmaceutical compositions may be specially formulated for administration in solid or liquid form, including those adapted for the following: oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, or capsules; and parenteral administration, for example, by subcutaneous, intramuscular, or intravenous injection. The term “pharmaceutically acceptable excipient,” as used herein, refers to any inactive ingredient (for example, a vehicle capable of suspending or dissolving the active compound) that is biocompatible and suitable for administration to a subject. Typical excipients include, for example: antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes, emollients, emulsifiers, diluents, film formers or coatings, flavors, fragrances, glidants, lubricants, preservatives, printing inks, sorbents, suspending or dispersing agents, sweeteners, or waters of hydration. Excipients include, but are not limited to: butylated optionally substituted hydroxytoluene (e.g., BHT), calcium carbonate, calcium phosphate dibasic, calcium stearate, croscarmellose, crosslinked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, optionally substituted hydroxypropyl cellulose, optionally substituted hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methyl paraben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propyl paraben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethyl cellulose, sodium citrate, sodium starch glycolate, sorbitol, starch, stearic acid, stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol. Those of ordinary skill in the art are familiar with a variety of agents and materials useful as excipients. The term “acyl,” as used herein, refers to a group –C(=O)–R, where R is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, or heterocyclyl. Acyl may be optionally substituted as described herein for each respective R group. The term acyl, as used herein, also includes carboxyl and amido groups. The term “alkyl,” as used herein, refers to a branched or straight-chain monovalent saturated aliphatic radical containing only C and H when unsubstituted. The monovalency of an alkyl group does not include the optional substituents on the alkyl group. For example, if an alkyl group is attached to a compound, monovalency of the alkyl group refers to its attachment to the compound and does not include any additional substituents that may be present on the alkyl group. In some embodiments, the alkyl group may contain, e.g., 1-8, 1-6, 1-4, or 1-2 carbon atoms (e.g., C1-C8, C1-C6, C1-C4, or C1-C2). Examples include, but are not limited to, methyl, ethyl, isobutyl, sec-butyl, tert-butyl, 2-methylpropyl, and 2,2- dimethylpropyl. The term “amino,” as used herein, refers to –N(RN1)2, where, if amino is unsubstituted, both RN1are H; or, if amino is substituted, each RN1is independently H, -OH, -NO2, -N(RN2)2, -SO2ORN2, -SO2RN2, - SORN2, -COORN2, an N-protecting group, alkyl, alkenyl, alkynyl, alkoxy, aryl, arylalkyl, aryloxy, cycloalkyl, cycloalkenyl, heteroalkyl, or heterocyclyl, provided that at least one RN1is not H, and where each RN2is independently H, alkyl, or aryl. Each of the substituents may itself be unsubstituted or substituted with unsubstituted substituent(s) defined herein for each respective group. In some embodiments, amino is unsubstituted amino (i.e., -NH2) or substituted amino (e.g., NHRN1), where RN1is independently -OH, - SO2ORN2, -SO2RN2, -SORN2, -COORN2, optionally substituted alkyl, or optionally substituted aryl, and each RN2can be optionally substituted alkyl or optionally substituted aryl. In some embodiments, substituted amino may be alkylamino, in which the alkyl groups are optionally substituted as described herein for alkyl. In some embodiments, an amino group is –NHRN1, in which RN1is optionally substituted alkyl. The term “alkoxy,” as used herein, represents a chemical substituent of formula -OR, where R is an alkyl or cycloalkyl group as defined herein. In some embodiments, the alkoxy group may be optionally substituted. The term “aryl,” as used herein, refers to a carbocyclic ring system having one or more aromatic rings. Aryl group may include from 6 to 10 carbon atoms. All atoms within an unsubstituted carbocyclic aryl group are carbon atoms. The aryl group may be unsubstituted or substituted with more than one (e.g., two, three, four, five, etc.) substituents. The term “biaryl,” as used herein, refers to a to a carbocyclic ring system having two or more fused or unfused aromatic rings, e.g., naphthyl. A biaryl group may have from 6 to 20 carbon atoms (e.g., C6-C20, C6-C15, C6-C12). The biaryl group may be unsubstituted or substituted with more than one (e.g., two, three, four, five, etc.) substituents. The term “cycloalkyl,” as used herein, refers to a monovalent, saturated cyclic group containing only C and H when unsubstituted. A cycloalkyl may have, e.g., three to eight carbons (e.g., a C3-C4, C3- C5, C3-C6, C3-C7, or C3-C8 cycloalkyl). Examples of cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. The term “cycloalkyl” also includes cyclic groups having a bridged multicyclic structure in which one or more carbons bridges two non-adjacent members of a monocyclic ring, e.g., norbornyl and bicyclo[1.1.1]pentyl. The term “halo,” as used herein, refers to a fluorine (fluoro), chlorine (chloro), bromine (bromo), or iodine (iodo) group. The term “heteroalkyl,” as used herein, refers to a branched or straight-chain monovalent saturated aliphatic radical containing, C, H, and one or more heteroatoms such as, e.g., N, O, or S, when unsubstituted. In some embodiments, the heteroalkyl group may contain, e.g., 1-8, 1-6, 1-4, or 1-2 carbon atoms (e.g., C1-C8, C1-C6, C1-C4, or C1-C2). The term “heteroalkyl” also includes groups described herein described by the term alkyl, further including one or more heteroatoms. The term “heteroaryl,” as used herein, refers to a cyclic ring system having one or more aromatic rings. Heteroaryl groups may include from 2 to 10 carbon atoms and at least one non-carbon atom (e.g., N, O, or S) when unsubstituted. Heteroaryl groups of the present disclosure may include, e.g., 1 non- carbon atom, two non-carbon atoms, three non-carbon atoms, four non-carbon atoms, etc. The heteroaryl group may be substituted or unsubstituted as defined herein independently at each atom. Examples of heteroaryls include but are not limited to pyrazyls and thiazyls. The term “heterocycloalkyl,” as used herein, refers to a monovalent cyclic groups, both saturated and unsaturated, containing, C, H, and at least one heteroatom selected from, e.g., N, O, or S, when unsubstituted. A heterocycloalkyl may have, e.g., three to eight carbons (e.g., a C3-C4, C3-C5, C3-C6, C3- C7, or C3-C8 cycloalkyl). Examples of heterocycloalkyls include, but are not limited to, tetrahydrofuryl, tetrahydrothiophenyl, pyrrolidyl, piperidyl, pyrazolyl, and piperizyl. The term “heterobicycloalkyl,” as used herein, refers to a heterocycloalkyl that is attached to a second nonaromatic ring selected from a heterocycloalkyl and a cycloalkyl in a fused or unfused manner. A heterobicycloalkyl group may have from 5 to 20 carbon atoms (e.g., C5-C20, C5-C15, C5-C12). The heterobicycloalkyl group may be substituted or unsubstituted as defined herein independently at each atom capable of bearing a substituent. Examples of compounds including a heterobicycloalkyl group include, e.g., Compound 46 and Compound 179. The terms “hydroxyl” and “hydroxy,” as used interchangeably herein, represent an -OH group. The term “sulfonyl,” as used herein, represents -S(=O)2RS, where RSis independently -OH, hydroxyl, amino, optionally substituted C1-C6alkyl, optionally substituted C3-C10aryl or optionally substituted C3-C8 cycloalkyl. The term “optionally substituted,” as used herein, refers to the replacement of one or more hydrogen atoms on the described group with a group selected from: halo, alkyl, C1-C8alkyl, C3-C8cycloalkyl, amino, hydroxyl, acyl, carboxyl, amido, sulfonyl, and C3-C10aryl. Any substituent group including one or more carbon atoms may further be optionally substituted by one or more terminal unsubstitued substituents selected from halo, amino, hydroxyl, acyl, carboxyl, amido, and sulfonyl. For example, a methyl optional substituent may be further substituted with fluoro (e.g., trifluoromethyl). DETAILED DESCRIPTION Disclosed herein are compounds, pharmaceutical compositions, and the use of the pharmaceutical compositions for the treatment of cancer in a subject. The disclosure is based, at least in part, on the realization that certain structural modifications to the BAX activator compounds provide advantageous properties (e.g., as compared to other BAX activator compounds such as Gav2-006 disclosed in PCT / US2018 / 034279), such as improved solubility in aqueous media, increased metabolic stability, improved pharmacokinetic properties (e.g., increased serum half-life), increased BAX activation, and / or increased BAX selectivity. Compounds The compounds for treating cancer herein include compounds of formula (I): In one aspect, the disclosure features compounds of formula (A-I): (A-I); or a pharmaceutically acceptable salts thereof, wherein G is CH or N; R1is optionally substituted aryl or optionally substituted heteroaryl; X is an optionally substituted C1-C3alkyl group or a C1-C3heteroalkyl group R2is selected from optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted bicycloalkyl, optionally substituted heterobicycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; R3ais selected from optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroalkyl, optionally substituted heterocycloalkyl, or CHR4(CR5aR5b)0-4R6; wherein R4, R5a, and R5bare independently selected from H, optionally substituted C1-C4 alkyl, and R6is selected from CONR7R8, SO2NR7R8, NR7COR7, NR7SO2R8; wherein R7and R8are independently selected from H, optionally substituted alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or R7and R8together with the atoms to which they are attached form a optionally substituted C3-C7 cycloalkyl, optionally substituted C3-C7 heterocycloalkyl, optionally substituted C3-C7 bicycloalkyl, or optionally substituted C3-C7 heterobicycloalkyl; R3bis optionally substituted alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted bicycloalkyl; Y is selected from O, NR9, S, (CHR9)1-4, CO, or SO2; each R9is independently selected from H or optionally substituted C1-C4alkyl; p is 0 or 1; and q is 0 or 1, provided that: when p is 0 and R2is optionally substituted aryl or optionally substituted heteroaryl, then R3bis an optionally substituted bicycloalkyl. The compounds may be synthesized as described in the Examples. Pharmaceutical Compositions A pharmaceutical composition of the invention contains one or more of the compounds disclosed herein (e.g., one or more of the compounds of formula (I), formula (IA), and Table 1) as the therapeutic compound. In addition to a therapeutically effective amount of the compound, the pharmaceutical compositions also contain a pharmaceutically acceptable excipient, which can be formulated by methods known to those skilled in the art. In some embodiments, the pharmaceutical compositions for treating cancer contain one or more of the compounds disclosed herein (e.g., one or more of the compounds of formula (I), formula (IA), and Table 1) may be formulated and / or administered with or without other therapeutics for a particular condition. Examples of such therapeutics (second therapeutic agents) are described herein. The compounds disclosed herein (e.g., the compounds of formula (I), formula (IA), and Table 1) may be used in the form of free base, or in the form of salts, and as solvates. All forms are within the scope of the disclosure. Exemplary routes of administration of the pharmaceutical compositions (or the compounds of the composition) include oral, sublingual, buccal, transdermal, intradermal, intramuscular, parenteral, intravenous, intra-arterial, intracranial, subcutaneous, intraorbital, intraventricular, intraspinal, intraperitoneal, intranasal, inhalation, and topical administration. Formulations for Oral Administration The pharmaceutical compositions of the invention include those formulated for oral administration (“oral dosage forms”). Oral dosage forms can be, for example, in the form of tablets, capsules, a liquid solution or suspension, a powder, or liquid or solid crystals, which contain the active ingredient(s) in a mixture with non-toxic pharmaceutically acceptable excipients. These excipients may be, for example, inert diluents or fillers (e.g., sucrose, sorbitol, sugar, mannitol, microcrystalline cellulose, starches including potato starch, calcium carbonate, sodium chloride, lactose, calcium phosphate, calcium sulfate, or sodium phosphate); granulating and disintegrating agents (e.g., cellulose derivatives including microcrystalline cellulose, starches including potato starch, croscarmellose sodium, alginates, or alginic acid); binding agents (e.g., sucrose, glucose, sorbitol, acacia, alginic acid, sodium alginate, gelatin, starch, pregelatinized starch, microcrystalline cellulose, magnesium aluminum silicate, carboxymethylcellulose sodium, methylcellulose, hydroxypropyl methylcellulose, ethylcellulose, polyvinylpyrrolidone, or polyethylene glycol); and lubricating agents, glidants, and antiadhesives (e.g., magnesium stearate, zinc stearate, stearic acid, silicas, hydrogenated vegetable oils, or talc). Other pharmaceutically acceptable excipients can be colorants, flavoring agents, plasticizers, humectants, buffering agents, and the like. Pharmaceutical compositions for oral administration may also be presented as chewable tablets, as hard gelatin capsules where the active ingredient is mixed with an inert solid diluent (e.g., potato starch, lactose, microcrystalline cellulose, calcium carbonate, calcium phosphate or kaolin), or as soft gelatin capsules where the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin, or olive oil. Powders, granulates, and pellets may be prepared using the ingredients mentioned above under tablets and capsules in a conventional manner using, e.g., a mixer, a fluid bed apparatus or a spray drying equipment. The liquid forms in which the compounds and compositions of the present invention can be incorporated for administration orally include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils, e.g., cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Formulations for Parenteral Administration The pharmaceutical compositions of the invention can be administered in a pharmaceutically acceptable parenteral (e.g., intravenous, intramuscular, subcutaneous or the like) formulation as described herein. The pharmaceutical composition may also be administered parenterally in dosage forms or formulations containing conventional, non-toxic pharmaceutically acceptable carriers and adjuvants. In particular, formulations suitable for parenteral administration include aqueous and non- aqueous sterile injection solutions which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non- aqueous sterile suspensions which may include suspending agents and thickening agents. For example, to prepare such a composition, the compounds of the invention may be dissolved or suspended in a parenterally acceptable liquid vehicle. Among acceptable vehicles and solvents that may be employed are water; water adjusted to a suitable pH by addition of an appropriate amount of hydrochloric acid, sodium hydroxide, or a suitable buffer; 1,3-butanediol; Ringer’s solution; and isotonic sodium chloride solution. The aqueous formulation may also contain one or more preservatives, for example, methyl, ethyl, or n-propyl p-hydroxybenzoate. Additional information regarding parenteral formulations can be found, for example, in the United States Pharmacopeia-National Formulary (USP-NF), herein incorporated by reference in its entirety. The parenteral formulation can be any of the five general types of preparations identified by the USP-NF as suitable for parenteral administration: (1) “Drug Injection:” a liquid preparation that is a drug substance (e.g., a compound of the invention), or a solution thereof; (2) “Drug for Injection:” the drug substance (e.g., a compound of the invention) as a dry solid that will be combined with the appropriate sterile vehicle for parenteral administration as a drug injection; (3) “Drug Injectable Emulsion:” a liquid preparation of the drug substance (e.g., a compound of the invention) that is dissolved or dispersed in a suitable emulsion medium; (4) “Drug Injectable Suspension:” a liquid preparation of the drug substance (e.g., a compound of the invention) suspended in a suitable liquid medium; and (5) “Drug for Injectable Suspension:” the drug substance (e.g., a compound of the invention) as a dry solid that will be combined with the appropriate sterile vehicle for parenteral administration as a drug injectable suspension. Exemplary formulations for parenteral administration include solutions of the compound prepared in water suitably mixed with a surfactant, e.g., hydroxypropyl cellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, DMSO and mixtures thereof with or without alcohol, and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms. Conventional procedures and ingredients for the selection and preparation of suitable formulations are described, for example, in Remington: The Science and Practice of Pharmacy, 23rdEd., Adejare, Ed., Academic Press (2020) and in The United States Pharmacopeia and National Formulary (USP-NF 2021 Issues 1-3), published in 2021. Formulations for parenteral administration may, for example, contain sterile water, saline, polyalkylene glycols (e.g., polyethylene glycol), oils of vegetable origin, or hydrogenated naphthalenes. Biocompatible, biodegradable lactide polymer, lactide / glycolide copolymer, or polyoxyethylene- polyoxypropylene copolymers may be used to control the release of the compounds. Other potentially useful parenteral delivery systems for compounds include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation may contain, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel. Methods of Treatment The compounds disclosed herein (e.g., the compounds of formula (I), formula (IA), and Table 1) are, in general, suitable for any therapeutic use. In some embodiments, compounds disclosed herein (e.g., the compounds of formula (I), formula (IA), and Table 1) may be used to treat any disease or disorder that may benefit from BAX activation, e.g., cancer. In some embodiments, compounds disclosed herein (e.g., the compounds of formula (I), formula (IA), and Table 1) may be used to induce apoptosis in cancer cells and / or leukemic stem cells. The cancer may be a solid tumor or a “liquid tumor” (i.e., a cancer that is present in body fluids). Examples of cancers that can be treated with compounds of the disclosure include, but are not limited to, breast cancer, such as breast carcinoma; skin cancer, such as melanoma (e.g., malignant melanoma); central nervous system cancer, such as brain cancer (e.g., primary brain carcinoma, medulloblastoma, glioma, or glioblastoma) and spinal cord cancer; head and neck cancer, such as head and neck carcinoma; bladder cancer, such as bladder carcinoma; kidney cancer, such as renal cell carcinoma and Wilms' tumor; cancer of the gastrointestinal tract, such as colon cancer (e.g., colon carcinoma), rectal cancer, liver cancer, stomach cancer (e.g., stomach carcinoma), esophageal cancer (e.g., esophageal carcinoma), and pancreatic cancer (e.g., pancreatic carcinoma); lung cancer, such as small cell lung cancer and non-small cell lung cancer (e.g., lung carcinoma); eye cancer, such as retinoblastoma; genitourinary cancer, such as urethra cancer, testicular cancer (e.g., testicular carcinoma), and prostate cancer (e.g., prostatic carcinoma); gynecologic cancer, such as placental cancer (e.g., choriocarcinoma), ovarian cancer (e.g., ovarian carcinoma), cervical cancer (e.g., cervical carcinoma), vulvar cancer, and uterine cancer (e.g., endometrial carcinoma); endocrine cancer, such as thyroid cancer (e.g., thyroid carcinoma) and adrenal cancer (e.g., adrenal carcinoma or adrenal cortex carcinoma); soft tissue sarcoma, such as rhabdomyosarcoma, Kaposi's sarcoma, and osteosarcoma; hematopoietic cancer, such as myeloma (e.g., multiple myeloma), leukemia (e.g., acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic granulocytic leukemia, acute granulocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, hairy cell leukemia, polycythemia vera, or essential thrombocytosis), Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma (e.g., primary macroglobulinemia or mycosis fungoides); or neuroendocrine cancer, such as neuroblastoma, malignant pancreatic insulinoma, and malignant carcinoid carcinoma. In some embodiments, the cancer is resistant to apoptosis. The dosage of the compound of the disclosure depends on factors including the route of administration, the disease to be treated, and physical characteristics, e.g., age, weight, and general health, of the subject. Typically, the amount of a compound disclosed herein (e.g., a compound of formula (I), formula (IA), or Table 1) contained within a single dose may be an amount that effectively treats the disease without inducing significant toxicity. A pharmaceutical composition of the disclosure for use in a method of treating a disease or disorder that may benefit from BAX activation, e.g., cancer, includes a dosage of a compound disclosed herein (e.g., a compound of formula (I), formula (IA), or Table 1) ranging from 0.001 to 500 mg / kg / day and, in a more specific embodiment, about 0.1 to about 100 mg / kg / day. The dosage may be adapted by the clinician in accordance with conventional factors such as the extent of the disease and different parameters of the subject. Typically, a pharmaceutical composition of the disclosure can be administered in an amount from about 0.001 mg up to about 500 mg / kg / day of a compound disclosed herein (e.g., a compound of formula (I), formula (IA), or Table 1). Pharmaceutical compositions of the disclosure that contain one or more of the compounds disclosed herein (e.g., one or more of the compounds of formula (I), formula (IA), and Table 1) may be administered to a subject in need thereof one or more times (e.g., 1-10 times or more) daily, or as medically necessary. Combination Therapy In some embodiments, a compound disclosed herein (e.g., any one of the compounds of formula (I), (IA), and Table 1) is administered in combination with one or more second therapeutic agents. The compound and the second therapeutic agent may be administered concurrently or sequentially (in any order), either through the same route or different routes of administration. In some embodiments, the second therapeutic agent is provided with a compound disclosed herein (e.g., any one of the compounds of formula (I), (IA), and Table 1) in a single formulation. In some embodiments, the one or more second therapeutic agents include an inhibitor of one or more anti-apoptotic proteins of the BCL-2 family, e.g., one or more of BCL-2, BCL-XL, BCL-w, BFL-1, and MCL-1. BCL-2, BCL-XL, BCL-w, BFL-1, and MCL-1 are proteins that inhibit cellular apoptosis through various mechanisms, such as the inhibition of BAX. Thus, in some embodiments, the second therapeutic agent (e.g., an inhibitor of one or more anti-apoptotic proteins) is administered in an amount sufficient to inhibit an anti-apoptotic activity of one or more anti-apoptotic proteins (e.g., one or more of BCL-2, BCL- XL, BCL-w, BFL-1, and MCL-1) in a subject. In some embodiments, the one or more second therapeutic agents include an inhibitor of BCL- XL. Examples of inhibitors of BCL-XL include, but are not limited to, Navitoclax (AbbVie), A-1331852 (AbbVie, Genentech), A-1155463 (AbbVie, Genentech), AZD-0466 (AstraZeneca), AZD-4320 (AstraZeneca), ABBV-155 (AbbVie), APG-1252 (Ascentage Pharma), and DT2216 (Dialectic Therapeutics). In some embodiments, the one or more second therapeutic agents include an inhibitor of MCL-1. Examples of inhibitors of MCL-1 include, but are not limited to, AMG-176 (Amgen), AZD5991 (AstraZeneca), MIK554 (Servier and Novartis), and VU661013 (Vanderbilt University). In some embodiments, the one or more second therapeutic agents include ABT-737 (AbbVie), ABT-199 (AbbVie), or AMG 397 (Amgen). In some embodiments, the one or more second therapeutic agents include an anti-cancer agent. Examples of anti-cancer agents include, but are not limited to, MEK (e.g., MEK1, MEK2, or MEK1 and MEK2) inhibitors (e.g., XL518, CI-1040, PD035901, selumetinib / AZD6244, GSK1120212 / trametinib, GDC-0973, ARRY-162, ARRY-300, AZD8330, PD0325901, U0126, PD98059, TAK-733, PD318088, AS703026, BAY 869766, PD184352, SB239063, BAY 43-9006); alkylating agents such as nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, uramustine, chlorambucil, melphalan, ifosfamide), ethylenimine and methylmelamines (e.g., hexamethlymelamine and thiotepa), alkyl sulfonates (e.g., busulfan and hepsulfam), nitrosoureas (e.g., carmustine, lomusitne, semustine, and streptozocin), and triazenes (e.g., decarbazine); anti-metabolites such as folic acid analogs (e.g., methotrexate, leucovorin, raltitrexed, and pemetrexed), pyrimidine analogs (e.g., fluorouracil, floxouridine, cytarabine, capecitabine, and gemcitabine), and purine analogs (e.g., mercaptopurine, thioguanine, pentostatin, fludarabine, and 5- azathioprine); plant alkaloids (e.g., vincristine, vinblastine, vinorelbine, vindesine, podophyllotoxin, paclitaxel, docetaxel, and homoharringtonine); topoisomerase inhibitors such as camptothecin derivatives (e.g., irinotecan and topotecan), amsacrine, and epipodophyllotoxins (e.g., etoposide (VP16), etoposide phosphate, and teniposide); antibiotics such as anthracenediones (e.g., mitoxantrone), anthracyclines (e.g., doxorubicin, daunorubicin, epirubicin, and fluorodaunorunicin hydrochloride), streptomyces-derived antibiotics or derivatives thereof (e.g., dactinomycin, bleomycin, mitomycin, geldanamycin, plicamycin, and 17-N-allylamino-17-demethoxygeldanamycin (17-AAG; tanespimycin), clofazimine, and beta lactam derivatives; platinum-based compounds (e.g., cisplatin, oxaliplatin, carboplatin); substituted ureas (e.g., hydroxyurea); methyl hydrazine derivatives (e.g., procarbazine), adrenocortical suppressants (e.g., mitotane and aminoglutethimide); angiogenesis-inhibiting enzymes (e.g., L-asparaginase and arginine deiminase); PI3K inhibitors (e.g., wortmannin and LY294002); mTOR inhibitors (e.g., sertraline); DNA methyltransferase inhibitors (e.g., 5-aza-2'-deoxycytidine); antisense oligonucleotides; apoptosis gene modulators; apoptosis regulators (e.g., deoxyadenosine and triptolide); BCR / ABL antagonists; bFGF inhibitor; casein kinase inhibitors (ICOS); gallium nitrate; gelatinase inhibitors; glutathione inhibitors (e.g., etanidazole); immunostimulant peptides; insulin-like growth factor-1 receptor inhibitors; leukemia inhibiting factor; matrilysin inhibitors; matrix metalloproteinase inhibitors; MIF inhibitors; mismatched double stranded RNA; mycobacterial cell wall extract; nitric oxide modulators; phosphatase inhibitors; plasminogen activator inhibitor; proteasome inhibitors (e.g., bortezomib); protein A-based immune modulators; protein kinase C inhibitors; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitors; ribozymes; signal transduction inhibitors / modulators (e.g., itraconazole); single chain antigen-binding proteins; stem cell inhibitors; stem-cell division inhibitors; stromelysin inhibitors; synthetic glycosaminoglycans; telomerase inhibitors; thyroid stimulating hormones; translation inhibitors; urokinase receptor antagonists; gonadotropin-releasing hormone agonists (GnRH) such as goserelin and leuprolide (leuprorelin); steroids such as adrenocorticosteroids (e.g., prednisone and dexamethasone); progestins (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate); antiprogestrogens (e.g., mifepristone); estrogens (e.g., diethylstilbestrol and ethinylestradiol); antiestrogens such as aromatase inhibitors (e.g., exemestane, fadrozole, letrozole, pentrozole, and anastrozole), selective estrogen receptor modulators (e.g., tamoxifen, tamoxifen methiodide, panomifene, and clomifene analogues); androgens (e.g., testosterone propionate and fluoxymesterone); antiandrogens (e.g., flutamide, finasteride, and bicalutamide); immunostimulants such as levamisole, interleukins (e.g., interleukin-2) and interferons / interferon agonists (e.g., alpha-interferon); monoclonal antibodies such as anti-CD20 (e.g., rituximab), anti-HER2 (e.g., trastuzumab), anti-CD52, anti-CD25 (e.g., daclizumab, anti-HLA-DR, and anti-VEGF monoclonal antibodies); immunotoxins (e.g., anti-CD33 monoclonal antibody-calicheamicin conjugates and anti-CD22 monoclonal antibody-pseudomonas exotoxin conjugates); radioimmunotherapeutic agents (e.g., anti-CD20 monoclonal antibody conjugatedto111In,90Y, or131I, etc.); statins (e.g., cerivastatin and pitavastatin); 5-T1Breceptor agonists (e.g., 5- nonyloxytryptamine); BRAF kinase inhibitors (e.g., vemurafenib and dabrafenib); tyrosine kinase inhibitors such as inhibitors of one or more of EGFR, HER2, KDR, FLT4, EphB4, and Src (e.g., gefitinib (Iressa™), erlotinib (Tarceva™), cetuximab (Erbitux™), lapatinib (Tykerb™), panitumumab (Vectibix™) vandetanib (Caprelsa™), afatinib / BIBW2992, CI-1033 / canertinib, neratinib / HKI-272, CP-724714, TAK-285, AST- 1306, ARRY334543, AG-1478, dacomitinib / PF299804, OSI-420 / desmethyl erlotinib, AZD8931, ARRY- 380, AEE788, pelitinib / EKB-569, CUDC-101, WZ8040, WZ4002, WZ3146, AG-490, XL647, PD153035, BMS-599626, sorafenib, imatinib (Gleevec®), sunitinib, and dasatinib; immune-checkpoint inhibitors (e.g., anti-CTLA-4, anti-PD1 / L1 antibodies); PLK1 inhibitors (GSK461364, BI2536, Tak960, NMS-P937, BI6727), mitotic kinase inhibitors, or the like, or mixtures thereof (e.g., a combination of euprolide, estrogen, and progesterone). In some embodiments, a compound disclosed herein (e.g., any one of the compounds of formula (I), formula (IA), and Table 1) is administered in combination with radiation therapy and / or surgical intervention.

[0015] EXAMPLES Example 1: Synthesis of Compound 1; (Z)-4-(2-(4-(2-(4,5-dimethylthiazol-2-yl)hydrazono)-5-oxo-3- phenyl-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4-yl)-2-methylbenzoic acid To a solution of (4-fluorophenyl)methanamine (1.00 g, 7.99 mmol, 909 uL, 1.00 eq) in H2O (10.0 mL) was added HCl (832 mg, 7.99 mmol, 816 uL, 35.0% purity, 1.00 eq) at 25 °C and PH = 1. The solution was kept at 40 °C and 2,5-dimethoxy-2,5-dihydrofuran (1.14 g, 8.79 mmol, 1.10 eq) was added. The resulting mixture was stirred at 40 °C for 5 min. The reaction mixture was cooled to 25 °C. The mixture was added DCM (100 mL) and slowly added saturated aqueous Na2HPO4 solution to pH = 7. The reaction mixture was extracted with DCM (10.0 mL). The combined organic phase was washed with H2O (10.0 mL x 2), brine (20.0 mL), dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chomatography (ISCO®; 4 g SepaFlash® Silica Flash Column, Eluent of 0~40% Ethyl acetate / Petroleum ether gradient @ 30 mL / min) to give 1-(4-fluorobenzyl)-1,5-dihydro-2H-pyrrol-2-one (650 mg, 1.22 mmol, 29.2% yield, 36.0% purity) as a black brown oil. MS: product: m / z 191.8 (M+H)+.1H NMR (400 MHz, CHLOROFORM-d) δ = 7.25 - 7.09 (m, 2H), 7.01 - 6.91 (m, 2H), 4.53 (s, 1H), 3.80 (s, 1H), 1.93 - 1.69 (m, 4H). To a solution of 1-(4-fluorobenzyl)-1,5-dihydro-2H-pyrrol-2-one (650 mg, 3.40 mmol, 1.00 eq) in EtOH (6.00 mL) was added NH2NH2.H2O (4.03 g, 80.5 mmol, 3.91 mL, 23.7 eq) at 20 °C. The mixture was stirred at 80 °C for 2 h. The mixture was concentrated at 40 °C to give 1-(4-fluorobenzyl)-4- hydrazineylpyrrolidin-2-one (1.20 g, crude) as a yellow solid. MS: product: m / z 223.7 (M+H)+. To a solution of 1-(4-fluorobenzyl)-4-hydrazineylpyrrolidin-2-one (1.20 g, 5.38 mmol, 1.00 eq) in EtOH (10.0 mL) was added ethyl 4-cyclopropyl-3-oxobutanoate (914 mg, 5.38 mmol, 1.00 eq) at 80 °C. The mixture was stirred at 80 °C for 2 h. The reaction mixture was concentrated. The residue was purified by flash silica gel chomatography (ISCO®; 4g SepaFlash® Silica Flash Column, Eluent of 0~50% Ethylacetate / Petroleum ether gradient @ 30 mL / min) to give 4-(3-(cyclopropylmethyl)-5-hydroxy-4,5- dihydro-1H-pyrazol-1-yl)-1-(4-fluorobenzyl)pyrrolidin-2-one (230 mg, 516 μmol, 9.61% yield, 74.0% purity) as a black brown oil. MS: product: m / z 329.9 (M+H)+.1H NMR (400 MHz, CHLOROFORM-d) δ = 7.27 - 7.21 (m, 2H), 7.01 (br t, J = 8.6 Hz, 2H), 4.99 - 4.88 (m, 1H), 4.58 (d, J = 14.8 Hz, 1H), 4.43 - 4.35 (m, 1H), 3.60 - 3.51 (m, 1H), 3.29 (d, J = 4.0 Hz, 2H), 2.85 - 2.70 (m, 2H), 2.32 - 2.22 (m, 2H), 0.87 - 0.79 (m, 2H), 0.64 - 0.53 (m, 2H), 0.26 - 0.11 (m, 2H).19F NMR (376 MHz, CHLOROFORM-d) δ = -114.75 (s, 1F). To a solution of 4-(3-(cyclopropylmethyl)-5-hydroxy-4,5-dihydro-1H-pyrazol-1-yl)-1-(4- fluorobenzyl)pyrrolidin-2-one (230 mg, 698 μmol, 1.00 eq) in EtOH (3.00 mL) was added NaOH in water (2.50 M, 279 uL, 2.50 eq). The mixture was stirred at 20 °C for 0.5 h. The product of sodium 3- (cyclopropylmethyl)-1-(1-(4-fluorobenzyl)-5-oxopyrrolidin-3-yl)-4,5-dihydro-1H-pyrazol-5-olate in EtOH / water as a yellow solution was used in next step without further purification. To a solution of 4,5-dimethylthiazol-2-amine (89.5 mg, 698 μmol, 1.00 eq) in HCl (960 mg, 9.22 mmol, 941 uL, 35% purity, 13.2 eq) was added a solution of NaNO2 (48.2 mg, 698 μmol, 1.00 eq) in H2O (1.00 mL) at 0 °C. The mixture was stirred at 0 °C for 0.5 h. The product of 4,5-dimethylthiazole-2- diazonium chloride in water as a yellow solution was used in next step without further purification. The solution of 4,5-dimethylthiazole-2-diazonium chloride (122 mg, 698 μmol, 1.00 eq, in water) was added to the solution of sodium 3-(cyclopropylmethyl)-1-(1-(4-fluorobenzyl)-5-oxopyrrolidin-3-yl)-4,5- dihydro-1H-pyrazol-5-olate (245 mg, 698 μmol, 1.00 eq, in EtOH / H2O) at 0 °C. The resulting mixture was stirred at 20 °C for 1 h. The mixture was extracted with DCM (10.0 mL x 3). The combined organic was washed with brine (10.0 mL x 2), dried over Na2SO4, filtered. The filtrate was concentrated to give a crude product. The residue was purified by prep-HPLC (column: Welch Ultimate C18 150*25mm*5um;mobile phase: [water(FA)-ACN];B%: 56%-86%,10min) to give (Z)-5-(cyclopropylmethyl)- 4-(2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-2-(1-(4-fluorobenzyl)-5-oxopyrrolidin-3-yl)-2,4-dihydro-3H- pyrazol-3-one (28.7 mg, 60.5 μmol, 8.67% yield, 98.8% purity) as a red solid. MS: product: m / z 469.3 (M+H)+.1H NMR (400 MHz, CHLOROFORM-d) δ = 7.27 (dd, J = 5.6, 8.6 Hz, 2H), 7.02 (t, J = 8.6 Hz, 2H), 5.07 - 4.97 (m, 1H), 4.62 - 4.55 (m, 1H), 4.46 - 4.38 (m, 1H), 3.59 (dd, J = 8.0, 10.0 Hz, 1H), 3.43 (dd, J = 4.8, 10.0 Hz, 1H), 2.90 - 2.81 (m, 2H), 2.48 (d, J = 6.8 Hz, 2H), 2.36 - 2.21 (m, 6H), 1.09 - 0.97 (m, 1H), 0.61 - 0.51 (m, 2H), 0.33 - 0.24 (m, 2H). Example 2: Alternative Synthesis of Compound 1; (Z)-4-(2-(4-(2-(4,5-dimethylthiazol-2- yl)hydrazono)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4-yl)-2-methylbenzoic acid To a solution of (4-fluorophenyl)methanamine ((5.00 g, 39.9 mmol, 4.55 mL, 1.00 eq)) in H2O (20.0 mL) was added HCl (4.16 g, 39.9 mmol, 4.08 mL, 35.0% purity, 1.00 eq) at 25 °C and PH = 1. The solution was kept at 40 °C and 2,5-dimethoxy-2,5-dihydrofuran (5.72 g, 43.9 mmol, 1.10 eq) was added. The resulting mixture was stirred at 40 °C for 0.5 h. The reaction mixture was cooled to 25 °C. The mixture was added DCM (100 mL) and slowly added saturated aqueous Na2HPO4 solution to pH = 7. The reaction mixture was extracted with DCM (10.0 mL). The combined organic phase was washed with H2O (10.0 mL x 2), brine (20.0 mL), dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chomatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0~43% Ethyl acetate / Petroleum ethergradient @ 50 mL / min) to give 1-(4-fluorobenzyl)-1,5-dihydro-2H-pyrrol-2-one (3.60 g, 17.7 mmol, 44.4% yield, 94.2% purity) as a black brown oil. MS: product: m / z 191.8 (M+H)+.1H NMR (400 MHz, CHLOROFORM-d) δ = 7.19 (dd, J = 5.2, 8.0 Hz, 2H), 7.04 (br d, J = 6.0 Hz, 1H), 7.01 - 6.95 (m, 2H), 6.21 - 6.15 (m, 1H), 4.57 (s, 2H), 3.85 (s, 2H). To a solution of 1-(4-fluorobenzyl)-1,5-dihydro-2H-pyrrol-2-one (3.50 g, 18.3 mmol, 1.00 eq) in EtOH (6.00 mL) was added NH2NH2.H2O (11.1 g, 188. mmol, 10.8 mL, 85.0% purity, 10.3 eq). The mixture was stirred at 80 °C for 2 h. The mixture was stirred at 80 °C for 2 h. The mixture was concentrated at 40 °C to give 1-(4-fluorobenzyl)-4-hydrazineylpyrrolidin-2-one (3.95 g, crude) as a brown oil. MS: product: m / z 224.0 (M+H)+. To a solution of 1-(4-fluorobenzyl)-4-hydrazineylpyrrolidin-2-one (3.85 g, 17.2 mmol, 1.00 eq) in EtOH (20.0 mL) was added ethyl 4-cyclopropyl-3-oxobutanoate (2.94 g, 17.2 mmol, 1.00 eq). The mixture was stirred at 80 °C for 2 h. The reaction mixture was concentrated to give 4-(3- (cyclopropylmethyl)-5-hydroxy-4,5-dihydro-1H-pyrazol-1-yl)-1-(4-fluorobenzyl)pyrrolidin-2-one (6.50 g, crude) as a brown solid. MS: product: m / z 330.0 (M+H)+. To a solution of 4-(3-(cyclopropylmethyl)-5-hydroxy-4,5-dihydro-1H-pyrazol-1-yl)-1-(4- fluorobenzyl)pyrrolidin-2-one (2.00 g, 6.07 mmol, 1.00 eq) in EtOH (6.00 mL) was added a solution of NaOH in water (2.50 M, 6.07 mL, 2.50 eq) 25 °C. The mixture was stirred at 25 °C for 0.5 h. The product of sodium 3-(cyclopropylmethyl)-1-(1-(4-fluorobenzyl)-5-oxopyrrolidin-3-yl)-4,5-dihydro-1H-pyrazol-5-olate in EtOH / water as a yellow solution. It was used in next step without further purification. To a solution of 4,5-dimethylthiazol-2-amine (778 mg, 6.07 mmol, 1.00 eq) in HCl (8.11 g, 80.1 mmol, 7.96 mL, 36.0% purity, 13.2 eq) was added to a solution of NaNO2 (419 mg, 6.07 mmol, 1.00 eq) in H2O (6.00 mL) at 0 °C. The mixture was stirred at 0 °C for 0.5 h. The product of 4,5-dimethylthiazole-2- diazonium chloride in water as a yellow solution. It was used in next step without further purification. The solution of 4,5-dimethylthiazole-2-diazonium chloride (1.07 g, 6.07 mmol, 1.00 eq, in water) was added dropwise to the solution of sodium 3-(cyclopropylmethyl)-1-(1-(4-fluorobenzyl)-5-oxopyrrolidin- 3-yl)-4,5-dihydro-1H-pyrazol-5-olate (2.13 g, 6.07 mmol, 1.00 eq, in EtOH / water) at 0 °C. The mixture was stirred at 25 °C for 1 h. The mixture was extracted with DCM (50.0 mL x 3). The combined organic was washed with brine (100 mL x 2), dried over Na2SO4, filtered. The filtrate was concentrated to give a residue. The residue was purified by reversed-phase HPLC (C18, 20 - 45um, 100 A, 40.0 g, eluent of 5 ~ 50% MeCN in water with 0.05% FA condition) to give (Z)-5-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol- 2-yl)hydrazineylidene)-2-(1-(4-fluorobenzyl)-5-oxopyrrolidin-3-yl)-2,4-dihydro-3H-pyrazol-3-one (251 mg, 527 μmol, 8.69% yield, 98.5% purity) as a red solid. MS: product: m / z 469.2 (M+H)+.1H NMR (400 MHz, CHLOROFORM-d) δ = 7.29 - 7.27 (m, 1H), 7.26 - 7.25 (m, 1H), 7.06 - 6.98 (m, 2H), 5.06 - 4.97 (m, 1H), 4.57 (d, J = 14.8 Hz, 1H), 4.42 (d, J = 15.2 Hz, 1H), 3.58 (dd, J = 8.0, 10.4 Hz, 1H), 3.41 (dd, J = 4.8, 10.4 Hz, 1H), 2.87 - 2.80 (m, 2H), 2.47 (d, J = 7.2 Hz, 2H), 2.33 - 2.30 (m, 3H), 2.27 - 2.24 (m, 3H), 1.05 - 0.98 (m, 1H), 0.58 - 0.51 (m, 2H), 0.30 - 0.23 (m, 2H).19F NMR (377 MHz, CHLOROFORM-d) δ = -114.752 (s, 1F). Example 3: Synthesis of Compound 2; (4Z)-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2- yl)hydrazono]-2-[1-(4-fluorophenyl)-5-oxo-pyrrolidin-3-yl]pyrazol-3-one To a solution of 4-fluoroaniline (1.00 g, 9.00 mmol, 862 uL, 1.00 eq) in H2O (10.0 mL) was added HCl (920 uL, 9.01 mmol, 35.0% purity) at 25 °C and pH = 1. The solution was kept at 40 °C and 2,5- dimethoxy-2,5-dihydrofuran (1.29 g, 9.90 mmol, 1.10 eq) was added. The resulting mixture was stirred at 40 °C for 5 min. The reaction mixture was cooled to 25 °C. The mixture was added DCM (10.0 mL) and slowly added saturated aqueous Na2HPO4solution to pH = 7. The reaction mixture was extracted with DCM (10.0 mL). The combined organic phase was washed with H2O (10.0 mL x 2), brine (20.0 mL), dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® SilicaFlash Column, Eluent of 0 ~ 60% Ethylacetate / Petroleum ethergradient @ 40 mL / min). The eluent was concentrated under reduced pressure to give 1-(4-fluorophenyl)-2H-pyrrol-5-one (347 mg, 1.81 mmol, 20.1% yield, 92.5% purity) as an off-white solid. MS: product: m / z 178.0 (M+H)+. To a solution of 1-(4-fluorophenyl)-2H-pyrrol-5-one (347 mg, 1.96 mmol, 1.00 eq) in EtOH (4.00 mL) was added NH2NH2·H2O (1.24 g, 21.0 mmol, 1.20 mL, 85% purity, 10.7 eq) at 25 °C. The mixture was stirred at 80 °C for 2 hr. The mixture was concentrated at 40 °C to give 1-(4-fluorophenyl)-4- hydrazino-pyrrolidin-2-one (405 mg, 1.58 mmol, 80.9% yield, 81.8% purity) as a yellow solid. MS: product: m / z 209.8 (M+H)+. A mixture of 1-(4-fluorophenyl)-4-hydrazino-pyrrolidin-2-one (405 mg, 1.94 mmol, 1.00 eq) and ethyl 4-cyclopropyl-3-oxo-butanoate (331 mg, 1.94 mmol, 1.00 eq) in MeOH (10.0 mL) was degassed and purged with N2 for 3 times. Then the mixture was stirred at 65 °C for 3 hr under N2 atmosphere. The mixture was filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was triturated with MeOH (20.0 mL) at 20 ~ 25 °C for 0.5 hr and filtered. The filtrate was concentrated under reduced pressure to give 4-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]-1-(4- fluorophenyl)pyrrolidin-2-one (241 mg, 648 μmol, 33.5% yield, 84.8% purity) as a yellow solid. MS: product: m / z 315.9 (M+H)+. To a solution of 4,5-dimethylthiazol-2-amine (98.0 mg, 764 μmol, 1.00 eq) in HCl (1.01 mL, 9.94 mmol, 35.0% purity) was added dropwise a solution of NaNO2 (53.0 mg, 764 μmol, 1.00 eq) in H2O (1.00 mL) at 0 ~ 5 °C. The resulting mixture was stirred at 0 ~ 5 °C for 0.5 hr. The mixture of 4,5-dimethyl- 2-[BLAH(nitrido)-λ5-azanyl]thiazole in H2O was used directly as theory amount in next step without work- up. To a solution of 4-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]-1-(4-fluorophenyl)pyrrolidin-2- one (240 mg, 761 μmol, 1.00 eq)in EtOH (1.00 mL) was added NaOH in H2O (2.50 M, 760 uL, 2.50 eq). The mixture was stirred at 15 ~ 20 °C for 0.5 hr. The mixture of [5-(cyclopropylmethyl)-2-[1-(4- fluorophenyl)-5-oxo-pyrrolidin-3-yl]pyrazol-3-yl]oxysodium in EtOH / H2O was used as theory amount in next step without work-up. The solution of 4,5-dimethyl-2-[BLAH(nitrido)-λ5-azanyl]thiazole (133 mg, 761 μmol, 1.00 eq, in H2O) was added dropwise to the mixture of [5-(cyclopropylmethyl)-2-[1-(4-fluorophenyl)-5-oxo-pyrrolidin- 3-yl]pyrazol-3-yl]oxysodium (256 mg, 761 μmol, 1.00 eq, in EtOH / H2O) at 0 ~ 5 °C. After complete addition, the mixture was stirred for 2 hr at 15 ~ 25 °C. The mixture was added H2O (10.0 mL) and Ethyl acetate (20.0 mL). The organic layer was separated, washed with brine, dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by prep- HPLC (column: Phenomenex Luna C18200 * 40mm * 10um; mobile phase: [water(HCl) - ACN]; B%: 53% - 83%, 10 min). The eluent was lyophilized to give (4Z)-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2- yl)hydrazono]-2-[1-(4-fluorophenyl)-5-oxo-pyrrolidin-3-yl]pyrazol-3-one (76.1 mg, 161 μmol, 21.2% yield, 96.4% purity) as a red solid. MS: product: m / z 455.3 (M+H)+;1H NMR (400 MHz): CDCl3δ: 7.57 (dd, J = 9.1, 4.8 Hz, 2H), 7.08 (t, J = 8.7 Hz, 2H), 5.16 (tt, J = 8.1, 6.1 Hz, 1H), 4.11 - 4.17 (m, 1H), 4.03 (dd, J = 10.0, 5.3 Hz, 1H), 3.00-3.08 (m, 1H), 2.92 - 3.00 (m, 1H), 2.50 (d, J = 7.0 Hz, 2H), 2.33 (s, 3H), 2.28 (s, 3H), 1.04 (s, 1H), 0.51 - 0.60 (m, 2H), 0.24 - 0.32 (m, 2H).19F NMR (400 MHz): CDCl3 δ: -116.94 (s, 1F). Example 4: Synthesis of Compound 3; (4Z)-2-[1-(benzenesulfonyl)pyrrolidin-3-yl]-5- (cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]pyrazol-3-one To a solution of tert-butyl 3-bromopyrrolidine-1-carboxylate (2.00 g, 8.00 mmol, 1.00 eq) in EtOH (20.0 mL) was added NH2NH2.H2O (4.71 g, 80.0 mmol, 4.57 mL, 85.0% purity, 10.0 eq) dropwise. The mixture was stirred at 80 °C for 16 hr. The reaction mixture was concentrated to dryness. The residue was diluted with an aqueous solution of NaCl (50.0 mL) and extracted with EtOAc (50.0 mLx2). The combined organic layers were dried over Na2SO4and concentrated to give crude product tert-butyl 3- hydrazinopyrrolidine-1-carboxylate (1.15 g, crude) as a yellow oil. MS: product: m / z 202.3 (M+H)+. To a solution of tert-butyl 3-hydrazinopyrrolidine-1-carboxylate (1.15 g, 5.71 mmol, 1.00 eq) in dioxane (10.0 mL) was added ethyl 4-cyclopropyl-3-oxo-butanoate (1.07 g, 6.29 mmol, 1.10 eq) and AcOH (34.3 mg, 571 μmol, 32.7 uL, 0.100 eq).The mixture was stirred at 100 °C for1 hr. The reaction mixture was concentrated to dryness. The residue was purified by prep-HPLC (Waters xbridge 150*25mm 10um;mobile phase: [water( NH4HCO3)-ACN];B%: 22%-52%,10min) to give tert-butyl 3-[3- (cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]pyrrolidine-1-carboxylate (423 mg, 1.35 mmol, 23.6% yield, 98.1% purity) as a yellow solid. MS: product: m / z 308.1 (M+H)+. To the mixture of tert-butyl 3-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]pyrrolidine-1- carboxylate (423 mg, 1.38 mmol, 1.00 eq) in EtOH (10.0 mL) was added NaOH in H2O (2.50 M, 1.38 mL, 2.50 eq) at 20°C. The mixture was stirred at 20 °C for 0.5 hr to give a clear solution. The product of [2-(1- tert-butoxycarbonylpyrrolidin-3-yl)-5-(cyclopropylmethyl)pyrazol-3-yl]oxysodium in EtOH / H2O as a light yellow liquid was used into the next step without further purification. To a mixture of 4,5-dimethylthiazol-2-amine (148 mg, 1.15 mmol, 1.00 eq) in HCl (1.20 g, 11.5 mmol, 1.18 mL, 35.0% purity, 10.0 eq) was added a solution of NaNO2(79.7 mg, 1.15 mmol, 1.00 eq) in H2O (2.00 mL) dropwise at 0 °C . The mixture was stirred at 0 °C for 0.5 hr. The product of 4,5- dimethylthiazole-2-diazonium chloride in H2O as a yellow liquid was used into the next step without urther purification. A solution of 4,5-dimethylthiazole-2-diazonium chloride (201 mg, 1.15 mmol, 1.00 eq in water) was added dropwise to the solution of [2-(1-tert-butoxycarbonylpyrrolidin-3-yl)-5- (cyclopropylmethyl)pyrazol-3-yl]oxysodium (453 mg, 1.38 mmol, 1.20 eq) at 0 °C. After complete addition, the mixture was stirred at 0 °C for 1 hr. The mixture was diluted with water (30.0 mL).The aqueous layer was extracted with DCM (30.0 mL) twice. The combined organic layers were concentrated to dryness. The residue was purified by prep-HPLC (Phenomenex luna C18150*25mm* 10um;mobile phase: [water(FA)-ACN];B%: 66%-96%) to give tert-butyl 3-[(4Z)-3-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2- yl)hydrazono]-5-oxo-pyrazol-1-yl]pyrrolidine-1-carboxylate (235 mg, 526 μmol, 45.9% yield, 100% purity) as a red solid. MS: product: m / z 447.1 (M+H)+. To a solution of tert-butyl 3-[(4Z)-3-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-5- oxo-pyrazol-1-yl]pyrrolidine-1-carboxylate (235 mg, 526 μmol, 1.00 eq) in DCM (5.00 mL) was added TFA (1.20 g, 10.5 mmol, 779 uL, 20.0 eq) .The mixture was stirred at 25 °C for 1 hr. The mixture was concentrated to give crude product (4E)-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-2- pyrrolidin-3-yl-pyrazol-3-one (467 mg, crude) as a red solid. MS: product: m / z 347.1 (M+H)+. To a solution of benzenesulfonyl chloride (129 mg, 732 μmol, 93.7 uL, 0.80 eq) in THF (10.0 mL) was added dropwise TEA (370 mg, 3.66 mmol, 509 uL, 4.00 eq) at 0°C. After addition, (4Z)-5- (cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-2-pyrrolidin-3-yl-pyrazol-3-one (317 mg, 915 μmol, 1.00 eq) in THF (2.00 mL) was added dropwise at 0°C. The resulting mixture was stirred at 25 °C for 1 hr. The mixture was concentrated to give a residue. The residue was purified by prep-HPLC (Phenomenex luna C18 (250*70mm,15 um);mobile phase: [water(FA)-ACN];B%: 60%-90%) to give (4Z)- 2-[1-(benzenesulfonyl)pyrrolidin-3-yl]-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2- yl)hydrazono]pyrazol-3-one (150 mg, 304 μmol, 33.2% yield, 98.5% purity) as a red solid. MS: product: m / z 487.6 (M+H)+.1H NMR (400 MHz): CDCl3δ ppm 7.86 - 7.84 (m, 2 H), 7.61 - 7.58 (m, 1 H), 7.55 - 7.50 (m, 2 H), 4.76 - 4.69 (m, 1 H), 3.66 (dd, J=7.60, 7.20 Hz, 1 H), 3.53 - 3.44 (m, 3 H), 2.34 (d, J=6.80 Hz, 2 H), 2.31 (s, 3 H), 2.26 - 2.21 (m, 4 H), 2.16 - 2.09 (m, 1 H), 0.97 - 0.90 (m, 1 H), 0.54 - 0.49 (m, 2 H), 0.24 - 0.20 (m, 2 H). Example 5: Synthesis of Compound 4; (Z)-1-(1-(bicyclo[2.2.1]heptan-2-yl)-5-oxopyrrolidin-3-yl)-3- (cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazono)-1H-pyrazol-5(4H)-one To a solution of norbornan-2-amine (500 mg, 3.39 mmol, 1.00 eq, HCl) in HCl in H2O (1.00 M, 4.06 mL, 1.20 eq) at 40 °C and pH = 1, then 2,5-dimethoxy-2,5-dihydrofuran (470 mg, 3.61 mmol, 1.07 eq) was added. The resulting mixture was stirred at 40 °C for 10 min. The reaction mixture was cooled to 25 °C. The mixture was added DCM (10.0 mL) and slowly added saturated NaHCO3aqueous to pH = 7. The reaction mixture was stirred for 10 min, extracted with DCM (10.0 mL x 3). The combined organic phase was dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was concnetrated to give1-norbornan-2-yl-2H-pyrrol-5-one (610 mg, crude) as yellow oil. The crude product was used as theory amount in next step without further purification. MS: product: m / z 178.1 (M+H)+. A mixture of 1-norbornan-2-yl-2H-pyrrol-5-one (600 mg, 3.39 mmol, 1.00 eq) , NH2NH2.H2O (3.99 g, 67.7 mmol, 3.86 mL, 85.0% purity, 20.0 eq) in i-PrOH (10.0 mL) was degassed and purged with N2 for 3 times. The mixture was stirred at 80 °C for 12hr under N2atmosphere. The mixture was concentrated to give a residue. The residue was concentrated to give 4-hydrazino-1-norbornan-2-yl-pyrrolidin-2-one (710 mg, crude) as yellow oil. The crude product was used as theory amount in next step without further purification. MS: product: m / z 210.1 (M+H)+. A mixture of 4-hydrazino-1-norbornan-2-yl-pyrrolidin-2-one (700 mg, 3.34 mmol, 1.00 eq), ethyl 4- cyclopropyl-3-oxo-butanoate (797 mg, 4.68 mmol, 1.40 eq) in i-PrOH (10.0 mL) was degassed and purged with N2 for 3 times. And then the mixture was stirred at 70 °C for 1hr under N2 atmosphere. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0~10% MeOH / DCM @ 60 mL / min) to give 4-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]-1-norbornan-2-yl- pyrrolidin-2-one (390 mg, 1.24 mmol, 36.9% yield) as a yellow solid. MS: product: m / z 316.1 (M+H)+. To a solution of 4-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]-1-norbornan-2-yl-pyrrolidin-2-one (390 mg, 1.24 mmol, 1.00 eq) in EtOH (2.00 mL) was added NaOH in H2O (2.50 M, 1.24 mL, 2.50 eq). The mixture was stirred at 25 °C for 0.5 hr. The product of sodium 1-(1-(bicyclo[2.2.1]heptan-2-yl)-5- oxopyrrolidin-3-yl)-3-(cyclopropylmethyl)-1H-pyrazol-5-olate in EtOH / water as a yellow solution was used in next step without further purification. To a solution of 4,5-dimethylthiazol-2-amine (200 mg, 1.56 mmol, 1.00 eq) in aqueous HCl (6.00 M, 2.86 mL, 11.0 eq) was cooled to 0°C. A solution of NaNO2 (96.8 mg, 1.40 mmol, 0.900 eq) in H2O (1.00 mL) was added dropwise. The mixture was stirred at 0 °C for 0.5 h. The product of 4,5-dimethylthiazole-2- diazonium chloride in water as a yellow solution was used in next step without further purification. The solution of [5-(cyclopropylmethyl)-2-(1-norbornan-2-yl-5-oxo-pyrrolidin-3-yl)pyrazol-3- yl]oxysodium (418 mg, 1.24 mmol, 1.00 eq, in EtOH / H2O) was added dropwise 4,5-dimethylthiazole-2- diazonium;chloride (274 mg, 1.56 mmol, 1.26 eq, in H2O) at 0 °C. After complete addition, the mixture was stirred for 0.5hr at 25°C. The reaction mixture was extracted with DCM (10.0 mLx3). The combined organic layers were washed with brine (10.0 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18150*25mm* 10um;mobile phase: [water(FA)-ACN];gradient:0%-30% B over 10 min) to give (4Z)-5- (cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-2-(1-norbornan-2-yl-5-oxo-pyrrolidin-3- yl)pyrazol-3-one (18.6 mg, 40.9 μmol, 3.30% yield) as a red solid. MS: product: m / z 455.1 (M+H)+.1H NMR (400 MHz, CHLOROFORM-d) δ = 5.12 - 4.94 (m, 1H), 4.22 - 4.12 (m, 1H), 3.88 - 3.56 (m, 2H), 2.95 - 2.62 (m, 3H), 2.53 - 2.46 (m, 2H), 2.32 (s, 3H), 2.26 (s, 3H), 1.87 (tt, J = 3.6, 12.4 Hz, 1H), 1.66 - 1.42 (m, 4H), 1.39 - 1.18 (m, 4H), 1.11 - 0.98 (m, 1H), 0.58 - 0.51 (m, 2H), 0.30 - 0.24 (m, 2H). Example 6: Alternative Synthesis of Compound 4; (Z)-1-(1-(bicyclo[2.2.1]heptan-2-yl)-5- oxopyrrolidin-3-yl)-3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazono)-1H-pyrazol- 5(4H)-one To a solution of norbornan-2-amine (500 mg, 3.39 mmol, 1.00 eq, HCl) in HCl in H2O (1.00 M, 4.06 mL, 1.20 eq) at 40 °C and pH = 1, then 2,5-dimethoxy-2,5-dihydrofuran (470 mg, 3.61 mmol, 1.07 eq) was added. The resulting mixture was stirred at 40 °C for 10 min. The reaction mixture was cooled to 25 °C. The mixture was added DCM (10.0 mL) and slowly added saturated NaHCO3aqueous to pH = 7. The reaction mixture was stirred for 10 min, extracted with DCM (10.0 mL x 3). The combined organic phase was dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was concnetrated to give1-norbornan-2-yl-2H-pyrrol-5-one (610 mg, crude) as yellow oil. The crude product was used as theory amount in next step without further purification. MS: product: m / z 178.1 (M+H)+. A mixture of 1-norbornan-2-yl-2H-pyrrol-5-one (600 mg, 3.39 mmol, 1.00 eq) , NH2NH2.H2O (3.99 g, 67.7 mmol, 3.86 mL, 85.0% purity, 20.0 eq) in i-PrOH (10.0 mL) was degassed and purged with N2for 3 times. The mixture was stirred at 80 °C for 12hr under N2atmosphere. The mixture was concentrated to give a residue. The residue was concentrated to give 4-hydrazino-1-norbornan-2-yl-pyrrolidin-2-one (710 mg, crude) as yellow oil. The crude product was used as theory amount in next step without further purification. MS: product: m / z 210.1 (M+H)+. A mixture of 4-hydrazino-1-norbornan-2-yl-pyrrolidin-2-one (700 mg, 3.34 mmol, 1.00 eq), ethyl 4- cyclopropyl-3-oxo-butanoate (797 mg, 4.68 mmol, 1.40 eq) in i-PrOH (10.0 mL) was degassed and purged with N2 for 3 times. And then the mixture was stirred at 70 °C for 1hr under N2 atmosphere. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0~10% MeOH / DCM @ 60 mL / min) to give 4-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]-1-norbornan-2-yl- pyrrolidin-2-one (390 mg, 1.24 mmol, 36.9% yield) as a yellow solid. MS: product: m / z 316.1 (M+H)+. To a solution of 4-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]-1-norbornan-2-yl-pyrrolidin-2-one (390 mg, 1.24 mmol, 1.00 eq) in EtOH (2.00 mL) was added NaOH in H2O (2.50 M, 1.24 mL, 2.50 eq). The mixture was stirred at 25 °C for 0.5 hr. The product of sodium 1-(1-(bicyclo[2.2.1]heptan-2-yl)-5- oxopyrrolidin-3-yl)-3-(cyclopropylmethyl)-1H-pyrazol-5-olate in EtOH / water as a yellow solution was used in next step without further purification. To a solution of 4,5-dimethylthiazol-2-amine (200 mg, 1.56 mmol, 1.00 eq) in aqueous HCl (6.00 M, 2.86 mL, 11.0 eq) was cooled to 0°C. A solution of NaNO2 (96.8 mg, 1.40 mmol, 0.900 eq) in H2O (1.00 mL) was added dropwise. The mixture was stirred at 0 °C for 0.5 h. The product of 4,5-dimethylthiazole-2- diazonium chloride in water as a yellow solution was used in next step without further purification. The solution of [5-(cyclopropylmethyl)-2-(1-norbornan-2-yl-5-oxo-pyrrolidin-3-yl)pyrazol-3- yl]oxysodium (418 mg, 1.24 mmol, 1.00 eq, in EtOH / H2O) was added dropwise 4,5-dimethylthiazole-2- diazonium;chloride (274 mg, 1.56 mmol, 1.26 eq, in H2O) at 0 °C. After complete addition, the mixture was stirred for 0.5hr at 25°C. The reaction mixture was extracted with DCM (10.0 mLx3). The combined organic layers were washed with brine (10.0 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18150*25mm* 10 μm;mobile phase: [water(FA)-ACN];gradient:0%-30% B over 10 min) to give (4Z)-5- (cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-2-(1-norbornan-2-yl-5-oxo-pyrrolidin-3- yl)pyrazol-3-one (18.6 mg, 40.9 μmol, 3.30% yield) as a red solid. MS: product: m / z 455.1 (M+H)+.1H NMR (400 MHz, CHLOROFORM-d) δ = 5.12 - 4.94 (m, 1H), 4.22 - 4.12 (m, 1H), 3.88 - 3.56 (m, 2H), 2.95 - 2.62 (m, 3H), 2.53 - 2.46 (m, 2H), 2.32 (s, 3H), 2.26 (s, 3H), 1.87 (tt, J = 3.6, 12.4 Hz, 1H), 1.66 - 1.42 (m, 4H), 1.39 - 1.18 (m, 4H), 1.11 - 0.98 (m, 1H), 0.58 - 0.51 (m, 2H), 0.30 - 0.24 (m, 2H). Example 7: Synthesis of Compound 193 and Compound 5; (R,Z)-5-(cyclopropylmethyl)-4-(2-(4,5- dimethylthiazol-2-yl)hydrazineylidene)-2-(1-(4-fluorobenzyl)-5-oxopyrrolidin-3-yl)-2,4-dihydro-3H- pyrazol-3-one; (S,Z)-5-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-2-(1-(4- fluorobenzyl)-5-oxopyrrolidin-3-yl)-2,4-dihydro-3H-pyrazol-3-one (Z)-5-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-2-(1-(4-fluorobenzyl)-5- oxopyrrolidin-3-yl)-2,4-dihydro-3H-pyrazol-3-one (380 mg, 811 μmol, 1.00 eq) was further separated by SFC (column: DAICEL CHIRALPAK AD(250mm*30mm,10um);mobile phase: [0.1%NH3H2O ETOH];B%:40%, isocratic elution mode). The SFC eluents was lyophilized to give two residues. The crude product 1 was purified by reversed-phase HPLC (column: Waters xbridge 150*25mm 10um;mobile phase: [water( NH4HCO3)-ACN];B%: 25%-55%,15min) to give (R,Z)-5-(cyclopropylmethyl)- 4-(2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-2-(1-(4-fluorobenzyl)-5-oxopyrrolidin-3-yl)-2,4-dihydro-3H- pyrazol-3-one (36.9 mg, 75.5 μmol, 9.31% yield, 95.9% purity) as a yellow solid. MS: product: 469.3 m / z (M+H)+.1H NMR (400 MHz, CHLOROFORM-d) δ = 7.28 (br s, 1H), 7.25 (d, J = 5.6 Hz, 1H), 7.05 - 6.98 (m, 2H), 5.04 - 4.96 (m, 1H), 4.61 - 4.54 (m, 1H), 4.45 - 4.38 (m, 1H), 3.58 (dd, J = 8.0, 10.0 Hz, 1H), 3.42 (dd, J = 4.8, 10.4 Hz, 1H), 2.88 - 2.79 (m, 2H), 2.50 - 2.44 (m, 2H), 2.32 (s, 3H), 2.24 (s, 3H), 1.08 - 0.96 (m, 1H), 0.59 - 0.51 (m, 2H), 0.31 - 0.23 (m, 2H).19F NMR (376 MHz, CHLOROFORM-d) δ = -114.752 (s, 1F). The crude product 2 was purified by reversed-phase HPLC (column: Waters xbridge 150*25mm 10um;mobile phase: [water( NH4HCO3)-ACN];B%: 26%-56%,10min) to give (S,Z)-5-(cyclopropylmethyl)- 4-(2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-2-(1-(4-fluorobenzyl)-5-oxopyrrolidin-3-yl)-2,4-dihydro-3H- pyrazol-3-one (42.0 mg, 85.8 μmol, 10.6% yield, 95.7% purity) as a yellow solid. MS: product: 469.1 m / z (M+H)+.1H NMR (400 MHz, CHLOROFORM-d) δ = 7.30 - 7.27 (m, 1H), 7.26 - 7.24 (m, 1H), 7.05 - 6.98 (m, 2H), 5.01 (ddt, J = 4.8, 6.4, 8.0 Hz, 1H), 4.61 - 4.53 (m, 1H), 4.46 - 4.37 (m, 1H), 3.58 (dd, J = 8.0, 10.0 Hz, 1H), 3.42 (dd, J = 4.8, 10.4 Hz, 1H), 2.86 - 2.81 (m, 2H), 2.47 (d, J = 7.2 Hz, 2H), 2.32 (s, 3H), 2.25 (s, 3H), 1.06 - 0.97 (m, 1H), 0.58 - 0.52 (m, 2H), 0.31 - 0.24 (m, 2H).19F NMR (376 MHz, CHLOROFORM-d) δ = -114.752 (s, 1F). Example 8: Synthesis of Compound 6; (Z)-2-(1-benzyl-5-oxopyrrolidin-3-yl)-5-(cyclopropylmethyl)- 4-(2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-2,4-dihydro-3H-pyrazol-3-one (BKX-908) To a solution of Phenylmethanamine (1.00 g, 9.33 mmol, 1.02 mL, 1.00 eq) in H2O (10.0 mL) was added HCl (971 mg, 9.33 mmol, 952 uL, 35.0% purity, 1.00 eq) at 25 °C and PH = 1. The solution was kept at 40 °C and 2,5-dimethoxy-2,5-dihydrofuran (1.34 g, 10.3 mmol, 1.10 eq) was added. The resulting mixture was stirred at 40 °C for 0.5 h. The reaction mixture was cooled to 25 °C. The mixture was added DCM (100 mL) and slowly added saturated aqueous Na2HPO4solution to pH = 7. The reaction mixture was extracted with DCM (10.0 mL). The combined organic phase was washed with H2O (10 mL x 2), brine (20 mL), dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure to give a crude 1-benzyl-2H-pyrrol-5-one (1.04 g, crude) as a black brown oil. It was used in next step without further purification. MS: product: m / z 173.9 (M+H)+.1H NMR (400 MHz, CHLOROFORM-d) δ = 7.25 - 7.18 (m, 5H), 7.08 - 6.97 (m, 2H), 4.61 (s, 2H), 3.85 (t, J = 1.6 Hz, 2H). To a solution of 1-benzyl-2H-pyrrol-5-one (1.00 g, 5.77 mmol, 1.00 eq) in EtOH (10.0 mL) was added NH2NH2.H2O (6.48 g, 129 mmol, 6.29 mL, 22.4 eq) at 20 °C. The mixture was stirred at 80 °C for 2 h. The mixture was concentrated at 40 °C to give a crude 1-benzyl-4-hydrazino-pyrrolidin-2-one (1.10 g, crude) as a yellow solid. It was used in next step without further purification. MS: product: m / z 205.8 (M+H)+. To a solution of 1-benzyl-4-hydrazino-pyrrolidin-2-one (1.10 g, 5.36 mmol, 1.00 eq) in EtOH (10.0 mL) was added ethyl 4-cyclopropyl-3-oxo-butanoate (912 mg, 5.36 mmol, 1.00 eq) at 20 °C. The mixture was stirred at 80 °C for 2 h. The reaction mixture was concentrated directly. The residue was purified by flash silica gel chomatography (ISCO®; 4 g SepaFlash® Silica Flash Column, Eluent of 0~10% Methanol / Dichloromethane@ 30 mL / min) to give 1-benzyl-4-(3-(cyclopropylmethyl)-5-hydroxy-1H-pyrazol-1- yl)pyrrolidin-2-one (1.08 g, 1.91 mmol, 35.6% yield, 55.0% purity) as a black brown oil. MS: product: m / z 312.1 (M+H)+. To a solution of 1-benzyl-4-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]pyrrolidin-2-one (970 mg, 3.12 mmol, 1.00 eq) in EtOH (10.0 mL) was added NaOH in water (2.50 M, 3.12 mL, 2.50 eq). The mixture was stirred at 20 °C for 0.5 h. The product of sodium 1-(1-benzyl-5-oxopyrrolidin-3-yl)-3- (cyclopropylmethyl)-1H-pyrazol-5-olate in EtOH / water as a yellow solution was used in next step without further purification. To a solution of 4,5-dimethylthiazol-2-amine (400 mg, 3.12 mmol, 1.00 eq) in HCl (4.29 g, 41.1 mmol, 4.21 mL, 35.0% purity, 13.2 eq) was added a solution of NaNO2 (215 mg, 3.12 mmol, 1.00 eq) in H2O (4 mL) at 0 °C. The mixture was stirred at 0 °C for 0.5 h. The product of 4,5-dimethylthiazole-2- diazonium chloride in water as a yellow solution was used in next step without further purification. The solution of 4,5-dimethylthiazole-2-diazonium chloride (548 mg, 3.12 mmol, 1.00 eq, in water) was added to the solution of sodium 1-(1-benzyl-5-oxopyrrolidin-3-yl)-3-(cyclopropylmethyl)-1H-pyrazol-5- olate (1.04 g, 3.12 mmol, 1.00 eq, in EtOH / H2O) at 0 °C. The resulting mixture was stirred at 20 °C for 1 h. The reaction mixture was extracted with DCM (10.0 mL x 3). The combined organic phase was washed with H2O (10.0 mL x 2), brine (20.0 mL), dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC ([water (FA)-ACN]; B%: 55%-85%, 58 min) to give (Z)-2-(1-benzyl-5-oxopyrrolidin-3-yl)-5-(cyclopropylmethyl)-4- (2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-2,4-dihydro-3H-pyrazol-3-one as a red solid. MS: product:m / z 451.5 (M+H)+. 1H NMR (400 MHz, CHLOROFORM-d) δ = 7.37 - 7.31 (m, 2H), 7.30 - 7.27 (m, 3H),5.05 - 4.95 (m, 1H), 4.58 - 4.48 (m, 2H), 3.61 - 3.54 (m, 1H), 3.44 (dd, J = 4.8, 10.4 Hz, 1H), 2.90 - 2.78 (m, 2H), 2.49 - 2.47 (d, J = 6.8, 2H), 2.32 (s, 3H), 2.25 (s, 3H), 1.07 - 0.99 (m, 1H), 0.58 - 0.50 (m, 2H), 0.31 - 0.23 (m, 2H). Example 9: Synthesis of Compound 7; (Z)-5-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2- yl)hydrazineylidene)-2-(3-phenylcyclobutyl)-2,4-dihydro-3H-pyrazol-3-one To a solution of 3-phenylcyclobutan-1-one (2.00 g, 13.7 mmol, 1.00 eq) in MeOH (30.0 mL) was added tert-butyl hydrazinecarboxylate (2.17 g, 16.4 mmol, 1.20 eq). The mixture was stirred at 25 °C for 1 h. NaBH3CN (2.58 g, 41.0 mmol, 3.00 eq) and AcOH (2.46 g, 41.0 mmol, 2.35 mL, 3.00 eq) was added to the mixture. The resulting mixture was stirred at 25 °C for 16 h. The mixture was adjusted pH ~ 7 by saturated NaHCO3, extracted with DCM (50.0 mL x 3). The combined organic was washed with brine (50.0 x 2), dried over Na2SO4, filtered. The filtrate was concentrated to give a residue. The residue was purified by flash silica gel chromatography (SiO2, DCM:MeOH=20:1) to give tert-butyl 2-(3- phenylcyclobutyl)hydrazine-1-carboxylate (3.12 g, 11.9 mmol, 86.9% yield, N / A purity) as a colorless oil. MS: product: m / z 207.1 (M+H)+.1H NMR (400 MHz): CDCl3δ 7.35 - 7.28 (m, 2H), 7.27 - 7.15 (m, 3H), 3.77 - 3.57 (m, 1H), 3.25 - 3.02 (m, 1H), 2.59 - 2.45 (m, 1H), 2.36 - 2.20 (m, 2H), 2.16 - 1.98 (m, 1H), 1.49 (s, 9H). To a solution of tert-butyl 2-(3-phenylcyclobutyl)hydrazine-1-carboxylate (1.50 g, 5.72 mmol, 1.00 eq) in DCM (25.0 mL) was added dropwise HCl / dioxane (4.00 M, 10.0 mL, 7.00 eq). The mixture was stirred at 25 °C for 3 h. The mixture was concentrated to give a crude (3-phenylcyclobutyl)hydrazine (1.23 g, crude, HCl) as a colorless oil was used in next step without further purification. MS: product: m / z 163.1 (M+H)+. To a solution of (3-phenylcyclobutyl)hydrazine (1.00 g, 5.03 mmol, 1.00 eq, HCl) in EtOH (10.0 mL) was added ethyl 4-cyclopropyl-3-oxobutanoate (857 mg, 5.03 mmol, 1.00 eq). The mixture was stirred at 80 °C for 1 h. The mixture was concentrated to give a residue. The residue was purified by flash silica gel chromatography (eluent of 0 ~ 10% MeOH in DCM gradient) to give 3-(cyclopropylmethyl)- 1-(3-phenylcyclobutyl)-1H-pyrazol-5-ol (1.16 g, 3.67 mmol, 72.9% yield, 84.9% purity) as a brown oil. MS: product: m / z 269.1 (M+H)+. To a solution of 3-(cyclopropylmethyl)-1-(3-phenylcyclobutyl)-1H-pyrazol-5-ol (200 mg, 745 μmol, 1.00 eq) in EtOH (0.60 mL) was added a solution of NaOH (2.50 M in water, 745 μL, 2.50 eq) 25 °C. The mixture was stirred at 25 °C for 0.5 h. The product of sodium 3-(cyclopropylmethyl)-1-(3- phenylcyclobutyl)-1H-pyrazol-5-olate in EtOH / water as a brown solution was used in next step without further purification. To a solution of 4,5-dimethylthiazol-2-amine (95.5 mg, 745 μmol, 1.00 eq) in HCl (996 mg, 9.84mmol, 977 μL 36.0% purity, 13.2 eq) was added a solution of NaNO2(51.4 mg, 745 μmol, 1.00 eq) in H2O(0.60 mL) 0 °C. The mixture was stirred at 0 °C for 0.5 h. The product of 4,5-dimethylthiazole-2- diazonium chloride in water as a brown solution was used in next step without further purification. The solution of 4,5-dimethylthiazole-2-diazonium chloride (131 mg, 745 μmol, 1.00 eq, in water) was added dropwise to the sodium 3-(cyclopropylmethyl)-1-(3-phenylcyclobutyl)-1H-pyrazol-5-olate (216 mg, 745 μmol, 1.00 eq, in EtOH / H2O) at 0 °C. The resulting mixture was stirred at 25 °C for 1 h to give a red solution. The mixture was extracted with DCM (20.0 mL x 3). The combined organic was washed with brine (50.0 mL x 2), dried over Na2SO4, filtered. The filtrate was concentrated to give a crude product. The crude product was purified by reversed-phase HPLC (C18, 20 – 45 um, 100 A, 40.0 g, eluent of 60 ~ 90% MeCN in water with 0.1% FA condition, over 10 min) to give (Z)-5-(cyclopropylmethyl)- 4-(2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-2-(3-phenylcyclobutyl)-2,4-dihydro-3H-pyrazol-3-one (6.80 mg, 16.1 μmol, 2.16% yield, 96.5% purity) as a red solid. MS: product: m / z 408.5 (M+H)+.1H NMR (400 MHz): CDCl3δ 7.37 - 7.32 (m, 4H), 7.26 - 7.20 (m, 1H), 5.06 - 4.74 (m, 1H), 3.76 - 3.22 (m, 1H), 3.04 - 2.97 (m, 1H), 2.74 - 2.69 (m, 1H), 2.60 - 2.49 (m, 4H), 2.32 (s, 3H), 2.26 (s, 3H), 1.15 - 1.06 (m, 1H), 0.60 - 0.53 (m, 2H), 0.35 - 0.29 (m, 2H). Example 10: Synthesis of Compound 8; (Z)-5-(cyclopropylmethyl)-2-(1-(4,4-difluorocyclohexane-1- carbonyl)pyrrolidin-3-yl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-2,4-dihydro-3H-pyrazol-3- one To a solution of (4Z)-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-2-pyrrolidin-3- yl-pyrazol-3-one (185 mg, 534 μmol, 1.00 eq) and 4,4-difluorocyclohexanecarboxylic acid (87.7 mg, 534 μmol, 1.00 eq) in DMF (2.00 mL) was added HATU (244 mg, 641 μmol, 1.20 eq) and DIEA (276 mg, 2.14 mmol, 372 uL, 4.00 eq). The mixture was stirred at 25 °C for 20 min. The mixture was concentrated to give a residue. The crude product was purified by reversed-phase HPLC (0.05% FA condition) to give (4Z)-5-(cyclopropylmethyl)-2-[1-(4,4-difluorocyclohexanecarbonyl)pyrrolidin-3-yl]-4-[(4,5-dimethylthiazol-2- yl)hydrazono]pyrazol-3-one (39.0 mg, 78.1 μmol, 14.6% yield, 98.6% purity) as a red solid. MS: m / z 493.2 (M+H)+.1H NMR (400 MHz): CDCl3 δ 4.94 - 4.86 (m, 1H), 3.82 - 3.80 (m, 1H), 3.78 - 3.75 (m, 2H), 3.51 - 3.51 (m, 1H), 2.46 (t, J = 8.0 Hz 3H), 2.45- 2.31 (m, 5H), 2.25 - 2.21 (m, 5H), 1.89 - 1.80 (m, 6H), 1.04 - 1.01 (m, 1H), 0.55- 0.52 (m, 2H), 0.27 - 0.25 (m, 2H).19F NMR (400 MHz): CDCl3δ -92.40 (d, J=249.2 Hz), -100.73 (d, J=249.2 Hz). Example 11: Synthesis of Compound 9; (Z)-5-(cyclopropylmethyl)-2-(1-(4,4-difluorocyclohexyl)-5- oxopyrrolidin-3-yl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-2,4-dihydro-3H-pyrazol-3-one The solution of 2,5-dimethoxy-2,5-dihydrofuran (1.06 g, 8.14 mmol, 1.10 eq) in HCl (1.00 M, 7.40 mL, 35% purity, 1.00 eq) at 25 °C (pH= 1). The solution was kept at 40 °C and 4,4- difluorocyclohexanamine (1.00 g, 7.40 mmol, 1.00 eq) was added. The resulting mixture was stirred at 40 °C for 30 min. The reaction mixture was cooled to 25 °C and was added DCM (100 mL) and slowly added saturated aqueousNa2HPO4solution to pH = 7. The reaction mixture was extracted with DCM (100 mL).The combined organic phase was washed with brine (100 mL x 2) dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure to give 1-(4,4-difluorocyclohexyl)-2H-pyrrol-5-one (1.5 g, crude) as a yellow solid. To a solution of 1-(4,4-difluorocyclohexyl)-2H-pyrrol-5-one (1.50 g, 7.45 mmol, 1.00 eq) in EtOH (10.0 mL) was added NH2NH2.H2O (8.78 g, 149 mmol, 8.53 mL, 85% purity, 20.0 eq) at 25 °C.The mixture was stirred at 80 °C for 2 hr . The mixture was concentrated at 40 °C to give 1-(4,4- difluorocyclohexyl)-4-hydrazino-pyrrolidin-2-one (2.00 g, crude) as a white solid. A mixture of 1-(4,4-difluorocyclohexyl)-4-hydrazino-pyrrolidin-2-one (100 mg, 429 μmol, 1.00 eq) and ethyl 4-cyclopropyl-3-oxo-butanoate (87.6 mg, 514 μmol, 1.20 eq) in EtOH (2.00 mL) was stirred at 25 °C for 16 hr. The mixture was diluted with water (10.0 mL) and extracted with DCM (20.0 mL x 2). The combined organic layers were washed with H2O (20.0 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give 4-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]-1-(4,4- difluorocyclohexyl)pyrrolidin-2-one (148 mg, crude) as a yellow oil. To a solution of 4-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]-1-(4,4- difluorocyclohexyl)pyrrolidin-2-one (148 mg, 435 μmol, 1.00 eq) in EtOH (1.00 mL) was added aqueous NaOH (2.50 M, 435 uL, 2.50 eq). The mixture was stirred at 15°C ~ 25 °C for 0.5 h. The product of [5- (cyclopropylmethyl)-2-[1-(4,4-difluorocyclohexyl)-5-oxo-pyrrolidin-3-yl]pyrazol-3-yl]oxysodium in EtOH / H2O as a light yellow liquid was used in the next step without further purification. To a solution of 4,5-dimethylthiazol-2-amine (110 mg, 858 μmol, 1.00 eq) in HCl (1.18 g, 11.3 mmol, 1.16 mL, 35% purity, 13.2 eq) was added NaNO2 (59.2 mg, 858 μmol, 1.00 eq) in H2O (1.00 mL) at 0 °C. The mixture was stirred for 1 hr at 0 ~ 5 °C. The product of 4,5-dimethylthiazole-2- diazonium;chloride in H2O as a yellow suspension was used in the next step without further purification. A solution of [5-(cyclopropylmethyl)-2-[1-(4,4-difluorocyclohexyl)-5-oxo-pyrrolidin-3-yl]pyrazol-3- yl]oxysodium (150 mg, 415 μmol, 1.00 eq, in EtOH / H2O) was added dropwise to the solution of 4,5- dimethyl-2-[BLAH(nitrido)-λ5-azanyl]thiazole (146 mg, 830 μmol, 2.00 eq, in H2O) at 0 °C. The resulting mixture was stirred at 25°C for 1 hr. The reaction mixture was filtered to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Luna C18150*25mm*10um;mobile phase: [water(FA)- ACN];B%: 53%-83%,8min) to give (4Z)-5-(cyclopropylmethyl)-2-[1-(4,4-difluorocyclohexyl)-5-oxo- pyrrolidin-3-yl]-4-[(4,5-dimethylthiazol-2-yl)hydrazono]pyrazol-3-one (56.4 mg, 116 μmol, 28.1% yield, 99% purity) as a red solid. MS: product: m / z 479.7 (M+H)+.1H NMR (400 MHz): CDCl3δ 5.05 - 4.96 (m, 1H), 4.23 - 4.13 (m, 1H), 3.66 (dd, J = 10.0, 8.0 Hz, 1H), 3.51 (dd, J = 10.0, 5.2 Hz, 1H), 2.79 - 2.74 (m, 2H), 2.47 (d, J = 7.2 Hz, 2H), 2.31 (s, 3H), 2.25 (s, 3H), 2.21 - 2.14 (m, 2H), 1.94 - 1.79 (m, 4H), 1.75 - 1.70 (m, 2H), 1.06 - 0.98 (m, 1H), 0.56 - 0.51 (m, 2H), 0.28 – 0.24 (m, 2H).19F NMR (400 MHz, CDCl3) δ - 93.53 (d, J = 252.4 Hz, 1 F), -102.83 (d, J = 252.0 Hz, 1 F). Example 12: Synthesis of Compound 10; (S,Z)-5-(cyclopropylmethyl)-2-(1-(4,4-difluorocyclohexyl)- 5-oxopyrrolidin-3-yl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-2,4-dihydro-3H-pyrazol-3-one To a solution of 4-(3-(cyclopropylmethyl)-5-hydroxy-1H-pyrazol-1-yl)-1-(4,4- difluorocyclohexyl)pyrrolidin-2-one (250 mg, 737 μmol, 1.00 eq) in EtOH (8.00 mL) was added NaOH in H2O (2.50 M, 737 uL, 2.50 eq). The mixture was stirred at 25 °C for 0.5 h. The product of sodium 3- (cyclopropylmethyl)-1-(1-(4,4-difluorocyclohexyl)-5-oxopyrrolidin-3-yl)-1H-pyrazol-5-olate in EtOH / H2O as a light yellow liquid was used in the next step without further purification. To a solution of 4,5-dimethylthiazol-2-amine (200 mg, 1.56 mmol, 1.00 eq) in HCl (2.15 g, 20.6 mmol, 2.10 mL, 35.0% purity, 13.2 eq) was added NaNO2 (108 mg, 1.56 mmol, 1.00 eq) in H2O (2.00 mL) at 0 °C. The mixture was stirred for 1 hr at 0 °C. The product of 4,5-dimethylthiazole-2-diazonium;chloride in H2O as a yellow suspension was used in the next step without further purification. A solution of sodium 3-(cyclopropylmethyl)-1-(1-(4,4-difluorocyclohexyl)-5-oxopyrrolidin-3-yl)-1H- pyrazol-5-olate (250 mg, 692 μmol, 1.00 eq, in EtOH / H2O) was added dropwise to the solution of 4,5- dimethylthiazole-2-diazonium;chloride (243 mg, 1.38 mmol, 2.00 eq, in H2O) at 0 °C. The resulting mixture was stirred at 25°C for 1 hr. The reaction mixture was filtered to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Luna C18150*25mm*10um;mobile phase: [water(FA)- ACN];B%: 47%-77%,min) to give (4Z)-5-(cyclopropylmethyl)-2-[1-(4,4-difluorocyclohexyl)-5-oxo-pyrrolidin- 3-yl]-4-[(4,5-dimethylthiazol-2-yl)hydrazono]pyrazol-3-one (68.1 mg, 139 μmol, 20.2% yield, 98.3% purity)as a red solid. MS: product: m / z 479.3 (M+H)+.1H NMR (400 MHz): CDCl3δ 5.09 - 4.93 (m, 1H), 4.24 -4.10 (m, 1H), 3.69 - 3.62 (m, 1H), 3.51 (dd, J = 10.0, 4.8 Hz, 1H), 2.82 - 2.70 (m, 2H), 2.46 (d, J = 7.2 Hz, 2H), 2.31 (s, 3H), 2.24 (s, 3H), 2.20 - 2.11 (m, 2H), 1.92 - 1.69 (m, 6H), 1.09 - 0.95 (m, 1H), 0.59 - 0.46 (m, 2H), 0.31 - 0.17 (m, 2H).19F NMR (400 MHz, CDCl3) δ -93.53 (d, J = 252.4 Hz, 1 F), -102.83 (d, J = 252.0 Hz, 1 F). The (4Z)-5-(cyclopropylmethyl)-2-[1-(4,4-difluorocyclohexyl)-5-oxo-pyrrolidin-3-yl]-4-[(4,5- dimethylthiazol-2-yl)hydrazono]pyrazol-3-one (146 mg, 305 μmol, 1.00 eq) was separated by SFC (column: DAICEL CHIRALPAK IC(250mm*30mm,10um);mobile phase: [IPA-ACN];B%: 70%- 70%,A7.5;60min) to give (R,Z)-5-(cyclopropylmethyl)-2-(1-(4,4-difluorocyclohexyl)-5-oxopyrrolidin-3-yl)-4- (2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-2,4-dihydro-3H-pyrazol-3-one (68.4 mg, 135 μmol, 44.4% yield, 94.7% purity) as a red solid MS: product: m / z 479.0 (M+H)+.1H NMR (400 MHz): CDCl3 δ 5.00 (s, 1H), 4.25 - 4.11 (m, 1H), 3.66 (s, 1H), 3.52 (s, 1H), 2.77 (s, 2H), 2.47 (d, J = 6.0 Hz, 2H), 2.31 (s, 3H), 2.25 (s, 3H), 2.16 (d, J = 0.9 Hz, 2H), 1.95 - 1.72 (m, 6H), 1.09 - 0.98 (m, 1H), 0.64 - 0.48 (m, 2H), 0.33 - 0.16 (m, 2H).19F NMR (400 MHz, CDCl3) δ -93.53 (d, J = 252.4 Hz, 1 F), -102.83 (d, J = 252.0 Hz, 1 F).and (S,Z)-5-(cyclopropylmethyl)-2-(1-(4,4-difluorocyclohexyl)-5-oxopyrrolidin-3-yl)-4-(2-(4,5- dimethylthiazol-2-yl)hydrazineylidene)-2,4-dihydro-3H-pyrazol-3-one (54.1 mg, 110 μmol, 36.2% yield, 97.7% purity) as a red solid MS: product: m / z 479.1 (M+H)+.1H NMR (400 MHz): CDCl3δ 5.09 - 4.93 (m, 1H), 4.24 - 4.10 (m, 1H), 3.69 - 3.62 (m, 1H), 3.51 (dd, J = 4.8, 10.0 Hz, 1H), 2.82 - 2.70 (m, 2H), 2.46 (d, J = 7.2 Hz, 2H), 2.31 (s, 3H), 2.24 (s, 3H), 2.20 - 2.11 (m, 2H), 1.92 - 1.69 (m, 6H), 1.09 - 0.95 (m, 1H), 0.59 - 0.46 (m, 2H), 0.31 - 0.17 (m, 2H).19F NMR (400 MHz, CDCl3) δ -93.53 (d, J = 252.4 Hz, 1 F), - 102.83 (d, J = 252.0 Hz, 1 F). Example 13: Synthesis of Compound 11; (4Z)-5-(cyclopropylmethyl)-2-[2-(4,4-difluorocyclohexyl)- 1,1-dioxo-1,2-thiazolidin-4-yl]-4-[(4,5-dimethylthiazol-2-yl)hydrazono]pyrazol-3-one To a solution of 4,4-difluorocyclohexanamine;hydrochloride (1.00 g, 5.83 mmol, 1.00 eq) in DCM (10.0 mL) was added Py (1.18 mL, 14.57 mmol, 2.50 eq) . The mixture was stirred at 25 °C for 10 min. (E)-2-phenylethenesulfonyl chloride (1.18 g, 5.83 mmol, 1.00 eq) was added to the reaction mixture. The mixture was stirred at 25 °C for 1 hr. The mixture was washed with H2O (10.0 mL x 2), dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether / Ethyl acetate = 1 / 0 to 5 / 1) to give (E)-N- (4,4-difluorocyclohexyl)-2-phenyl-ethenesulfonamide (1.07 g, crude) as a yellow solid. To a mixture of (E)-N-(4,4-difluorocyclohexyl)-2-phenyl-ethenesulfonamide (1.07 g, 3.55 mmol, 1.00 eq) in MeCN (10.0 mL) was added NaI (533 mg, 3.56 mmol, 1.00 eq) and K2CO3 (981 mg, 7.10 mmol, 2.00 eq). The mixture was stirred at 60 °C for 2.5 hr. Then 3-bromoprop-1-ene (430 mg, 3.55 mmol, 1.00 eq) was added to the mixture. The mixture was stirred at 60 °C for 1 hr. The mixture was filtered and the filtrate was concentrated under reduce pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 4 g SepaFlash® Silica Flash Column, Eluent of 0 ~ 25% Ethyl acetate / Petroleum ether gradient @ 20 mL / min) to recycle (E)-N-(4,4-difluorocyclohexyl)-2- phenyl-ethenesulfonamide (900 mg, 2.99 mmol, 84.11% yield) as a yellow solid. MS: product: m / z 302.1 (M+H)+;1H NMR (400 MHz): DMSO-d6 δ: 7.67 - 7.73 (m, 2H), 7.46 (m, 1H), 7.42 - 7.45 (m, 2H), 7.32 - 7.38 (m, 1H), 7.19 - 7.25 (m, 1H), 3.97 - 4.08 (m, 1H), 1.92 - 2.05 (m, 3H), 1.85 - 1.92 (m, 2H), 1.79 - 1.85 (m, 2H), 1.50 - 1.62 (m, 2H); To a mixture of (E)-N-(4,4-difluorocyclohexyl)-2-phenyl-ethenesulfonamide (850 mg, 2.82 mmol, 1.00 eq) in MeCN (20.0 mL) was added NaI (423 mg, 2.82 mmol, 1.00 eq) and Cs2CO3 (1.84 g, 5.64 mmol, 2.00 eq). The mixture was stirred at 40 °C for 2 hr. Then the mixture was added 3-bromoprop-1- ene (341 mg, 2.82 mmol, 1.00 eq) and stirred at 40 °C for 16 hr. The mixture was filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was triturated with EtOAc (5.00 mL) at 20 ~ 25 °C for 0.5 hr and filtered. The filtrate was concentrated under reduced pressure to give (E)-N-allyl-N-(4,4-difluorocyclohexyl)-2-phenyl-ethenesulfonamide (965 mg, 2.56 mmol, 90.7% yield, 90.5% purity) as a yellow oil. MS: product: m / z 342.1 (M+H)+;1H NMR (400 MHz): DMSO-d6 δ: 7.67 - 7.76 (m, 2H), 7.41 - 7.47 (m, 3H), 7.29 - 7.41 (m, 2H), 5.78 - 5.91 (m, 1H), 5.23 - 5.32 (m, 1H), 5.07 - 5.19 (m, 1H), 4.03 (q, J = 7.2 Hz, 1H), 3.77 (br d, J = 5.8 Hz, 2H), 2.02 (br s, 2H), 1.99 (s, 2H), 1.72 - 1.82 (m, 4H);19F NMR (400 MHz): DMSO-d6 δ: -91.50 (d, J = 246 Hz, 1F), -100.50 (d, J = 246 Hz,1F). To a solution of (E)-N-allyl-N-(4,4-difluorocyclohexyl)-2-phenyl-ethenesulfonamide (860 mg, 2.52 mmol, 1.00 eq) in DCM (20.0 mL) was added dropwise Grubbs II catalyst (107 mg, 126 μmol, 0.05 eq) in DCM (20.0 mL) at 45 °C over 30 min under N2 atmosphere. Then the mixture was stirred at 45 °C for 2 hr. The mixture was concentrated under reduce pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 10 ~ 85% Ethyl acetate / Petroleum ether gradient @ 60 mL / min) to give 2-(4,4-difluorocyclohexyl)-3H-isothiazole 1,1- dioxide (374 mg, 1.49 mmol, 59.2% yield, 94.6% purity) as a brown solid. MS: product: m / z 238.0 (M+H)+;1H NMR (400 MHz): DMSO-d6 δ: 7.09 - 7.17 (m, 2H), 4.02 - 4.06 (m, 2H), 3.51 - 3.61 (m, 1H), 1.94 - 2.13 (m, 4H), 1.78 - 1.91 (m, 4H);19F NMR (400 MHz): DMSO-d6 δ: -92.95 (d, J = 255 Hz,1F), -97.76 (d, J = 255 Hz, 1F). To a solution of 2-(4,4-difluorocyclohexyl)-3H-isothiazole 1,1-dioxide (374 mg, 1.58 mmol, 1.00 eq) in EtOH (10.0 mL) was added NH2-NH2·H2O (0.96 g, 16.3 mmol, 930 μL, 85% purity, 10.3 eq) at 25 °C. The mixture was stirred at 80 °C for 2 hr. The mixture was concentrated at 40 °C to give [2-(4,4- difluorocyclohexyl)-1,1-dioxo-1,2-thiazolidin-4-yl]hydrazine (420 mg, crude) as a yellow gum. A mixture of [2-(4,4-difluorocyclohexyl)-1,1-dioxo-1,2-thiazolidin-4-yl]hydrazine (420 mg, 1.56 mmol, 1.00 eq) and ethyl 4-cyclopropyl-3-oxo-butanoate (266 mg, 1.56 mmol, 1.00 eq) in EtOH (10.0 mL) was stirred at 80 °C for 1 hr. The reaction mixture was concentrated under reduce pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 10 ~ 80% Ethyl acetate / Petroleum ether gradient @ 40 mL / min) to give 5- (cyclopropylmethyl)-2-[2-(4,4-difluorocyclohexyl)-1,1-dioxo-1,2-thiazolidin-4-yl]pyrazol-3-ol (317 mg, 773 μmol, 49.6% yield, 91.6% purity) as a yellow solid. MS: product: m / z 376.1 (M+H)+;1H NMR (400 MHz): DMSO-d6 δ: 11.19 (s, 1H), 5.29 (s, 1H), 5.06 (quin, J = 8.4 Hz, 1H), 3.76 - 3.88 (m, 1H), 3.62 (br t, J = 8.4 Hz, 1H), 3.47 - 3.56 (m, 2H), 3.38 (br t, J = 8.6 Hz, 1H), 2.29 (d, J = 6.8 Hz, 2H), 1.97 - 2.10 (m, 4H), 1.74 - 1.88 (m, 4H), 0.84 - 0.95 (m, 1H), 0.42 (br d, J = 6.8 Hz, 2H), 0.12 (br d, J = 4.4 Hz, 2H);19F NMR (400 MHz): DMSO-d6 δ: -92.52 (d, J = 249 Hz, 1F), -98.27 (d, J = 243 Hz, 1F). To a solution of 4,5-dimethylthiazol-2-amine (106 mg, 826 μmol, 1.00 eq) in HCl (1.10 mL, 10.7 mmol, 35% purity) was added dropwise a solution of NaNO2 (58.0 mg, 840 μmol, 1.02 eq) in H2O (1.00 mL) at 0 ~ 5 °C. The resulting mixture was stirred at 0 ~ 5 °C for 0.5 hr. The resulting mixture was stirred at 0 ~ 5 °C for 0.5 hr. The mixture of 4,5-dimethylthiazole-2-diazonium;chloride in H2O was used as theory amount in next step without work-up. To a solution of 5-(cyclopropylmethyl)-2-[2-(4,4-difluorocyclohexyl)-1,1-dioxo-1,2-thiazolidin-4- yl]pyrazol-3-ol (310 mg, 825.71 μmol, 1.00 eq) in EtOH (1.00 mL) was added NaOH in H2O (2.50 M, 830 μL, 2.51 eq). The mixture was stirred at 15 ~ 20 °C for 0.5 hr. The mixture of [5-(cyclopropylmethyl)-2-[2- (4,4-difluorocyclohexyl)-1,1-dioxo-1,2-thiazolidin-4-yl]pyrazol-3-yl]oxysodium in EtOH / H2O was used as theory amount in next step without work-up. The mixture of 4,5-dimethylthiazole-2-diazonium;chloride (145mg, 825 μmol, 1.00 eq, in H2O) was added dropwise to the mixture of [5-(cyclopropylmethyl)-2-[2-(4,4-difluorocyclohexyl)-1,1-dioxo-1,2- thiazolidin-4-yl]pyrazol-3-yl]oxysodium (328 mg, 825 μmol, 1.00 eq, in EtOH / H2O) at 0 ~ 5 °C. After complete addition, the mixture was stirred for 2 hr at 15 ~ 25 °C. The mixture was filtered and the wet cake was washed with H2O (10.0 mL x 2). The wet cake was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Welch Ultimate C18150 * 25 mm * 5 um; mobile phase: [water (HCl) - ACN]; gradient: 65% - 95% B over 10 min). The eluent was concentrated under reduced pressure to give (4Z)-5-(cyclopropylmethyl)-2-[2-(4,4-difluorocyclohexyl)-1,1- dioxo-1,2-thiazolidin-4-yl]-4-[(4,5-dimethylthiazol-2-yl)hydrazono]pyrazol-3-one (128 mg, 248 μmol, 30.1% yield, 99.4% purity) as a red solid. MS: product: m / z 515.7 (M+H)+;1H NMR (400 MHz): DMSO-d6 δ: 5.08 (quin, J = 7.8 Hz, 1H), 3.75 (dd, J = 13.4, 8.8 Hz, 2H), 3.53 - 3.60 (m, 4H), 2.50 - 2.40 (m, 2H), 2.22 (s, 3H), 2.15 (s, 3H), 1.94 - 2.11 (m, 4H), 1.72 - 1.88 (m, 4H), 0.94 - 1.26 (m, 1H), 0.39 - 0.51 (m, 2H), 0.16 - 0.25 (m, 2H);19F NMR (400 MHz): DMSO-d6 δ: -92.69 (d, J = 255 Hz, 1F), -98.27 (d, J = 255 Hz, 1F). Example 14: Synthesis of Compound 12; (4E)-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2- yl)hydrazono]-2-[1-[1-(2,2,2-trifluoroethyl)piperidine-4-carbonyl]pyrrolidin-3-yl]pyrazol-3-one To a solution of 1-tert-butoxycarbonylpiperidine-4-carboxylic acid (100 mg, 436 μmol, 1.00 eq) and (4E)-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-2-pyrrolidin-3-yl-pyrazol-3-one (200 mg, 577 μmol , 1.32 eq ) in DCM (7.00 mL) was added HATU (199 mg, 523 μmol, 1.20 eq) and DIPEA (563 mg, 4.36 mmol, 759 uL, 10.0 eq ). The mixture was stirred at 20 °C for 20 min. The reaction mixture was partitioned between DCM (30.0 mL) and H2O (20.0 mL). The organic phase was separated, dried over Na2SO4, filtered and concentrated under reduced pressure to give tert-butyl 4-[3- [(4E)-3-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-5-oxo-pyrazol-1-yl]pyrrolidine-1- carbonyl]piperidine-1-carboxylate (231 mg, crude) as red oil, and directly used in next step without purification. MS: product: m / z 558.6 (M+H)+. To a solution of tert-butyl 4-[3-[(4E)-3-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]- 5-oxo-pyrazol-1-yl]pyrrolidine-1-carbonyl]piperidine-1-carboxylate (200 mg, 358 μmol, 1.00 eq) in DCM (3.00 mL) was added TFA (817 mg, 7.17mmol, 531 uL, 20.0 eq). The mixture was stirred at 25°C for 15 min. The mixture was concentrated to give (4E)-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2- yl)hydrazono]-2-[1-(piperidine-4-carbonyl)pyrrolidin-3-yl]pyrazol-3-one (150 mg, 327 μmol, 91.4% yield) as red oil and directly used in next step without further purification. MS: product: m / z 458.3 (M+H)+. To a solution of (4E)-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-2-[1- (piperidine-4-carbonyl)pyrrolidin-3-yl]pyrazol-3-one (100 mg, 218 μmol, 1.00 eq) and 2,2,2-trifluoroethyl trifluoromethanesulfonate (50.7 mg, 218.5 μmol, 1.00 eq) in EtOH (5.00 mL) was added K2CO3 (60.4 mg, 437 μmol, 2.00 eq). The mixture was stirred at 60 °C for 2 hr. The reaction was quenched by addition of water (20.0 mL), and extracted with ethyl acetate (50.0 mL). The separated organic layer was washed with water (10.0 mL), dried over Na2SO4and evaporated to dryness. The crude product was purified by reversed-phase HPLC (0.1% FA condition) to give (4E)-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2- yl)hydrazono]-2-[1-[1-(2,2,2-trifluoroethyl)piperidine-4-carbonyl]pyrrolidin-3-yl]pyrazol-3-one (21.6 mg, 39.1 μmol, 17.9% yield, 97.6% purity) as a red solid. MS: product: m / z 540.4 (M+H)+.1H NMR (400 MHz): CDCl3δ 4.96 - 4.80 (m, 1H), 3.87 - 3.72 (m, 4H), 3.65 - 3.50 (m, 1H), 3.15 - 3.02 (m, 4H), 2.60 - 2.15 (m, 12H), 1.95 - 1.83(m, 2H), 1.83 - 1.70 (m, 2H), 1.06 - 0.96(m, 1H), 0.57 - 0.52 (m, 2H), 0.28 - 0.22 (m, 2H).19F NMR (400 MHz): CDCl3 δ - 68.1. Example 15: Synthesis of Compound 13; (R,Z)-5-(cyclopropylmethyl)-2-(1-(4,4-difluorocyclohexyl)- 5-oxopyrrolidin-3-yl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-2,4-dihydro-3H-pyrazol-3-one Example 16: Synthesis of Compound 14; (Z)-3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2- yl)hydrazono)-1-((5-oxo-1-phenylpyrrolidin-3-yl)methyl)-1H-pyrazol-5(4H)-one A mixture of methyl 5-oxopyrrolidine-3-carboxylate (4.61 g, 32.2 mmol, 1.00 eq), iodobenzene (5.46 g, 26.7 mmol, 0.83 eq), CuI (246 mg, 1.29 mmol, 0.04 eq) , DMEDA (227 mg, 2.58 mmol, 0.08 eq) and K2CO3 (7.44 g, 53.8 mmol, 1.67 eq) in dioxane (50.0 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 110 °C for 15 h under N2 atmosphere. The mixture was filtered via a celite pad and the pad was washed with EA (200 mL). The combined organic layer was concentrated to dryness to give a residue which was purified by column chromatography (SiO2, Petroleum ether / Ethyl acetate=5 / 1 to 5 / 4). Compound methyl 5-oxo-1-phenyl-pyrrolidine-3-carboxylate (5.53 g, 24.4 mmol, 75.9% yield, 97.0% purity) was obtained as a yellow solid. MS: product: m / z 219.8 (M+H)+. To a solution of methyl 5-oxo-1-phenyl-pyrrolidine-3-carboxylate (4.87 g, 22.2 mmol, 1.00 eq) in THF (80.0 mL) was slowly added NaBH4 (1.43 g, 37.8 mmol, 1.70 eq) and then MeOH (20.0 mL) was added dropwise at 0 °C. The resulting mixture was stirred at 25 °C for 3 h. The reaction mixture was quenched by addition NH4Cl (10.0 mL) at 0 °C, and then diluted with H2O (100 mL) and extracted with EA (80.0 mL x 2). The combined organic layers were washed with brine (80.0 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0~10% MeOH / DCM @ 40 mL / min) to give 4-(hydroxymethyl)-1-phenyl-pyrrolidin-2-one (3.25 g, 16.7 mmol, 75.3% yield, 98.3% purity) as a white solid. MS: product: m / z 192.0 (M+H)+. To a solution of 4-(hydroxymethyl)-1-phenyl-pyrrolidin-2-one (2.64 g, 13.8 mmol, 1.00 eq) in DCM (30.0 mL) was added SOCl2(2.47 g, 20.7 mmol, 1.50 eq) and DIPEA (1.79 g, 13.8 mmol, 2.41 mL, 1.00 eq) .The mixture was stirred at 25 °C for 15 h. The mixture was diluted with DCM (60 mL), then washed once with water (50.0 mL) and once with brine (50.0 mL), then dried over Na2SO4 and concentrated to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 20~100% EA / PE @ 40 mL / min) to give 4-(chloromethyl)-1-phenyl- pyrrolidin-2-one (2.00 g, 8.94 mmol, 64.8% yield, 93.8% purity) as a light yellow oil. MS: product: m / z 206.3 (M+H)+. A solution of 4-(chloromethyl)-1-phenyl-pyrrolidin-2-one (1.00 g, 4.77 mmol, 1.00 eq) in EtOH (10.0 mL) was added NH2NH2.H2O (2.94 g, 49.9 mmol, 2.85 mL, 85% purity, 10.0 eq). The mixture was stirred at 80 °C for 15 h. The reaction mixture was concentrated under reduced pressure to give a residue which was purified by reversed-phase HPLC (0.05% FA condition) to give 4-(hydrazinomethyl)-1-phenyl- pyrrolidin-2-one (498 mg, 2.37 mmol, 49.8% yield, 97.7% purity) as a brown oil. MS: product: m / z 210.3(M+H)+.A mixture of 4-(hydrazinomethyl)-1-phenyl-pyrrolidin-2-one (398 mg, 1.94 mmol, 1.00 eq) , methyl 4-cyclopropyl-3-oxo-butanoate (333 mg, 2.13 mmol, 1.10 eq), and AcOH (11.64 mg, 193.90 μmol, 0.10 eq) in dioxane (5.00 mL) was degassed and purged with N2for 3 times, and then the mixture was stirred at 100 °C for 1 h under N2atmosphere. The reaction mixture was concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (ISCO®; 25 g SepaFlash® Silica Flash Column, Eluent of 0~10% MeOH / DCM @ 25 mL / min) to give 4-[[3-(cyclopropylmethyl)-5-hydroxy- pyrazol-1-yl]methyl]-1-phenyl-pyrrolidin-2-one (147 mg, 298 μmol, 15.4% yield, 63.1% purity) as a yellow oil. MS: product: m / z 312.2 (M+H)+. To a solution of 4-[[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]methyl]-1-phenyl-pyrrolidin-2-one (147 mg, 472.10 μmol, 1.00 eq) in EtOH (2.00 mL) was added a solution of NaOH in water (2.5 M, 472 uL, 2.50 eq) at 25 °C. The mixture was stirred at 25 °C for 0.5 h. The product of sodium 3- (cyclopropylmethyl)-1-((5-oxo-1-phenylpyrrolidin-3-yl)methyl)-1H-pyrazol-5-olate in EtOH / H2O as a light yellow liquid was used into the next step without further purification. To a solution of 4,5-dimethylthiazol-2-amine (75.0 mg, 585 μmol, 1.00 eq) in HCl (804 mg, 7.72 mmol, 789 uL, 35% purity, 13.2 eq) was added a solution of NaNO2(40.4 mg, 585 μmol, 1.00 eq) in H2O (1.00 mL) dropwise at 0 °C. The mixture was stirred at 0 °C for 0.5 hr. The product of 4,5- dimethylthiazole-2-diazonium chloride in H2O as a yellow liquid was used into the next step without further purification. The solution of 4,5-dimethylthiazole-2-diazonium chloride (82.9 mg, 472 μmol, 1.00 eq, in water) was added to the solution of sodium 3-(cyclopropylmethyl)-1-((5-oxo-1-phenylpyrrolidin-3-yl)methyl)-1H- pyrazol-5-olate (157 mg, 472 μmol, 1.00 eq, in EtOH / H2O) dropwise at 0 °C. The resulting mixture was stirred at 25 °C for 1 h. The reaction mixture was partitioned between DCM (50 mL) and H2O (30.0 mL). The organic phase was separated, dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (C18; 40 g SepaFlash® Silica Flash Column, Eluent of 0~70% CAN / H2O (0.05%FA)@ 35 mL / min) to give(Z)-3-(cyclopropylmethyl)-4-(2-(4,5- dimethylthiazol-2-yl)hydrazono)-1-((5-oxo-1-phenylpyrrolidin-3-yl)methyl)-1H-pyrazol-5(4H)-one (20.1 mg, 42.2 μmol, 8.94% yield, 94.6% purity) as a red solid. MS: product: m / z 451.2 (M+H)+.1H NMR (400 MHz): CDCl3δ 7.58 (d, J = 8.0 Hz, 2H), 7.35 (t, J = 7.6 Hz, 2H), 7.13 (t, J = 7.2 Hz, 1H), 3.94 - 3.90 (m, 3H), 3.80 - 3.76 (m, 1H), 2.95 - 2.79 (m, 1H), 2.78 - 2.74 (m, 1H), 2.56 - 2.49 (m, 1H), 2.48 (d, J = 6.8 Hz, 2H), 2.31 (s, 3H), 2.24 (s, 3H), 1.06 - 1.03 (m, 1H), 0.56 - 0.52 (m, 2H), 0.29 - 0.25 (m, 2H). Example 17: Synthesis of Compound 15 and Compound 17; (2R,4Z)-2-[1- (benzenesulfonyl)pyrrolidin-3-yl]-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2- yl)hydrazono]pyrazol-3-one; (4Z)-2-[1-(benzenesulfonyl)pyrrolidin-3-yl]-5-(cyclopropylmethyl)-4- [(4,5-dimethylthiazol-2-yl)hydrazono]pyrazol-3-one (4Z)-2-[1-(benzenesulfonyl)pyrrolidin-3-yl]-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2- yl)hydrazono]pyrazol-3-one (150 mg, 304 μmol, 33.2% yield, 98.5% purity) was separated by SFC (column: DAICEL CHIRALPAK IG (250mm*30mm,10um);mobile phase: [ACN / IPA(0.1%NH3H2O);B%: 65%-65%,A6;50min) to give Peak 1(Rt=0.732min) and Peak 2(Rt=1.856min), and then purified by prep- HPLC (Phenomenex luna C18 (250*70mm,15 um);mobile phase: [water(FA)-ACN];B%: 64%-94%) to give (2R,4Z)-2-[1-(benzenesulfonyl)pyrrolidin-3-yl]-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2- yl)hydrazono]pyrazol-3-one (15.6 mg, 30.9 μmol, 12.0% yield, 96.2% purity) as a red solid. MS: product: m / z 487.2 (M+H)+.1H NMR (400 MHz): CDCl3 δ ppm 7.86 - 7.84 (m, 2 H), 7.60 - 7.58 (m, 1 H), 7.53 - 7.51 (m, 2 H), 4.76 - 4.70 (m, 1 H), 3.66 (dd, J=7.60, 7.20 Hz, 1 H), 3.53 - 3.44 (m, 3 H), 2.34 (d, J=7.20 Hz, 2 H), 2.32 (s, 3 H), 2.28 - 2.21 (m, 4 H), 2.16 - 2.11 (m, 1 H), 1.00-0.87 (m,1 H), 0.54 - 0.49 (m, 2 H), 0.24 - 0.21 (m, 2 H) and (4Z)-2-[1-(benzenesulfonyl)pyrrolidin-3-yl]-5-(cyclopropylmethyl)-4-[(4,5- dimethylthiazol-2-yl)hydrazono]pyrazol-3-one (36.9 mg, 73.4 μmol, 28.6% yield, 96.9% purity) as a red solid. MS: product: m / z 487.2 (M+H)+.1H NMR (400 MHz): CDCl3δ ppm 7.86 - 7.84 (m, 2 H), 7.61 - 7.60 (m, 1 H), 7.60 - 7.57 (m, 2 H), 4.76 - 4.69 (m, 1 H), 3.66 (dd, J=7.60, 7.20 Hz, 1 H), 3.53 - 3.42 (m, 3 H), 2.37 - 2.33 (m, 2 H), 2.32 (s, 3 H), 2.27- 2.20 (m, 4 H), 2.16 - 2.08 (m, 1 H), 0.97 - 0.92 (m, 1 H), 0.55 - 0.46 (m, 2 H), 0.26 - 0.17 (m, 2 H). Example 18: Synthesis of Compound 16; (Z)-2-(1-benzoylpyrrolidin-3-yl)-5-(cyclopropylmethyl)-4- (2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-2,4-dihydro-3H-pyrazol-3-one To a solution of (4Z)-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-2-pyrrolidin-3- yl-pyrazol-3-one (85.0 mg, 245 μmol, 1.00 eq) in DCM (2.00 mL) was added dropwise Et3N (49.7 mg, 491 μmol, 68.3 uL, 2.00 eq) at 0°C. After addition, benzoyl chloride (37.9 mg, 270 μmol, 31.4 uL, 1.10 eq) in DCM (1.00 mL) was added dropwise at 0°C. The resulting mixture was stirred at 25 °C for 0.5 hr. The reaction mixture was concentrated to dryness to give a residue. The crude product was purified by reversed-phase HPLC (0.05% FA condition) to give (4Z)-2-(1-benzoylpyrrolidin-3-yl)-5- (cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]pyrazol-3-one (42.8 mg, 94.3 μmol, 38.4%yield, 99.3% purity) as a red solid. MS: m / z 451.4 (M+H)+.1H NMR (400 MHz): CDCl3δ 7.55 - 7.52 (m,2H), 7.43 -7.41 (m, 3H), 4.99 - 4.84 (m, 1H), 4.00 - 3.50 (m, 4H), 2.52 - 2.43 (m, 3H), 2.33 - 2.24 (m, 7H), 1.10 - 1.04 (m, 1H), 0.56 - 0.55 (m, 2H), 0.30 - 0.28 (m, 1H). Example 19: Synthesis of Compound 18; (Z)-2-(1-benzoylpiperidin-4-yl)-5-(cyclopropylmethyl)-4- (2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-2,4-dihydro-3H-pyrazol-3-one To a solution of piperidin-4-one (1.00 g, 7.38 mmol, 1.00 eq, HCl) in DCM (10.0 mL) was added TEA (1.87 g, 18.4 mmol, 2.57 mL, 2.50 eq) and BzCl (1.24 g, 8.85 mmol, 1.03 mL, 1.20 eq). The mixture was stirred at 25 °C for 2.0 h. The mixture was filtered. The filtrate was concentrated to give a residue. The residue was purified by flash silica gel chromatography (eluent of 0 ~ 100% ethyl acetate in petroleum ether gradient over 15 min) to give 1-benzoylpiperidin-4-one (1.43 g, 6.99 mmol, 94.82% yield, 99.39% purity) as a colorless oil. MS: product: m / z 204.1 (M+H)+.1H NMR (400 MHz): CDCl3 δ 7.54 - 7.37 (m, 5H), 4.11 - 3.61 (m, 4H), 2.70 - 2.36 (m, 4H). A solution of 1-benzoylpiperidin-4-one (1.40 g, 6.89 mmol, 1.00 eq) and tert-butyl hydrazinecarboxylate (1.09 g, 8.27 mmol, 1.20 eq) in MeOH (20.0 mL) was stirred at 25 °C for 1 h. Then AcOH (1.24 g, 20.7 mmol, 1.18 mL, 3.00 eq) and NaBH3CN (1.30 g, 20.7 mmol, 3.00 eq) were added to the mixture. The mixture was stirred at 25 °C for 16 h. The mixture was adjusted pH ~ 7 by saturated NaHCO3, extracted with DCM (20.0 mL x 3). The combined organic was washed with brine (50.0 mL x 2), dried over Na2SO4, filtered. The filtrate was concentrated to give a residue. The residue was purified by flash silica gel chromatography (eluent of 0 ~ 100% ethyl acetate in petroleum ether gradient over 15 min) to give tert-butyl 2-(1-benzoylpiperidin-4-yl)hydrazine-1-carboxylate (1.82 g, 5.65 mmol, 82.0% yield, 99.1% purity) as a colorless oil. MS: product: m / z 320.2 (M+H)+.1H NMR (400 MHz): CDCl3δ 7.46 - 7.35 (m, 5H), 6.33 - 6.00 (m, 1H), 4.60 - 4.37 (m, 1H), 3.80 - 3.65 (m, 1H), 3.29 - 2.99 (m, 4H), 1.78 (br s, 1H), 1.59 - 1.48 (m, 2H), 1.47 (s, 9H). A solution of tert-butyl 2-(1-benzoylpiperidin-4-yl)hydrazine-1-carboxylate (500 mg, 1.57 mmol, 1.00 eq) in HCl / dioxane (4.00 M, 5.00 mL, 12.8 eq) was stirred at 25 °C for 16 h. The mixture was concentrated to give a (4-hydrazineylpiperidin-1-yl)(phenyl)methanone (409 mg, crude, HCl) as a colorless oil was used in next step without further purification. MS: product: m / z 220.1 (M+H)+. To a solution of (4-hydrazineylpiperidin-1-yl)(phenyl)methanone (400 mg, 1.82 mmol, 1.00 eq) in EtOH (5.00 mL) was added ethyl 4-cyclopropyl-3-oxobutanoate (310 mg, 1.82 mmol, 1 eq). The mixture was stirred at 80 °C for 1h to give a brown solution. The mixture was concentrated to give a residue. The residue was purified by flash silica gel chromatography (eluent of 0 ~ 20% MeOH in ethyl acetate gradient) to give (4-(3-(cyclopropylmethyl)-5-hydroxy-1H-pyrazol-1-yl)piperidin-1-yl)(phenyl)methanone (256 mg, 578 μmol, 31.7% yield, 73.5% purity) as a colorless oil. MS: product: m / z 326.1 (M+H)+. To a solution of (4-(3-(cyclopropylmethyl)-5-hydroxy-1H-pyrazol-1-yl)piperidin-1- yl)(phenyl)methanone (250 mg, 768 μmol, 1.00 eq) in EtOH (0.75 mL) was added a solution of NaOH in water (4.00 M, 480 μL, 2.50 eq) 25 °C. The mixture was stirred at 25 °C for 0.5 h to give a brown solution. The product of sodium 1-(1-benzoylpiperidin-4-yl)-3-(cyclopropylmethyl)-1H-pyrazol-5-olate in EtOH / water as a brown solution was used in next step without further purification. To a solution of 4,5-dimethylthiazol-2-amine (98.5 mg, 768 μmol, 1.00 eq) in HCl (1.03 g, 10.1 mmol, 1.01 mL, 36.0% purity, 13.2 eq) was added a solution of NaNO2 (53.0 mg, 768 μmol, 1.00 eq) in H2O (1.20 mL) 0 °C. The mixture was stirred at 0 °C for 0.5 h to give a brown solution. The product of 4,5-dimethylthiazole-2-diazonium chloride in water as a brown solution was used in next step without further purification. The solution of 4,5-dimethylthiazole-2-diazonium chloride (135 mg, 768 μmol, 1.00 eq, in water) was added dropwise to the sodium 1-(1-benzoylpiperidin-4-yl)-3-(cyclopropylmethyl)-1H-pyrazol-5-olate (267 mg, 768 μmol, 1.00 eq, in EtOH / H2O) at 0 °C. The resulting mixture was stirred at 25 °C for 1 h to give a red solution. The mixture was extracted with DCM (10.0 mL x 3). The combined organic was washed with brine (20.0 mL x 2), dried over Na2SO4, filtered. The filtrate was concentrated to give a crude product. The crude product was purified by reversed-phase HPLC (C18, 20 - 45 um, 100 A, 40.0 g, eluent of 5 ~ 80% MeCN in water with 0.1% FA condition, over 10 min) to give (Z)-2-(1-benzoylpiperidin- 4-yl)-5-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-2,4-dihydro-3H-pyrazol-3-one (28.7 mg, 61.0 μmol, 7.94% yield, 98.7% purity) as a red solid. MS: product: m / z 465.4 (M+H)+.1H NMR (400 MHz): CDCl3δ 7.49 - 7.38 (m, 5H), 4.98 - 4.73 (m, 1H), 4.41 - 4.33 (m, 1H), 3.95 - 3.73 (m, 1H), 3.21 - 3.07 (m, 1H), 3.01 - 2.88 (m, 1H), 2.50 (d, J = 6.8 Hz, 2H), 2.34 - 2.29 (m, 3H), 2.29 - 2.23 (m, 3H), 2.13 - 2.00 (m, 2H), 1.94 - 1.72 (m, 2H), 1.11 - 1.01 (m, 1H), 0.61 - 0.51 (m, 2H), 0.35 - 0.24 (m, 2H). Example 20: Synthesis of Compound 19; (Z)-5-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2- yl)hydrazineylidene)-2-phenethyl-2,4-dihydro-3H-pyrazol-3-one To a solution of 2-chloroethylbenzene (500 mg, 3.56 mmol, 467 uL, 1.00 eq) in EtOH (5.00 mL) was added NH2NH2.H2O (4.19 g, 71.1 mmol, 4.07 mL, 85% purity, 20.0 eq) at 25 °C .The mixture was stirred at 80 °C for 2 hr. The mixture was concentrated at 40 °C to give phenethylhydrazine (480 mg, 3.27 mmol, 91.9% yield, 92.8% purity) as a white solid. MS: product: m / z 137.0 (M+H)+. To a solution of phenethylhydrazine (480 mg, 3.52 mmol, 1.00 eq) and methyl 4-cyclopropyl-3- oxobutanoate (599 mg, 3.52 mmol, 1.00 eq) in EtOH (10.0 mL) was stirred at 25°C. The mixture was stirred at 80 °C for 1 hr. The reaction mixture was poured into water (20.0 mL) and extracted with dichloromethane (20.0 mL x 2). The combined organic phase was washed with brine (20.0 mL), dried withanhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flashsilica gel chromatography (ISCO®; 4.00 g SepaFlash® Silica Flash Column, Eluent of 0~10% DCM / MeOH @ 80.0 mL / min) to give 3-(cyclopropylmethyl)-1-phenethyl-1H-pyrazol-5-ol (430 mg, 818 μmol, 23.2% yield, 46.1% purity) as a red solid. MS: product: m / z 242.9 (M+H)+. To the mixture of 3-(cyclopropylmethyl)-1-phenethyl-1H-pyrazol-5-ol (200 mg, 825 μmol, 1.00 eq) in EtOH (0.60 mL) was added aqueous NaOH (2.5 M, 825 uL, 2.50 eq) at 15~25 °C. The reaction mixture was stirred of 0.5 hr at 15~25 °C to give sodium 3-(cyclopropylmethyl)-1-phenethyl-1H-pyrazol-5-olate in EtOH / H2O as clear solution. The clear solution was directly used as theory amount in next step without work-up. The solution of 4,5-dimethylthiazol-2-amine (106 mg, 826 μmol, 1.00 eq) in HCl (1.11 mL, 10.9 mmol, 35% purity) was cooled to 0 °C. The solution of NaNO2 (57.1 mg, 826 μmol, 1.00 eq) in H2O (0.50 mL) was added dropwise to the above mixture at 0 °C. The mixture was stirred for 0.5 hr at 0 °C to give [4,5- dimethylthiazol-2-amine]oxysodium in H2O as turbid liquid. The mixture was directly used as theory amount in next step without work-up. The reaction mixture of sodium 3-(cyclopropylmethyl)-1-phenethyl-1H-pyrazol-5-olate (218 mg, 825 μmol, 1.00 eq, in EtOH / H2O) was added dropwise to the solution of [4,5-dimethylthiazol-2- amine]oxysodium (144 mg, 825 mmol, 1.00 eq, in H2O) at 0 °C. The resulting mixture was stirred at 0~25 °C for 0.5 hr. The solid was precipitated out and collected by filtration. And the solid was washed with water (20.0 mL × 2), dried under reduced pressure to give the crude product. The crude product was purified by prep-HPLC(column: Phenomenex C18150*25mm*10um;mobile phase: [water(FA)-ACN];B%: 68%-98%, 8 min) to give (Z)-5-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-2- phenethyl-2,4-dihydro-3H-pyrazol-3-one (10.0 mg, 25.5 μmol, 3.09% yield, 97.2% purity) as a red solid. MS: product: m / z 382.5 (M+H)+.1H NMR (400 MHz, CHLOROFORM) δ ppm 7.31 - 7.26 (m, 2H), 7.25 - 7.17 (m, 3H), 3.98 (t, J = 7.6 Hz, 2H), 3.03 (t, J = 7.6 Hz, 2H), 2.49 (d, J = 7.2 Hz, 2H), 2.30 (s, 3H), 2.23 (s, 3H), 1.12 - 1.01 (m, 1H), 0.59 - 0.52 (m, 2H), 0.28 (q, J = 5.2 Hz, 2H) Example 21: Synthesis of Compound 20; (4Z)-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2- yl)hydrazono]-2-[2-[4-(4-fluorophenyl)-2-oxo-pyrrolidin-1-yl]ethyl]pyrazol-3-one;

[0016] To a solution of NaH (446 mg, 11.2 mmol, 60% purity, 2.00 eq) in THF (6.00 mL) was added a solution of 4-(4-fluorophenyl)pyrrolidin-2-one (1.00 g, 5.58 mmol, 1.00 eq) in THF (6.00 mL) at 0 °C. After stirred at 0 °C for 0.5 h, 1,2-dibromoethane (10.5 g, 55.8 mmol, 4.21 mL, 10.0 eq) was added at 0 °C. The mixture was stirred at 55°C for 5 h. The reaction mixture was quenched with ice H2O (20.0 mL) at 25 °C, extracted with DCM (30.0 mLx2). The combined organic layers were washed with brine (20.0 mL), dried over Na2SO4 and concentrated under vacuum to give a residue. The residue was purified by prep-HPLC (column: Welch Xtimate C18100*40mm*3um;mobile phase: [water(HCl)-ACN];B%: 10%-60%,8min) to give compound 1-(2-bromoethyl)-4-(4-fluorophenyl)pyrrolidin-2-one (120 mg, 419 μmol, 7.51% yield, N / A purity) as a yellow oil. MS: product: m / z 287.8(M+H)+. To a solution of 1-(2-bromoethyl)-4-(4-fluorophenyl)pyrrolidin-2-one (120 mg, 419 μmol, 1.00 eq) in EtOH (2.00 mL) was added NH2NH2.H2O (610 mg, 11.9 mmol, 592 uL, 98% purity, 28.5 eq). The mixture was stirred at 80°C for 2 h. The reaction mixture was cooled to 25°C and concentrated under vacuum to give a residue. The residue was purified by prep-HPLC (column: Welch Xtimate C18 100*40mm*3um;mobile phase: [water(TFA)-ACN];B%: 0%-30%,8min) to give 4-(4-fluorophenyl)-1-(2- hydrazinoethyl)pyrrolidin-2-one (90.0 mg, 373 μmol, 89.0% yield, 98.4% purity) as a yellow oil. MS: product: m / z 237.9(M+H)+. To a solution of 4-(4-fluorophenyl)-1-(2-hydrazinoethyl)pyrrolidin-2-one (90.0 mg, 379 μmol, 1.00 eq) in EtOH (5.00 mL) was added ethyl 4-cyclopropyl-3-oxo-butanoate (83.9 mg, 493 μmol, 1.30 eq). The mixture was stirred at 80 °C for 1 h. The reaction mixture was cooled to 25 °C and concentrated under vacuum to give a residue. The residue was purified by prep-HPLC (column: Welch Xtimate C18 100*40mm*3um;mobile phase: [water(TFA)-ACN];B%: 3%-43%,8min) to give compound 1-[2-[3- (cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]ethyl]-4-(4-fluorophenyl)pyrrolidin-2-one (90.0 mg, 241 μmol, 63.6% yield, 92% purity) as a yellow oil. MS: product: m / z 343.9(M+H)+. To a mixture of 4,5-dimethylthiazol-2-amine (60.0 mg, 468 μmol, 1.00 eq) in HCl (623 mg, 6.32 mmol, 610 uL, 37% purity, 13.5 eq) was dropwise added a solution of NaNO2(48.44 mg, 702.05 μmol, 1.5 eq) in H2O (1.00 mL) at -5 °C. The mixture was stirred at -5°C for 0.5 h. The product of 2-BLAH-4,5- dimethyl-thiazole in H2O as a yellow liquid was used into the next step without further purification. To a solution of 1-[2-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]ethyl]-4-(4- fluorophenyl)pyrrolidin-2-one (80.0 mg, 233 μmol, 1.00 eq) in EtOH (1.50 mL) was added NaOH in H2O (2.50 M, 233 uL, 2.50 eq). The mixture was stirred at 25 °C for 0.5 h. The product of [5- (cyclopropylmethyl)-2-[2-[4-(4-fluorophenyl)-2-oxo-pyrrolidin-1-yl]ethyl]pyrazol-3-yl]oxysodium in EtOH / H2O as a yellow liquid was used into the next step without further purification. To a mixture of 2-BLAH-4,5-dimethyl-thiazole (57.7 mg, 328 μmol, 1.50 eq, in H2O) was dropwise added a solution of [5-(cyclopropylmethyl)-2-[2-[4-(4-fluorophenyl)-2-oxo-pyrrolidin-1-yl]ethyl]pyrazol-3- yl]oxysodium (80.0 mg, 219 μmol, 1.00 eq, in EtOH / H2O) at -5°C. The mixture was stirred at 25 °C for 0.5 h. The reaction mixture was quenched with H2O (15.0 mL), extracted with DCM (20.0 mLx2). The combined organic layers were washed with brine (20.0 x2 mL), dried over Na2SO4, filtered and concentrated under vacuum to give a red solid. The red solid was purified by prep-HPLC (column: Welch Xtimate C18100*40mm*3um;mobile phase: [water(HCl)-ACN];B%: 31%-71%,8min) to give compound (4Z)-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-2-[2-[4-(4-fluorophenyl)-2-oxo- pyrrolidin-1-yl]ethyl]pyrazol-3-one (4.90 mg, 10.2 μmol, 4.64% yield, 100% purity) as a red solid. MS: product: m / z 483.3(M+H)+.1H NMR (400MHz, CHLOROFORM-d) δ =7.65 - 7.55 (m, 2H), 7.04 (t, J=8.40 Hz, 2H), 4.01 - 3.88 (m, 2H), 3.82 - 3.46 (m, 5H), 2.75 - 2.65 (m, 1H), 2.53-2.40 (m, 3H), 2.32 (s, 6H), 1.08 - 0.95 (m, 1H), 0.57 - 0.51 (m, 2H), 0.28-0.22 (m, 2H).19F NMR (377MHz, CHLOROFORM-d) δ = - 155.7 (s, 1F). Example 22: Synthesis of Compound 21; (Z)-3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2- yl)hydrazono)-1-(2-oxo-1-phenylpyrrolidin-3-yl)-1H-pyrazol-5(4H)-one To a solution of 1-phenylpyrrolidin-2-one (1.00 g, 6.20 mmol, 1.00 eq) and tert-butyl (NE)-N-tert- butoxycarbonyliminocarbamate (2.00 g, 8.68 mmol, 1.40 eq) in THF (30.0 mL) was added dropwise NaHMDS in THF (1.00 M, 7.42 mL, 1.20 eq) at -70 °C over 30 min. After addition, the mixture was stirred at -70 °C for 2.5 hr. The reaction mixture was quenched by aqueous solution of NH4Cl (10.0 mL) at -78 °C, and then diluted with H2O (40.0 mL), extracted with EA (50.0 mL x 2). The combined organic layers were washed with brine (40.0 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (eluent of 20 ~ 60% EA in PE gradient) to give di-tert-butyl 1-(2-oxo-1-phenylpyrrolidin-3-yl)hydrazine-1,2- dicarboxylate (1.03 g, 2.39 mmol, 38.6% yield, 91% purity) as a light yellow solid. MS: product: m / z 392.1 (M+H)+. A mixture of tert-butyl N-(tert-butoxycarbonylamino)-N-(2-oxo-1-phenyl-pyrrolidin-3-yl)carbamate 877 (1.00 g, 2.55 mmol, 1.00 eq) in HCl / EA (4.00 M , 10.0 mL) was stirred at 50 °C for 1 hr. The mixture was concentrated to give 3-hydrazino-1-phenyl-pyrrolidin-2-one (580 mg, crude, 2HCl) as a yellow solid. MS: product: m / z 192.1 (M+H)+. A mixture of 3-hydrazino-1-phenyl-pyrrolidin-2-one (500 mg, 1.89 mmol, 1.00 eq, 2HCl) and methyl 4-cyclopropyl-3-oxo-butanoate (325 mg, 2.08 mmol, 1.10 eq) in AcOH (10.0 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 100 °C for 2 h under N2 atmosphere. The reaction mixture was concentrated to dryness to give a residue. The residue was purified by flash silica gel chromatography (eluent of 0 ~ 5% MeOH in DCM gradient) to give 3-[3- (cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]-1-phenyl-pyrrolidin-2-one (315 mg, 837 μmol, 44.2% yield, 79.3% purity) a light yellow solid. MS: product: m / z 297.8 (M+H)+. To a solution of 3-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]-1-phenyl-pyrrolidin-2-one (315 mg, 1.06 mmol, 1.00 eq) in EtOH (4.00 mL) was added a solution of NaOH in water (2.5 M, 1.06 mL, 2.50 eq) at 25 °C. The mixture was stirred at 25 °C for 0.5 hr. The product of sodium 3- (cyclopropylmethyl)-1-(2-oxo-1-phenylpyrrolidin-3-yl)-1H-pyrazol-5-olate in EtOH / H2O as a light yellow liquid was used into the next step without further purification. To a solution of 4,5-dimethylthiazol-2-amine (170 mg, 1.33 mmol, 1.00 eq) in HCl (691 mg, 6.63 mmol, 677 uL, 35.0% purity, 5.00 eq) was added a solution of NaNO2 (91.5 mg, 1.33 mmol, 1.00 eq) in H2O (2.00 mL) dropwise at 0 °C. The mixture was stirred at 0 °C for 0.5 hr. The product of 4,5- dimethylthiazole-2-diazonium chloride in H2O as a yellow liquid was used into the next step without further purification. The solution of 4,5-dimethylthiazole-2-diazonium chloride (223 mg, 1.27 mmol, 1.20 eq, in water) was added to the solution of the product of sodium 3-(cyclopropylmethyl)-1-(2-oxo-1-phenylpyrrolidin-3- yl)-1H-pyrazol-5-olate (338 mg, 1.06 mmol, 1.00 eq, in EtOH / H2O) dropwise at 0 °C. The resulting mixture was stirred at 25 °C for 1 hr. The reaction mixture was partitioned between DCM (40.0 mL) and H2O (20.0 mL). The organic phase was separated, dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (C18; 40 g SepaFlash® Silica Flash Column, Eluent of 0~70% ACN / H2O (0.05%FA)@ 35 mL / min) to give (Z)-3- (cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazono)-1-(2-oxo-1-phenylpyrrolidin-3-yl)-1H- pyrazol-5(4H)-one (75.0 mg, 170 μmol, 16.0% yield, 98.8% purity) as a red solid. MS: product: m / z 437.2 (M+H)+.1H NMR (400 MHz): CDCl3 δ 7.68 - 7.66 (m, 2H), 7.40 - 7.36 (m, 2H), 7.19 - 7.15 (m, 1H), 5.18 (t, J = 9.2 Hz, 1H), 3.99 - 3.88 (m, 1H), 3.95 - 3.87 (m, 1H), 2.60 - 2.50 (m, 2H), 2.50 (dd, J = 4.4, 6.8 Hz, 2H), 2.31 (s, 3H), 2.24 (s, 3H), 1.07 - 1.03 (m, 1H), 0.55 - 0.52 (m, 2H), 0.29 - 0.28 (m, 2H). Example 23: Synthesis of Compound 22; (Z)-2-(1-benzoylpiperidin-3-yl)-5-(cyclopropylmethyl)-4- (2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-2,4-dihydro-3H-pyrazol-3-one To a solution of piperidin-3-one (1.00 g, 7.38 mmol, 1.00 eq, HCl) in DCM (10.0 mL) was added TEA (1.87 g, 18.4 mmol, 2.57 mL, 2.50 eq) and BzCl (1.24 g, 8.85 mmol, 1.03 mL, 1.20 eq). The mixture was stirred at 25 °C for 2.0 h. The mixture was filtered. The filtrate was concentrated to give a residue. The residue was purified by flash silica gel chromatography (eluent of 0 ~ 100% ethyl acetate in petroleum ether gradient over 15 min) to give 1-benzoylpiperidin-3-one (1.06 g, 4.19 mmol, 56.8% yield, 80.3% purity) as a colorless oil. MS: product: m / z 204.0 (M+H)+.1H NMR (400 MHz): CDCl3δ 7.47 - 7.37 (m, 5H), 4.36 (s, 2H), 3.89 - 3.60 (m, 2H), 2.57 (br t, J = 7.2 Hz, 2H), 2.12 - 2.03 (m, 2H). A solution of 1-benzoylpiperidin-3-one (1.00 g, 4.92 mmol, 1.00 eq) and tert-butyl hydrazinecarboxylate (780 mg, 5.90 mmol, 1.20 eq) in MeOH (10.0 mL) was stirred at 25 °C for 1 h. Then AcOH (886 mg, 14.7 mmol, 845 μL, 3.00 eq) and NaBH3CN (928 mg, 14.7 mmol, 3.00 eq) were added to the mixture. The mixture was stirred at 25 °C for 16 h. The mixture was adjusted pH ~ 7 by saturated NaHCO3, extracted with DCM (20.0 mL x 3). The combined organic was washed with brine (50.0 x 2), dried over Na2SO4, filtered. The filtrate was concentrated to give a residue. The residue was purified by flash silica gel chromatography (eluent of 0 ~ 100% ethyl acetate in petroleum ether gradient over 15 min) to give tert-butyl 2-(1-benzoylpiperidin-3-yl)hydrazine-1-carboxylate (1.15 g, 3.15 mmol,64.1% yield, 87.6% purity) as a light yellow oil. MS: product: m / z 320.1 (M+H)+. 1H NMR (400 MHz):CDCl3 δ 7.40 (s, 5H), 3.85 - 3.62 (m, 2H), 3.42 - 3.29 (m, 2H), 3.23 - 3.15 (m, 1H), 3.06 - 2.92 (m, 1H), 1.97 - 1.79 (m, 2H), 1.55 - 1.51 (m, 1H), 1.47 (s, 9H), 1.43 (br dd, J = 2.1, 3.2 Hz, 2H). A solution of tert-butyl 2-(1-benzoylpiperidin-3-yl)hydrazine-1-carboxylate (500 mg, 1.57 mmol, 1.00 eq) in HCl / dioxane (4.00 M, 5.00 mL, 12.8 eq) was stirred at 25 °C for 16 h. The mixture was concentrated to give a (3-hydrazineylpiperidin-1-yl)(phenyl)methanone (412 mg, crude, HCl) as a colorless oil was used in next step without further purification. MS: product: m / z 220.1 (M+H)+. To a solution of (3-hydrazineylpiperidin-1-yl)(phenyl)methanone (400 mg, 1.56 mmol, 1.00 eq) in EtOH (5.00 mL) was added ethyl 4-cyclopropyl-3-oxobutanoate (266 mg, 1.56 mmol, 1.00 eq). The mixture was stirred at 80 °C for 1h to give a brown solution. The mixture was concentrated to give a residue. The residue was purified by flash silica gel chromatography (eluent of 0 ~ 20% MeOH in ethyl acetate gradient) to give (3-(3-(cyclopropylmethyl)-5-hydroxy-1H-pyrazol-1-yl)piperidin-1- yl)(phenyl)methanone (283 mg, 571 μmol, 36.5% yield, 65.7% purity) as a brown oil. MS: product: m / z 326.1 (M+H)+. To a solution of (3-(3-(cyclopropylmethyl)-5-hydroxy-1H-pyrazol-1-yl)piperidin-1- yl)(phenyl)methanone (250 mg, 768 μmol, 1.00 eq) in EtOH (0.75 mL) was added a solution of NaOH in water (4.00 M, 480 μL, 2.50 eq) at 25 °C. The mixture was stirred at 25 °C for 0.5 h to give a brown solution. The product of sodium 1-(1-benzoylpiperidin-3-yl)-3-(cyclopropylmethyl)-1H-pyrazol-5-olate in EtOH / water as a brown solution was used in next step without further purification. To a solution of 4,5-dimethylthiazol-2-amine (98.5 mg, 768 μmol, 1.00 eq) in HCl (1.03 g, 10.1 mmol, 1.01 mL, 36.0% purity, 13.2 eq) was added a solution of NaNO2 (53.0 mg, 768 μmol, 1.00 eq) in H2O (1.20 mL) 0 °C. The mixture was stirred at 0 °C for 0.5 h to give a brown solution. The product of 4,5-dimethylthiazole-2-diazonium chloride in water as a brown solution was used in next step without further purification. The solution of 4,5-dimethylthiazole-2-diazonium chloride (135 mg, 768 μmol, 1.00 eq, in water) was added dropwise to the sodium 1-(1-benzoylpiperidin-3-yl)-3-(cyclopropylmethyl)-1H-pyrazol-5-olate(267 mg, 768 μmol, 1.00 eq, in EtOH / H2O) at 0 °C. The resulting mixture was stirred at 25 °C for 1 h togive a red solution. The mixture was extracted with DCM (10.0 mL x 3). The combined organic was washed with brine (20.0 mL x 2), dried over Na2SO4, filtered. The filtrate was concentrated to give a crude product. The crude product was purified by reversed-phase HPLC (C18, 20 – 45 um, 100 A, 40.0 g, eluent of 5 ~ 80% MeCN in water with 0.1% FA condition, over 10 min) to give (Z)-2-(1- benzoylpiperidin-3-yl)-5-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-2,4-dihydro- 3H-pyrazol-3-one (24.6 mg, 51.5 μmol, 6.70% yield, 97.2% purity) as a red solid. MS: product: m / z 465.4 (M+H)+.1H NMR (400 MHz): CDCl3δ 7.46 - 7.38 (m, 5H), 4.80 - 4.55 (m, 1H), 4.34 - 4.16 (m, 1H), 3.89 - 3.64 (m, 1H), 3.42 - 3.24 (m, 1H), 3.07 - 2.85 (m, 1H), 2.46 (d, J = 4.8 Hz, 2H), 2.32 (s, 3H), 2.26 (s, 3H), 2.09 - 2.00 (m, 2H), 1.91 - 1.56 (m, 2H), 1.10 - 0.98 (m, 1H), 0.60 - 0.49 (m, 2H), 0.34 - 0.22 (m, 2H). Example 24: Synthesis of Compound 23; (Z)-2-benzyl-5-(cyclopropylmethyl)-4-(2-(4,5- dimethylthiazol-2-yl)hydrazineylidene)-2,4-dihydro-3H-pyrazol-3-one To a solution of benzylhydrazine;dihydrochloride (500 mg, 2.56 mmol, 1.00 eq ) in AcOH (5.00 mL) was added methyl 4-cyclopropyl-3-oxo-butanoate (559 mg, 3.58 mmol, 1.40 eq ), and then the mixture was stirred at 120 °C for 1hr. The mixture was diluted with water (25.00 mL), neutralized with solid NaHCO3until no CO2was evolved. The mixture was extracted with DCM (50.0 mL x 2). The combined organic layers were washed with H2O (50.0 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether / Ethyl acetate=10 / 1 to 1 / 1) to give 2-benzyl-5- (cyclopropylmethyl)pyrazol-3-ol (508 mg, 2.18 mmol, 85.19% yield, 98% purity) as a white solid. MS: product: m / z 229.1 (M+H)+.1H NMR (400 MHz): CDCl3δ 7.37 - 7.26 (m, 5H), 4.82 (s, 2H), 3.31 (s, 2H), 2.27 (J = 7.2 Hz, 2H), 0.91 - 0.81 (m, 1H), 0.59 - 0.52 (m, 2H), 0.19 - 0.14 (m, 2H) To a solution of 2-benzyl-5-(cyclopropylmethyl)pyrazol-3-ol (200 mg, 876 μmol, 1.00 eq ) in EtOH (0.50 mL) was added NaOH (2.50 M, 876 uL, 2.50 eq). The mixture was stirred for 0.5 h at 15~25°C. Theproduct of sodium 1-benzyl-3-(cyclopropylmethyl)-1H-pyrazol-5-olate in EtOH / H2O as a light green liquidwas used in the next step without further purification. To a solution of 4,5-dimethylthiazol-2-amine (110 mg, 858 μmol, 1.00 eq ) in HCl (1.18 g, 11.3 mmol, 1.16 mL, 35% purity, 13.2 eq ) was added NaNO2(59.2 mg, 858 μmol, 1.00 eq) in H2O at 0 °C. Then the mixture was stirred at 0 °C - 5 °C for 0.5 hr. The product of 4,5-dimethylthiazole-2-diazonium chloride in H2O was used in the next step without further purification. The solution of 4,5-dimethylthiazole-2-diazonium chloride (112 mg, 639 μmol, 1.00 eq, in EtOH / H2O) was added dropwise to the solution of sodium 1-benzyl-3-(cyclopropylmethyl)-1H-pyrazol-5- olate (160 mg, 639 μmol, 1.00 eq, in H2O) at 0~5°C. The resulting mixture was stirred at 25°C for 1 h. The reaction mixture was filtered. The wet cake was collected, purified by prep-HPLC (column: Phenomenex luna C18150*25mm* 10um;mobile phase: [water(FA)-ACN];B%: 63%-93%,10min) to give (4Z)-2-benzyl- 5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]pyrazol-3-one (57.4 mg, 154 μmol, 24.19%yield, 99% purity) as a red solid. MS: product: m / z 368.6 (M+H)+.1H NMR (400 MHz): CDCl3δ = 7.35 -7.26 (m, 5H), 4.92 (s, 2H), 2.47 (J = 7.2 Hz, 2H), 2.30 (s, 3H), 2.24 (s, 3H), 1.09 - 0.98 (m, 1H), 0.56 - 0.49 (m, 2H), 0.29 - 0.24 (m, 2H). Example 25: Synthesis of Compound 24 & Compound 29 (BKX-835); (R,Z)-3-(cyclopropylmethyl)- 1-(1-(4,4-difluoropiperidin-1-yl)-1-oxopropan-2-yl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazono)-1H- pyrazol-5(4H)-one; (S,Z)-3-(cyclopropylmethyl)-1-(1-(4,4-difluoropiperidin-1-yl)-1-oxopropan-2-yl)- 4-(2-(4,5-dimethylthiazol-2-yl)hydrazono)-1H-pyrazol-5(4H)-one To a solution of 2-[(4Z)-3-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-5-oxo- pyrazol-1-yl]propanoic acid (140 mg, 401 μmol, 1.00 eq) and 4,4-difluoropiperidine (69.5 mg, 441 μmol, 1.10 eq, HCl) in DMF (2.00 mL) was added HATU (168 mg, 441 μmol, 1.10 eq) and DIPEA (155 mg, 1.20 mmol, 209 uL, 3.00 eq). The mixture was stirred at 25 °C for 0.5 h. The reaction mixture was poured into water (20.0 mL) and extracted with ethyl acetate (20.0 mL x 2). The combined organic phase was washed with brine (20.0 mL), dried over Na2SO4,filtered and concentrated to give a residue. The residue was Separated by SFC (column: DAICEL CHIRALPAK AD (250mm*30mm,10um);mobile phase: [0.1%NH3H2O EtOH];B%: 30%-30%,C7.2;80min). Compound (S,Z)-3-(cyclopropylmethyl)-1-(1-(4,4-difluoropiperidin-1-yl)-1-oxopropan-2-yl)-4-(2- (4,5-dimethylthiazol-2-yl)hydrazono)-1H-pyrazol-5(4H)-one (37.4 mg, 77.7 μmol, 38.8% yield, 94.0% purity) as a red solid. MS: product: m / z 453.5 (M+H)+.1H NMR (400 MHz): CDCl3 δ 5.17 (q, J = 13.6 Hz, 1H), 4.09 - 4.03 (m, 1H), 3.64 - 3.60 (m, 1H), 3.49 - 3.43 (m, 2H), 2.54 - 2.48 (m, 2H), 2.32 (s, 3H), 2.25 (s, 3H), 2.00 - 1.91 (m, 4H), 1.55 (d, J = 6.8 Hz, 3H), 1.04 - 1.01 (m, 1H), 0.52 - 0.49 (m, 2H), 0.27 - 0.23 (m, 2H).19F NMR (400 MHz): CDCl3 δ -95.9 (d, J = 255.2 Hz,1F), -99.97(d, J = 255.2 Hz,1F). Compound (R,Z)-3-(cyclopropylmethyl)-1-(1-(4,4-difluoropiperidin-1-yl)-1-oxopropan-2-yl)-4-(2- (4,5-dimethylthiazol-2-yl)hydrazono)-1H-pyrazol-5(4H)-one (33.1 mg, 66.6 μmol, 33.2% yield, 91.0% purity) as a red solid. MS: product: m / z 453.4 (M+H)+.1H NMR (400 MHz): CDCl3δ 5.17 (q, J = 13.6 Hz, 1H), 4.05 - 4.03 (m, 1H), 3.63 - 3.61 (m, 1H), 3.46 - 3.43 (m, 2H), 2.53 - 2.44 (m, 2H), 2.32 (s, 3H), 2.25 (s, 3H), 1.97 - 1.88 (m, 4H), 1.55 (d, J = 6.8 Hz, 3H), 1.04 - 1.01 (m, 1H), 0.52 - 0.49 (m, 2H), 0.27 - 0.23 (m, 2H).19F NMR (400 MHz): CDCl3δ -95.9 (d, J = 255.2 Hz,1F), -99.97(d, J = 255.2 Hz,1F). Example 26: Synthesis of Compound 25; (Z)-5-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2- yl)hydrazineylidene)-2-(1-phenylpropan-2-yl)-2,4-dihydro-3H-pyrazol-3-one To a solution of 2-bromopropylbenzene (1.00 g, 5.02 mmol, 774 μL, 1.00 eq) in EtOH (10.0 mL) was added NH2NH2.H2O (2.96 g, 50.2 mmol, 2.87 mL, 85.0% purity, 10.0 eq). The mixture was degassed and purged with N2 for 3 times. The mixture was stirred at 80°C for 1 h under N2 atmosphere. The mixture was cooled to room temperature and concentrated in vacuo to give a residue. The residue was purified by prep-HPLC (0.1%TFA condition) to give (1-methyl-2-phenyl-ethyl)hydrazine (259 mg, 1.72 mmol, 34.3% yield) as colorless oil. MS:m / s 151.2(M+H)+.1H NMR (400MHz, CDCl3-d) δ ppm 7.3 - 7.1 (m, 5H), 3.45 - 3.3 (m, 1H), 3.17 (dd, J=5.2 Hz, J=13.6 Hz, 1H), 2.68 (dd, J=9.2 Hz,J=13.6 Hz, 1H), 1.22 (d, J=6.8 Hz, 3H). To the mixture of (1-methyl-2-phenyl-ethyl)hydrazine (249 mg, 1.66 mmol, 1.00 eq) in acetic acid (6.00 mL) added ethyl 4-cyclopropyl-3-oxo-butanoate (423 mg, 2.49 mmol, 1.50 eq). The mixture stirred at 120 °C for 1h. The mixture was cooled to room temperature and concentrated in vacuo to give a residue. The product of 5-(cyclopropylmethyl)-2-(1-methyl-2-phenyl-ethyl)pyrazol-3-ol (157 mg, 612 μmol, 36.9% yield) as a yellow solid. MS: m / z 257.1(M+H)+.1H NMR (400MHz, CDCl3-d) δ ppm 7.28 - 7.22 (m, 3H), 7.20 - 7.14 (m, 3H), 4.64 - 4.64 (m, 1H), 3.17 (s, 1H), 3.12 (s, 1H), 3.07 - 2.98 (m, 1H), 2.92 - 2.85 (m, 1H), 2.3 (d, J=7.2 Hz, 2H), 1.32 (d, J=6.4 Hz, 3H), 0.92 - 0.81 (m, 1H), 0.61 - 0.47 (m, 2H), 0.25 - 0.15 (m, 2H). To the mixture of 5-(cyclopropylmethyl)-2-(1-methyl-2-phenyl-ethyl)pyrazol-3-ol (157 mg, 612 μmol, 1.00 eq) in EtOH (3.00 mL) was added NaOH in H2O (2.50 M, 612 μL, 2.50 eq). The mixture was stirred at 25°C for 0.5 h. The product of [5-(cyclopropylmethyl)-2-(1-methyl-2-phenyl-ethyl)pyrazol-3- yl]oxysodium in EtOH / H2O as a yellow liquid was directly used for the next step. To a solution of 4,5-dimethylthiazol-2-amine (80.0 mg, 624 μmol, 1.00 eq) and H2SO4(612 mg, 6.24 mmol, 332 μL, 10.0 eq) was added NaNO2 (43.1 mg, 624 μmol, 1.00 eq) in H2O (1.00 mL) at 0°C. The mixture was stirred at 0°C for 1 h. The product of 4,5-dimethylthiazole-2-diazonium;chloride in H2O was directly used for the next step. The solution of 4,5-dimethylthiazole-2-diazonium;chloride (107 mg, 612 μmol, 1.00 eq, in H2O) was added dropwise to the mixture of [5-(cyclopropylmethyl)-2-(1-methyl-2-phenyl-ethyl)pyrazol-3- yl]oxysodium (170 mg, 612 μmol, 1.00 eq, in EtOH / H2O) at 0°C. The mixture was stirred at 0°C for 1h. Water (5.00mL) was added. The mixture was extracted with dichloromethane (25.0 mL × 3). The combined organic phase was dried over Na2SO4, filtered and concentrated to give a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18150*25mm* 10um;mobile phase: [water(FA)- ACN];gradient:70%-100% B over 11 min) to give (4Z)-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2- yl)hydrazono]-2-(1-methyl-2-phenyl-ethyl)pyrazol-3-one (66.3 mg, 168 μmol, 27.4% yield) as a red solid.MS: m / z 396.2(M+H)+.1H NMR (400MHz, CDCl3-d) δ ppm 7.32 - 7.15 (m, 5H), 4.65 - 4.52 (m, 1H), 3.15 -3.07 (m, 1H), 2.99 - 2.91 (m, 1H), 2.61 - 2.46 (m, 2H), 2.32 (s, 3H), 2.25 (s, 3H), 1.41 (d, J=6.8 Hz, 3H), 1.03 - 1.14 (m, 1H), 0.62 - 0.53 (m, 2H), 0.36 - 0.26 (m, 2H). Example 27: Synthesis of Compound 26; (4Z)-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2- yl)hydrazono]-2-[1-(3-methylsulfonylphenyl)-5-oxo-pyrrolidin-3-yl]pyrazol-3-one To a solution of 3-methylsulfonylaniline (2.50 g, 14.6 mmol, 1.00 eq) in H2O (30.0 mL) was added HCl (1.44 g, 14.6 mmol, 1.41 mL, 37% purity, 1.00 eq). After the mixture was stirred at 25 °C for 0.5 h, 2,5-dimethoxy-2,5-dihydrofuran (1.90 g, 14.6 mmol, 1.00 eq) was added at 25 °C. The mixture was stirred at 40 °C for 2 h. The reaction mixture was cooled to 25 °C and adjusted to pH=7-8 with NaHCO3, extracted with DCM (60.0 mLx3). The combined organic layers were washed with brine (30.0 mL), dried over Na2SO4, filtered and concentrated under vacuum to give a residue. The residue was purified by flash silica gel chromatography (Eluent of 0~17% Ethyl acetate / Petroleum ether) to give 1-(3- methylsulfonylphenyl)-2H-pyrrol-5-one (600 mg, 2.34 mmol, 16.0% yield, 92.4% purity) as a white solid. MS: product: m / z 237.8 (M+H)+. To a solution of 1-(3-methylsulfonylphenyl)-2H-pyrrol-5-one (0.60 g, 2.53 mmol, 1.00 eq) in EtOH (6.00 mL) was added NH2NH2.H2O (2.80 g, 47.5 mmol, 2.72 mL, 85% purity, 18.8 eq) at 25 °C. The mixture was stirred at 60 °C for 2 h. The reaction mixture was concentrated under vacuum to give a residue. The residue was purified by prep-HPLC (column: Welch Xtimate C18100*40mm*3um;mobile phase: [water(HCl)-ACN];B%: 0%-15%,3min) to give 4-hydrazino-1-(3-methylsulfonylphenyl)pyrrolidin-2- one (450 mg, 1.55 mmol, 61.5% yield, 93% purity) as a white solid. MS: product: m / z 539.2(2M+H)+. A mixture of ethyl 4-cyclopropyl-3-oxo-butanoate (190 mg, 1.11 mmol, 1.50 eq) and 4-hydrazino- 1-(3-methylsulfonylphenyl)pyrrolidin-2-one (200 mg, 743 μmol, 1.00 eq) was dissolved in EtOH (8.00 mL). The reaction mixture was stirred at 80 °C for 1 h. The reaction mixture was concentrated under vacuum to give a residue. The residue was purified by prep-HPLC (column: Welch Xtimate C18 100*40mm*3um;mobile phase: [water(HCl)-ACN];B%: 7%-37%,3min) to give 4-[3-(cyclopropylmethyl)-5- hydroxy-pyrazol-1-yl]-1-(3-methylsulfonylphenyl)pyrrolidin-2-one (65.0 mg, 149 μmol, 20.1% yield, 86.0% purity) as a yellow solid. MS: product: m / z 343.9(M+H)+. To a mixture of 4,5-dimethylthiazol-2-amine (43.0 mg, 335 μmol, 1.00 eq) in HCl (446 mg, 4.53 mmol, 437uL, 37% purity, 13.5 eq) was dropwise added a solution of NaNO2(34.7 mg, 503 μmol, 1.50 eq) in H2O (0.7 mL) at -5 °C. The mixture was stirred at -5°C for 0.5 h. The product of 2-BLAH-4,5- dimethyl-thiazole in H2O as a yellow liquid was used into the next step without further purification. To a solution of 4-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]-1-(3- methylsulfonylphenyl)pyrrolidin-2-one (65.0 mg, 173 μmol, 1.00 eq) in EtOH (1.00 mL) was added NaOH in H2O (2.50 M, 173 uL, 2.50 eq). The mixture was stirred at 25 °C for 0.5 h. The product of [5- (cyclopropylmethyl)-2-[1-(3-methylsulfonylphenyl)-5-oxo-pyrrolidin-3-yl]pyrazol-3-yl]oxysodium in EtOH / H2O as a yellow liquid was used into the next step without further purification. To a mixture of 2-BLAH-4,5-dimethyl-thiazole (43.1 mg, 245 μmol, 1.50 eq, in H2O) was dropwise added a solution of [5-(cyclopropylmethyl)-2-[1-(3-methylsulfonylphenyl)-5-oxo-pyrrolidin-3-yl]pyrazol-3- yl]oxysodium (65 mg, 163.55 μmol, 1.00 eq, in EtOH / H2O) at -5 °C. The mixture was stirred at 25 °C for 0.5 h. The reaction mixture was quenched with H2O (20.0 mL), extracted with DCM (30.0 mLx2). The combined organic layers were washed with brine (10.0 mL), dried over Na2SO4, filtered and concentrated under vacuum to give the red solid. The red solid was purified by prep-HPLC (column: Welch Xtimate C18 100*40mm*3um;mobile phase: [water(HCl)-ACN];B%: 35%-65%,8min) to give (4Z)-5-(cyclopropylmethyl)- 4-[(4,5-dimethylthiazol-2-yl)hydrazono]-2-[1-(3-methylsulfonylphenyl)-5-oxo-pyrrolidin-3-yl]pyrazol-3-one (13.8 mg, 25.1 μmol, 15.4% yield, 93.7% purity) as a red solid.MS: product: m / z 515.0(M+H)+.1H NMR (400MHz, CHLOROFORM-d) δ = 8.09 - 8.05 (m, 2H), 7.73 (d, J=7.60 Hz, 1H), 7.61 - 7.56 (m, 1H), 5.21 (s, 1H), 4.28 - 4.17 (m, 1H), 4.12 - 4.03 (m, 1H), 3.07 (s, 3H), 3.02 (d, J=7.20 Hz, 2H), 2.48 (br d, J=6.80 Hz, 2H), 2.33 (d, J=3.20 Hz, 6H), 1.06 - 0.95 (m, 1H), 0.57 - 0.51 (m, 2H), 0.27 - 0.22 (m, 2H).

[0017] Example 28: Synthesis of Compound 27; (Z)-3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2- yl)hydrazono)-1-(3-(methylsulfonyl)-3-azaspiro[5.5]undecan-9-yl)-1H-pyrazol-5(4H)-one A mixture of tert-butyl 9-oxo-3-azaspiro[5.5]undecane-3-carboxylate (950 mg, 3.55 mmol, 1.00 eq) and HCl / dioxane (4.00 M, 9.50 mL, 10.6 eq) was stirred at 15 ~ 25 °C for 16 hr. The mixture was concentrated under reduced pressure to give 3-azaspiro[5.5]undecan-9-one (815 mg, crude) was obtained as a gray solid. The crude was combined another batches of (43 mg, crude) and used in next step directly without further purification. To a solution of 3-azaspiro[5.5]undecan-9-one (858 mg, 5.13 mmol, 1.00 eq) in DCM (15.0 mL) was added TEA (1.61 g, 15.90 mmol, 3.10 eq) at 0 °C under N2 atmosphere. The mixture was kept 0 °C and MsCl (880 mg, 7.68 mmol, 594 uL, 1.50 eq) was added dropwise to the mixture over 10 min. The mixture was stirred at 20 °C for 16 hr. The mixture was kept 0 °C and cold H2O (20.0 mL) was added dropwise. The organic layer was separated, washed with brine (15.0 mL), dried over Na2SO4. The mixture was filtered and the filtrate was concentrated under reduced pressure to give 3-methylsulfonyl-3- azaspiro[5.5]undecan-9-one (883 mg, crude) as a yellow solid.1H NMR (400 MHz): CDCl3δ: 3.25 - 3.31 (m, 4H), 2.81 (s, 3H), 2.36 (t, J = 6.9 Hz, 4H), 1.70 - 1.82 (m, 8H) To a solution of 3-methylsulfonyl-3-azaspiro[5.5]undecan-9-one (300 mg, 1.22 mmol, 1.00 eq) in MeOH (60.0 mL) was added NH2NH2·H2O (360 mg, 6.11 mmol, 349 uL, 85.0% purity, 5.00 eq) at 25 °C. The mixture was stirred at 65 °C for 1 hr. Then the mixture was cooled to 25 °C and added NaBH3CN (116 mg, 1.85 mmol, 1.51 eq). After addition, the mixture was stirred at 65 °C for 1 hr. The mixture was concentrated at 40 °C to give (3-methylsulfonyl-3-azaspiro[5.5]undecan-9-yl)hydrazine (417 mg, crude) as a light yellow solid. The crude was used in next step directly without further purification. A mixture of (3-methylsulfonyl-3-azaspiro[5.5]undecan-9-yl)hydrazine (300 mg, 1.15 mmol, 1.00 eq) and methyl 4-cyclopropyl-3-oxo-butanoate (180 mg, 1.15 mmol, 1.00 eq) in EtOH (10.0 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 80 °C for 2.5 hr under N2 atmosphere. The mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Luna C18200*40mm*10um; mobile phase: [water(TFA) - ACN]; B%: 13% - 43%, 10min). The eluents were lyophilized to give two parts of product. One part of product 5-(cyclopropylmethyl)-2-(3-methylsulfonyl-3-azaspiro[5.5]undecan-9-yl)pyrazol-3-ol (44.0 mg, 107 μmol, 9.37% yield, 89.9% purity) was obtained as a yellow oil. MS: product: m / z 367.9 and 368.1 (M+H)+. Another part of product 5-(cyclopropylmethyl)-2-(3-methylsulfonyl-3-azaspiro[5.5]undecan-9-yl)pyrazol-3- ol (31.0 mg, 60.4 μmol, 5.26% yield, 71.6% purity) was obtained as a yellow oil. MS: product: m / z 367.8 (M+H)+. To a solution of 4,5-dimethylthiazol-2-amine (16.0 mg, 124 μmol, 1.00 eq) in HCl (170 uL, 1.66 mmol, 35.0% purity) was added dropwise a solution of NaNO2(9.00 mg, 130 μmol, 1.05 eq) in H2O (0.50 mL) at 0 ~ 5 °C. The resulting mixture was stirred at 0 ~ 5 °C for 0.5 hr. The mixture of 4,5-dimethyl-2- [BLAH(nitrido)-λ5-azanyl]thiazole in H2O was used directly as theory amount in next step without work-up. To a solution of 5-(cyclopropylmethyl)-2-(3-methylsulfonyl-3-azaspiro[5.5]undecan-9-yl)pyrazol-3- ol (44.0 mg, 119 μmol, 1.00 eq) in EtOH (0.50 mL) was added NaOH in H2O (2.50 M, 120 uL, 2.51 eq) .The mixture was stirred at 15 ~ 25 °C for 0.5 hr to give a mixture. The mixture of [5- (cyclopropylmethyl)-2-(3-methylsulfonyl-3-azaspiro[5.5]undecan-9-yl)pyrazol-3-yl]oxysodium in EtOH / H2O was used as theory amount in next step without work-up. The solution of 4,5-dimethyl-2-[BLAH(nitrido)-λ5-azanyl]thiazole (21.0 mg, 119 μmol, 1.00 eq, in H2O) was added dropwise to the mixture of [5-(cyclopropylmethyl)-2-(3-methylsulfonyl-3- azaspiro[5.5]undecan-9-yl)pyrazol-3-yl]oxysodium (46.6 mg, 119 μmol, 1.00 eq, in EtOH / H2O) at 0 ~ 5 °C. After complete addition, the mixture was stirred for 1 hr at 15 ~ 25 °C. And then to the mixture was added dropwise another batches of 4,5-dimethyl-2-[BLAH(nitrido)-λ5-azanyl]thiazole (21.0 mg, 119 μmol, 1.00 eq, in H2O) at 0 ~ 5 °C for 2 hr. The mixture was filtered. The wet cake was washed with H2O (10 mL x 2) and dried under reduce pressure to give a crude product. The crude was combined with another batch (31.0 mg) and purified by prep-HPLC (column: Welch Xtimate C18150 * 25mm * 5um; mobile phase: [water(NH3H2O) - ACN]; B%: 10% - 40%, 8min) to give (4Z)-5-(cyclopropylmethyl)-4-[(4,5- dimethylthiazol-2-yl)hydrazono]-2-(3-methylsulfonyl-3-azaspiro[5.5]undecan-9-yl)pyrazol-3-one (5.90 mg, 10.6 μmol, 11.0% yield, 91.3% purity) as a red solid. MS: product: m / z 507.6 (M+H)+.1H NMR (400 MHz): CDCl3δ: 4.02 - 4.14 (m, 1H), 3.20 - 3.25 (q, 4H), 2.79 (s, 3H), 2.49 (d, J = 7.0 Hz, 2H), 2.31 (s, 3H), 2.25 (s, 3H), 1.90 - 2.00 (m, 2H), 1.79 - 1.83 (m, 3H), 1.65 - 1.70 (m, 3H), 1.53 (m, 2H), 1.32 (m, 2H), 1.00 - 1.09 (m, 1H), 0.51 - 0.58 (m, 2H), 0.26 - 0.33 (m, 2H)

[0018] Example 29: Synthesis of Compound 28; (Z)-2-(3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2- yl)hydrazono)-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)-N-methyl-N-phenylacetamide To a solution of 2-[(4Z)-3-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-5-oxo- pyrazol-1-yl]acetic acid (188 mg, 560 μmol, 1.20 eq) and N-methylaniline (50.0 mg, 467 μmol, 1.00 eq) in DMF (2.00 mL) was added HATU (231 mg, 607 μmol, 1.30 eq) and DIPEA (241 mg, 1.87 mmol, 325 uL, 4.00 eq). The mixture was stirred at 25 °C for 1 h. The reaction mixture was concentrated to dryness to give a residue. The residue was purified by prep-HPLC (C18; 40 g SepaFlash® Silica Flash Column, Eluent of 0~70% CAN / H2O (0.05%FA)@ 35 mL / min) to give (Z)-2-(3-(cyclopropylmethyl)-4-(2-(4,5- dimethylthiazol-2-yl)hydrazono)-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)-N-methyl-N-phenylacetamide (43.1 mg, 95.2 μmol, 20.4% yield, 94.5% purity) as a red solid. MS: product: m / z 425.4 (M+H)+.1H NMR (400 MHz): CDCl3 δ 7.47 - 7.44 (m, 2H), 7.40- 7.32 (m, 1H), 7.30 - 7.27 (m, 2H), 4.30 (s, 2H), 3.30 (s, 3H), 2.49 (d, J = 6.8 Hz, 2H), 2.31 (s, 3H), 2.24 (s, 3H), 1.07 - 1.05 (m, 1H), 0.56 - 0.51 (m, 2H), 0.30 - 0.27 (m, 2H). Example 30: Synthesis of Compound 30; (Z)-3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2- yl)hydrazono)-1-(2-oxo-2-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)ethyl)-1H-pyrazol-5(4H)-one To a solution of ethyl 2-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]acetate (1.60 g, 7.13 mmol, 1.00 eq) in EtOH (15.00 mL) was added a solution of NaOH in water (2.5 M, 0.71 mL, 2.50 eq) at 25 °C. The mixture was stirred at 25 °C for 0.5 h. The product of sodium 2-(3-(cyclopropylmethyl)-5-oxido-1H- pyrazol-1-yl)acetate in EtOH / H2O as a light yellow liquid was used into the next step without further purification. To a solution of 4,5-dimethylthiazol-2-amine (1.20 g, 9.36 mmol, 1.00 eq) in HCl (731 mg, 7.02 mmol, 717 uL, 35% purity, 5.00 eq) was added a solution of NaNO2 (646 mg, 9.36 mmol, 1.00 eq) in H2O (8.00 mL) dropwise at 0 °C. The mixture was stirred at 0 °C for 0.5 h. The product of 4,5- dimethylthiazole-2-diazonium chloride 899.3 in H2O as a yellow liquid was used into the next step without further purification. The solution of 4,5-dimethylthiazole-2-diazonium chloride 899.3 (1.50 g, 8.54 mmol, 1.20 eq, in water) was added dropwise to the solution of sodium 2-(3-(cyclopropylmethyl)-5-oxido-1H-pyrazol-1- yl)acetate (1.71 g, 7.12 mmol, 1.00 eq, in EtOH / H2O) at 0 °C. The resulting mixture was stirred at 25 °C for 1 h. The reaction mixture was partitioned between DCM (100 mL) and H2O (40.0 mL). The organic phase was separated, dried over Na2SO4, filtered and concentrated under reduced pressure to give 2- [(4Z)-3-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-5-oxo-pyrazol-1-yl]acetic acid (2.1 g, crude) as a red solid. MS: product: m / z 335.9 (M+H)+. To a solution of 2-[(4Z)-3-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-5-oxo- pyrazol-1-yl]acetic acid (83.5 mg, 249 μmol, 1.20 eq) and 1-(2,2,2-trifluoroethyl)piperazine (50.0 mg, 207 μmol, 1.00 eq, 2HCl) in DMF (2.00 mL) was added HATU (103 mg, 270 μmol, 1.30 eq) and DIPEA (107 mg, 830 μmol, 145 uL, 4.00 eq). The mixture was stirred at 25 °C for 1 h. The reaction mixture was concentrated to dryness to give a residue. The residue was purified by prep-HPLC (C18; 40 g SepaFlash® Silica Flash Column, Eluent of 0~70% CAN / H2O (0.05%FA)@ 35 mL / min) to give (4Z)-5- (cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-2-[2-oxo-2-[4-(2,2,2-trifluoroethyl)piperazin-1- yl]ethyl]pyrazol-3-one (17.1 mg, 34.3 μmol, 16.5% yield, 98.1% purity) as a red solid. MS: product: m / z 486.3 (M+H)+.1H NMR (400 MHz): CDCl3δ 4.60 (s, 2H), 3.65 (t, J = 4.8 Hz, 2H), 3.50 (t, J = 4.8 Hz, 2H), 3.00 (q, J = 9.6 Hz, 2H), 2.72 - 2.68 (m, 4H), 2.52 (d, J = 7.2 Hz, 2H), 2.32 (s, 3H), 2.25 (s, 3H), 1.10 - 1.05 (m, 1H), 0.57 - 0.53 (m, 2H), 0.31 - 0.28 (m, 2H).19H NMR (400 MHz): CDCl3 δ -69.16. Example 31: Synthesis of Compound 31; (4Z)-2-(3-acetyl-3-azaspiro[5.5]undecan-9-yl)-5- (cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]pyrazol-3-one To a solution of tert-butyl 9-oxo-3-azaspiro[5.5]undecane-3-carboxylate (500 mg, 1.87 mmol, 1.00 eq) in DCM (2.00 mL) was added TFA (1.71 g, 14.9 mmol, 1.11 mL, 8.00 eq). The mixture was stirred at 40 °C for 16 h. The reaction mixture was concentrated under reduced pressure to give 3- azaspiro[5.5]undecan-9-one (312 mg, crude) as a yellow oil. The crude product was used in next step without further purification. To a solution of 3-azaspiro[5.5]undecan-9-one (312 mg, 1.87 mmol, 1.00 eq) in DCM (10.0 mL) was added TEA (377 mg, 3.73 mmol, 519 uL, 2.00 eq) and Ac2O (228 mg, 2.24 mmol, 209 uL, 1.20 eq) at 20 °C. The mixture was stirred at 20 °C for 2 h. The reaction mixture was diluted with H2O (10.0 mL) and extracted with DCM (10.0 mL x 3). The combined organic layers were washed with brine (10.0 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give 3-acetyl-3-azaspiro[5.5]undecan- 9-one (400 mg, crude) as a yellow oil.1H NMR (400 MHz): CDCl3δ 3.61 (t, J = 8.0 Hz, 2H), 3.45 (t, J = 8.0 Hz, 2H), 2.37 - 2.33 (m, 4H), 2.10 (s, 3H), 1.81 - 1.78 (m, 4H), 1.61 - 1.56 (m, 4H). To a solution of 3-acetyl-3-azaspiro[5.5]undecan-9-one (100 mg, 477 μmol, 1.00 eq) in MeOH (5.00 mL) was added AcOH (57.3 mg, 955 μmol, 54.6 uL, 2.00 eq) and tert-butyl N-aminocarbamate (94.7mg, 716 μmol, 1.50 eq). The mixture was stirred at 25 °C for 4 h. Then NaBH3CN (60.0 mg, 955 μmol,2.00 eq) was added and the mixture was stirred at 25 °C for 16 h. The reaction mixture was added NaHCO3 to pH = 7, and then diluted with H2O (20.0 mL) and extracted with DCM (20.0 mL x 3). The combined organic layers were washed with brine (20.0 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give tert-butyl N-[(3-acetyl-3-azaspiro[5.5]undecan-9-yl)amino]carbamate (150 mg, crude) as a yellow oil.1H NMR (400 MHz): CDCl3 δ 6.10 (s, 1H), 3.54 - 3.53 (m, 2H), 3.40 -3.34 (m, 2H), 2.85 - 2.80 (m, 1H), 2.08 (s, 3H), 1.69 (d, J = 8.0 Hz, 4H), 1.46 (s, 2H), 1.46 - 1.34 (m, 9H), 1.26 - 1.19 (m, 6H) To a solution of tert-butyl N-[(3-acetyl-3-azaspiro[5.5]undecan-9-yl)amino]carbamate (150 mg, 460 μmol, 1.00 eq) in DCM (1.00 mL) was added TFA (210 mg, 1.84 mmol, 136 uL, 4.00 eq). The mixture was stirred at 40 °C for 16 h. The reaction mixture was concentrated under reduced pressure to give 1-(9- hydrazino-3-azaspiro[5.5]undecan-3-yl)ethanone (103 mg, crude) as a yellow oil. To a solution of 1-(9-hydrazino-3-azaspiro[5.5]undecan-3-yl)ethanone (103 mg, 457 μmol, 1.00 eq) in EtOH (2.00 mL) was added ethyl 4-cyclopropyl-3-oxo-butanoate (77.8 mg, 457 μmol, 1.00 eq). The mixture was stirred at 80 °C for 1 h. The reaction mixture was concentrated under reduced pressure to give 1-[9-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]-3-azaspiro[5.5]undecan-3-yl]ethanone (200 mg, crude) as a yellow oil. MS: product: m / z 332.2 (M+H)+. To a solution of 1-[9-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]-3-azaspiro[5.5]undecan-3- yl]ethanone (200 mg, 603 μmol, 1.00 eq) in EtOH (0.50 mL) was added NaOH in H2O (2.50 M, 603 uL, 2.50 eq) at 25 °C. The mixture was stirred at 25 °C for 1 h. The product of sodium [2-(3-acetyl-3- azaspiro[5.5]undecan-9-yl)-5-(cyclopropylmethyl)pyrazol-3-yl]oxysodium in EtOH / H2O to give a clear solution was used in the next step without further purification. A solution of 4,5-dimethylthiazol-2-amine (80.0 mg, 624 μmol, 1.00 eq) in HCl (834 mg, 8.24 mmol, 817 uL, 36% purity, 13.2 eq) was cooled to 0 °C. The solution of NaNO2(43.0 mg, 624 μmol, 1.00 eq) in H2O (0.50 mL) was added dropwise to the mixture at 0 °C. The mixture was stirred at 0 °C for 0.5 h. The product of 4,5-dimethyl-2-[BLAH(nitrido)-λ5-azanyl]thiazole in H2O as a black suspension was used in the next step without further purification. To a solution of [2-(3-acetyl-3-azaspiro[5.5]undecan-9-yl)-5-(cyclopropylmethyl)pyrazol-3- yl]oxysodium (213 mg, 602 μmol, 1.00 eq, in EtOH and H2O) was added a solution of 4,5-dimethyl-2- [BLAH(nitrido)-λ5-azanyl]thiazole (105 mg, 602 μmol, 1.00 eq, in H2O) at 0 °C. The mixture was stirred at 0 °C for 1 h. The reaction mixture was diluted with H2O (20.0 mL) and extracted with DCM (20.0 mL x 3). The combined organic layers were washed with brine (30.0 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (FA condition; column: Welch Ultimate C18150*25mm*5um;mobile phase: [water(FA)-ACN];B%: 62%- 92%,10min) to give (4Z)-2-(3-acetyl-3-azaspiro[5.5]undecan-9-yl)-5-(cyclopropylmethyl)-4-[(4,5- dimethylthiazol-2-yl)hydrazono]pyrazol-3-one (8.50 mg, 16.7 μmol, 2.77% yield) as a red solid. MS: product: m / z 471.4 (M+H)+.1H NMR (400 MHz): CDCl3δ 4.11 - 4.05 (m, 1H), 3.57 (d, J = 2.4 Hz, 2H), 3.41 (d, J = 1.6 Hz, 2H), 2.50 - 2.48 (d, J = 6.8 Hz, 2H), 2.31 (s, 3H), 2.25 (s, 3H), 2.10 (s, 3H), 1.98 - 1.95 (m, 2H), 1.82 (d, J = 13.2 Hz, 2H), 1.67 - 1.66 (m, 4H), 1.38 - 1.27 (m, 4H), 1.05 - 1.03 (m, 1H), 0.54 (d, J = 7.2 Hz, 2H), 0.29 (d, J = 5.2 Hz, 2H). Example 32: Synthesis of compound 32; (Z)-2-(1-cyclohexyl-5-oxopyrrolidin-3-yl)-5- (cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-2,4-dihydro-3H-pyrazol-3-one To a solution of cyclohexanamine (1.00 g, 10.1 mmol, 1.15 mL, 1.00 eq) in H2O (5.00 mL) was added HCl (1.00 M, 10.1 mL, 35.0% purity, 1.00 eq) at 25 °C and pH = 1. The solution was kept at 40 °C and 2,5-dimethoxy-2,5-dihydrofuran (1.44 g, 11.1 mmol, 1.10 eq) was added. The resulting mixture was stirred at 40 °C for 30 min. The reaction mixture was cooled to 25 °C. The mixture was added DCM (100 mL) and slowly added saturated aqueousNa2HPO4 solution to pH = 7. The reaction mixture was extracted with DCM (100 mL). The combined organic phase was washed with H2O (100 mL x 2), brine (200 mL), dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue 1-cyclohexyl-1,5-dihydro-2H-pyrrol-2-one (1.60 g, crude) as a brown oil. To a solution of 1-cyclohexyl-1,5-dihydro-2H-pyrrol-2-one (500 mg, 3.03 mmol, 1.00 eq) in EtOH (10.0 mL) was added NH2NH2.H2O (3.56 g, 60.5 mmol, 3.45 mL, 85.0% purity, 20.0 eq) at 25 °C. The mixture was stirred at 80 °C for 16 hr. The reaction mixture was concentrated under reduced pressure to give a residue. The residue 1-cyclohexyl-4-hydrazineylpyrrolidin-2-one (300 mg, crude) as a yellow solid was used into the next step without further purification. A mixture of 1-cyclohexyl-4-hydrazineylpyrrolidin-2-one (300 mg, 1.52 mmol, 1.00 eq) and ethyl 4-cyclopropyl-3-oxo-butanoate (388 mg, 2.28 mmol, 1.50 eq) in EtOH (5.00 mL) was stirred at 80 °C for 1 hr. The reaction mixture was diluted with H2O (50.0 mL) and extracted with EA (100 mL x 3). The combined organic layers were washed with aqueous NaCl (100 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, DCM: MeOH = 10:1) to give 1-cyclohexyl-4-(3-(cyclopropylmethyl)-5-hydroxy-1H- pyrazol-1-yl)pyrrolidin-2-one (200 mg, 659 μmol, 43.3% yield, N / A purity) as a yellow oil. MS: product: m / z 304.2 (M+H)+. To the mixture of 1-cyclohexyl-4-(3-(cyclopropylmethyl)-5-hydroxy-1H-pyrazol-1-yl)pyrrolidin-2- one (200 mg, 659 μmol, 1.00 eq) in EtOH (2.00 mL) was added NaOH in H2O (2.50 M, 659 μL, 2.50 eq). The mixture was stirred at 25 °C for 0.5 h. The product of sodium 1-(1-cyclohexyl-5-oxopyrrolidin-3-yl)-3- (cyclopropylmethyl)-1H-pyrazol-5-olate in EtOH / H2O as a light yellow liquid was used in the next step without further purification. To a solution of 4,5-dimethylthiazol-2-amine (100 mg, 780. μmol, 1.00 eq) in HCl (1.07 g, 10.3 mmol, 1.05 mL, 35.0% purity, 13.2 eq) was added NaNO2(53.8 mg, 780 μmol, 1.00 eq) in H2O (2.00 mL) at 0 °C. The mixture was stirred for 0.5 hr at 0 °C. The product of 4,5-dimethylthiazole-2-diazonium chloride in H2O as a yellow suspension was used in the next step without further purification. A solution of 4,5-dimethylthiazole-2-diazonium chloride (108 mg, 615 μmol, 1.00 eq, in H2O) was added dropwise to the solution of sodium 1-(1-cyclohexyl-5-oxopyrrolidin-3-yl)-3-(cyclopropylmethyl)-1H- pyrazol-5-olate (200 mg, 615 μmol, 1.00 eq, in EtOH / H2O) at 0 °C. The resulting mixture was stirred at 25°C for 1 hr. The reaction mixture was filtered to give a solid. The solid was purified by prep-HPLC (column: Welch Xtimate C18150*25mm*5um;mobile phase: [water(HCl)-ACN];gradient:55%-85% B over 10 min) to give (4Z)-2-(1-cyclohexyl-5-oxo-pyrrolidin-3-yl)-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2- yl)hydrazono]pyrazol-3-one (6.50 mg, 14.6 μmol, 2.37% yield, 99.4% purity) as a red solid .MS: product: m / z 443.1 (M+H)+.1H NMR (400 MHz): CDCl3 δ 4.91 - 4.83 (m, 1H), 3.98 - 3.91 (m, 1H), 3.63 - 3.47 (m, 2H), 2.87 - 2.78 (m, 1H), 2.74 - 2.64 (m, 1H), 2.50 (dd, J = 2.8, 1.6 Hz, 2H), 2.27 (s, 3H), 2.10 (s, 3H), 1.77 (d, J = 7.2 Hz, 4H), 1.69 - 1.56 (m, 4H), 1.31 (d, J = 0.8 Hz, 2H), 1.06 (s, 2H), 0.51 - 0.47 (m, 2H), 0.29 - 0.24 (m, 2H) Example 33: Synthesis of Compound 33; (Z)-5-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2- yl)hydrazineylidene)-2-(1-(4-(methylsulfonyl)phenyl)-5-oxopyrrolidin-3-yl)-2,4-dihydro-3H-pyrazol- 3-one To a solution of 4-methylsulfonylaniline (1.00 g, 5.84 mmol, 1.00 eq) and 2,5-dimethoxy-2,5- dihydrofuran (1.52 g, 11.7 mmol, 2.00 eq) in MeCN (30.0 mL) was added dropwise HCl (2.50 M, 3.74 mL, 1.60 eq). The mixture was stirred at 20 °C for 1 hr. The mixture was neutralized with aqueous NaHCO3(20.0 mL), extracted with EtOAc (100 mLx3), dried over Na2SO4 and evaporated to dryness to give crude product. The crude product was purified by column chromatography (SiO2, DCM / MeOH=100:1 to 80:1) to give 1-(4-methylsulfonylphenyl)-2H-pyrrol-5-one (924 mg, 3.66 mmol, 62.7% yield, 94.0% purity) as a red solid. MS: m / z 237.7 (M+H)+. To a solution of 1-(4-methylsulfonylphenyl)-2H-pyrrol-5-one (924 mg, 3.89 mmol, 1.00 eq) in EtOH (10.0 mL) was added NH2NH2.H2O (457 g, 7.76 mol, 443.46 mL, 85% purity). The mixture was stirred at 80 °C for 4 hr. The mixture was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Dichloromethane : Methanol=1 / 0 to 10 / 1) to give 4-hydrazino-1-(4-methylsulfonylphenyl)pyrrolidin-2-one (524 mg, 1.95 mmol, 49.96% yield) as a black brown solid. A mixture of 4-hydrazino-1-(4-methylsulfonylphenyl)pyrrolidin-2-one (300 mg, 1.11 mmol, 1.00 eq), methyl 4-cyclopropyl-3-oxo-butanoate (174 mg, 1.11 mmol, 1.00 eq) and AcOH (6.69 mg, 111 μmol, 6.37 uL, 0.10 eq) in dioxane (6.00 mL) was degassed and purged with N2for 3 times, and then the mixture was stirred at 100 °C for 1 hr under N2atmosphere. The reaction mixture was concentrated to dryness. The residue was purified by column chromatography (SiO2, DCM / MeOH=150 / 1 to 80 / 1) to give 4-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]-1-(4-methylsulfonylphenyl)pyrrolidin-2-one (236 mg, 622 μmol, 55.9% yield, 99.0% purity) as light yellow solid. MS: m / z 375.8 (M+H)+. To a mixture of methyl 4-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]-1-(4- methylsulfonylphenyl)pyrrolidin-2-one (118 mg, 314 μmol, 1.00 eq) in EtOH (2.00 mL) was added a aqueous NaOH (2.50 M, 314 uL, 2.50 eq) at 25°C. The mixture was stirred for 0.5 h at 25°C to give a clear solution. The product of [5-(cyclopropylmethyl)-2-[1-(4-methylsulfonylphenyl)-5-oxo-pyrrolidin-3- yl]pyrazol-3-yl]oxysodium in EtOH / H2O was used in next step without work-up. To a solution of 4-ethyl-5-methyl-thiazol-2-amine (40.0 mg, 312 μmol, 1.00 eq) in HCl (163 mg, 1.56 mmol, 159 uL, 35.0% purity, 5.00 eq) was added NaNO2 (21.5 mg, 312 μmol, 1.00 eq) in H2O (1.00 mL) at 0 °C. The mixture was stirred at 0 °C for 1hr. The product of 4-ethyl-5-methyl-thiazole-2- diazonium;chloride in H2O as a yellow liquid was used into the next step without work-up. A solution of 4-ethyl-5-methyl-thiazole-2-diazonium;chloride (54.8 mg, 312 μmol, 1.00 eq, in H2O) was added dropwise to the solution of [5-(cyclopropylmethyl)-2-[1-(4-methylsulfonylphenyl)-5-oxo- pyrrolidin-3-yl]pyrazol-3-yl]oxysodium (124 mg, 312 μmol, 1.00 eq, in EtOH / H2O) at 0 °C. The mixture was stirred for 1 h at 25°C. The mixture was extracted with DCM (40.0 mL x 2). The combined organic layers were washed with water and dried over Na2SO4, concentrated to give a residue. The residue product was purified by reversed-phase HPLC (0.05% FA condition) to give (Z)-5-(cyclopropylmethyl)-4-(2-(4,5- dimethylthiazol-2-yl)hydrazineylidene)-2-(1-(4-(methylsulfonyl)phenyl)-5-oxopyrrolidin-3-yl)-2,4-dihydro- 3H-pyrazol-3-one (4.90 mg, 9.36 μmol, 2.83% yield, 98.3% purity) as a red solid. MS: m / z 530.9 (M+H)+.1H NMR (400 MHz): CDCl3 δ 7.95 (d, J = 8.8 Hz, 2H), 7.85 (d, J = 8.8 Hz, 2H), 5.18 (s, 1H), 4.20 - 4.10 (m, 2H), 3.10 - 3.02 (m, 5H), 2.48 (d, J = 6.8 Hz, 2H), 2.32 (s, 3H), 2.25 (s, 3H), 1.02 - 0.97 (m, 1H), 0.54 - 0.51 (m, 2H), 0.27 - 0.25 (m, 2H). Example 34: Synthesis of Compound 34; (Z)-4-(3-(3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol- 2-yl)hydrazineylidene)-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)pyrrolidin-1-yl)benzoic acid To a solution of 4-fluorobenzoic acid (6.00 g, 42.8 mmol, 1.00 eq) in EtOH (50.0 mL) was added thionyl chloride (10.2 g, 85.7 mmol, 6.21 mL, 2.00 eq) and then the mixture was stirred at 80 °C for 1 hr under N2atmosphere. The reaction mixture was diluted with H2O (100 mL) and extracted with EA (200 mL x 2). The combined organic layers were washed with brine (200 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give ethyl 4-fluorobenzoate (7.20 g, 42.4 mmol, 98.9% yield, 99% purity) as a yellow oil was used into the next step without further purification. MS: product: m / z 168.8 (M+H)+A mixture of ethyl 4-fluorobenzoate (5.90 g, 35.1 mmol, 5.18 mL, 1.00 eq), pyrrolidin-3-ol (3.67 g, 42.1 mmol, 3.40 mL, 1.20 eq), K2CO3 (7.27 g, 52.6 mmol, 1.50 eq) in DMF (50.0 mL) was stirred at 100 °C for 1 hr under N2 atmosphere. The reaction mixture was diluted with H2O (500 mL) and extracted with DCM (100 mL x 3). The combined organic layers were washed with brine (500 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether / Ethyl acetate=10 / 1 to 1 / 1) to give ethyl 4-(3- hydroxypyrrolidin-1-yl)benzoate (6.00 g, 24.5 mmol, 69.8% yield, 96% purity) as a yellow oil. MS: product: m / z 236.0 (M+H)+To the mixture of ethyl 4-(3-hydroxypyrrolidin-1-yl)benzoate (500 mg, 2.13 mmol, 1.00 eq), DMAP (25.9 mg, 212 μmol, 0.100 eq) in DCM (5.00 mL) was added TEA (430 mg, 4.25 mmol, 592 uL, 2.00 eq) at 0 °C. Then the mixture was stirred at 0 °C for 30 min, TosCl (486 mg, 2.55 mmol, 1.20 eq) was added dropwise at 0 °C and then the reaction mixture was stirred for 2 h at 25 °C. The reaction mixture wasdiluted with H2O (100 mL) and extracted with DCM (100 mL x 3). The combined organic layers werewashed with brine (100 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether / Ethyl acetate=10 / 1 to 1 / 1) to give ethyl 4-[3-(p-tolylsulfonyloxy)pyrrolidin-1-yl]benzoate (421 mg, 1.01 mmol, 47.3% yield, 93% purity) as a yellow solid. MS: product: m / z 389.9 (M+H)+To a solution of ethyl 4-[3-(p-tolylsulfonyloxy)pyrrolidin-1-yl]benzoate (400 mg, 1.03 mmol, 1.00 eq) in EtOH (5.00 mL) was added NH2NH2.H2O (1.21 g, 20.5 mmol, 1.17 mL, 85% purity, 20.0 eq) at 25 °C .The mixture was stirred at 80 °C for 16 hr. The mixture was concentrated at 40 °C to give ethyl 4- (3-hydrazinopyrrolidin-1-yl)benzoate (500 mg, crude) as a white solid which was used into the next step without further purification. A mixture of ethyl 4-cyclopropyl-3-oxo-butanoate (411 mg, 2.41 mmol, 1.20 eq) in EtOH (5.00 mL) and ethyl 4-(3-hydrazinopyrrolidin-1-yl)benzoate (500 mg, 2.01 mmol, 1.00 eq) was stirred at 80 °C for 3 hr. The mixture was diluted with water (10.0 mL) and extracted with DCM (20.0 mL x 2). The combined organic layers were washed with H2O (20.0 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether / Ethyl acetate = 10:1 to 1:1) to give ethyl 4-[3-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1- yl]pyrrolidin-1-yl]benzoate (159 mg, 447 μmol, 22.3% yield) as yellow solid. MS: product: m / z 356.2 (M+H)+To a solution of ethyl 4-[3-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]pyrrolidin-1-yl]benzoate (150 mg, 422 μmol, 1.00 eq) in EtOH (0.500 mL) was added aqueous NaOH (2.50 M, 422 uL, 2.50 eq). The mixture was stirred at 15°C ~ 25 °C for 0.5 h. The product of [5-(cyclopropylmethyl)-2-[1-(4- ethoxycarbonylphenyl)pyrrolidin-3-yl]pyrazol-3-yl]oxysodium in EtOH / H2O as a light yellow liquid was used in the next step without further purification. To a solution of 4,5-dimethylthiazol-2-amine (80.0 mg, 624 μmol, 1.00 eq) in HCl (858 mg, 8.24 mmol, 841 uL, 35% purity, 13.2 eq) was added NaNO2 (43.1 mg, 624 μmol, 1.00 eq) in H2O (1.00 mL) at 0 °C. The mixture was stirred for 1 hr at 0 ~ 5 °C. The product of 4,5-dimethylthiazole-2-diazonium chloride in H2O as a yellow suspension was used in the next step without further purification. A solution of 4,5-dimethylthiazole-2-diazonium chloride (71.0 mg, 404 μmol, 1.00 eq, in H2O) was added dropwise to the solution of [5-(cyclopropylmethyl)-2-[1-(4-ethoxycarbonylphenyl)pyrrolidin-3- yl]pyrazol-3-yl]oxysodium (152 mg, 404 μmol, 1.00 eq, in EtOH / H2O) at 0 °C. The resulting mixture was stirred at 25°C for 1 hr. The reaction mixture was filtered to give ethyl 4-[3-[(4Z)-3-(cyclopropylmethyl)-4- [(4,5-dimethylthiazol-2-yl)hydrazono]-5-oxo-pyrazol-1-yl]pyrrolidin-1-yl]benzoate (126 mg, crude) as a red solid. The solid was used into the next step without further purification. A mixture of ethyl 4-[3-[(4Z)-3-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-5-oxo- pyrazol-1-yl]pyrrolidin-1-yl]benzoate (126 mg, 255 μmol, 1.00 eq) in aqueous NaOH (4.00 M, 637 uL, 10.0 eq) , MeOH (0.500 mL) and THF (2.00 mL) was stirred at 60 °C for 16 hr. The reaction mixture was filtered to give a crude. The crude was purified by prep-HPLC (column: Phenomenex luna C18 250*50mm*10 μm;mobile phase: [water(FA)-ACN];B%: 58%-88%,min) to give 4-[3-[(4Z)-3- (cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-5-oxo-pyrazol-1-yl]pyrrolidin-1-yl]benzoic acid (10.8 mg, 22.5 μmol, 8.73% yield, 97% purity) as a red solid.MS: product: m / z 467.5 (M+H)+.1H NMR (400 MHz): CDCl3 δ 7.96 (d, J = 8.8 Hz, 2H), 6.54 (d, J = 8.8 Hz, 2H), 5.04 (quin, J = 7.2 Hz, 1H), 3.75 - 3.60 (m, 3H), 3.54 - 3.46 (m, 1H), 2.55 - 2.50 (m, 1H), 2.47 (d, J = 7.2 Hz, 2H), 2.39 - 2.34 (m, 1H), 2.31 (s, 3H), 2.25 (s, 3H), 1.06 - 0.98 (m, 1H), 0.57 - 0.48 (m, 2H), 0.30 - 0.21 (m, 2H) Example 35: Synthesis of Compound 35; (Z)-5-((3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2- yl)hydrazineylidene)-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)methyl)-1-phenylpiperidin-2-one

[0019] A mixture of methyl 6-oxopiperidine-3-carboxylate (1.00 g, 6.36 mmol, 2.00 eq), iodobenzene (649 mg, 3.18 mmol, 354 uL, 1.00 eq) , dipotassium;carbonate (879 mg, 6.36 mmol, 2.00 eq), iodocopper (303 mg, 1.59 mmol, 0.50 eq) and DMEDA (280 mg, 3.18 mmol, 342 uL, 1.00 eq) in 1,4-dioxane (10.0 mL) was degassed and purged with N2 for 3 times. Then the mixture was stirred at 20 °C for 16 h under N2 atmosphere. The mixture was extracted with EtOAc (5.00 mL x 3). The combined organic was washed with brine (5.00 mL x 2), dried over Na2SO4, filtered. The filtrate was concentrated to give a crude product. The crude was purified by flash silica gel chromatography (ISCO®; 4 g SepaFlash® Silica Flash Column, Eluent of 0~50% Ethylacetate / Petroleum ether gradient @ 30 mL / min) to give methyl 6- oxo-1-phenyl-piperidine-3-carboxylate (253 mg, 1.05 mmol, 33.1% yield, 97.0% purity) as a brown oil. MS: product: m / z 234.1 (M+H)+.1H NMR (400 MHz, CHLOROFORM-d) δ = 7.36 - 7.28 (m, 2H), 7.23 - 7.14 (m, 3H), 3.89 - 3.80 (m, 1H), 3.77 - 3.70 (m, 1H), 3.67 (s, 3H), 2.93 (tt, J = 4.8, 8.6 Hz, 1H), 2.64 - 2.45 (m, 2H), 2.24 - 2.05 (m, 2H) To a solution of methyl 6-oxo-1-phenyl-piperidine-3-carboxylate (350 mg, 1.50 mmol, 1.00 eq) in THF (4.00 mL) was added NaBH4(111 mg, 2.94 mmol, 1.96 eq) at 0 °C. The mixture was stirred at 20 °C for 16 h. The mixture was quenched by saturated NH4Cl (10.0 mL) at 0 °C, extracted with EtOAc (20.0 mL x 3). The combined organic was washed with brine (50.0 mL x 2), dried over Na2SO4, filtered. The filtrate was concentrated to give a crude product. The crude was purified by flash silica gel chromatography (ISCO®; 4g SepaFlash® Silica Flash Column, Eluent of 0~60% Ethylacetate / Petroleum ether gradient @ 30 mL / min) to give 5-(hydroxymethyl)-1-phenyl-piperidin-2-one (223 mg, 1.08 mmol, 71.7% yield, 99.0% purity) as a colorless oil. MS: product: m / z 206.3 (M+H)+.1H NMR (400 MHz, CHLOROFORM-d) δ = 7.46 - 7.39 (m, 2H), 7.32 - 7.26 (m, 3H), 3.76 - 3.68 (m, 2H), 2.75 - 2.52 (m, 2H), 2.34 - 2.20 (m, 1H), 2.13 - 1.97 (m, 2H), 1.78 - 1.63 (m, 2H). To a solution of 5-(hydroxymethyl)-1-phenyl-piperidin-2-one (220 mg, 1.07 mmol, 1.00 eq) in DCM (2.50 mL) was added DMAP (13.1 mg, 107 μmol, 0.10 eq),TEA (217 mg, 2.14 mmol, 298 uL, 2.00 eq) and TosCl (245 mg, 1.29 mmol, 1.20 eq). The mixture was stirred at 20 °C for 12 h. The mixture was extracted with EtOAc (5.00 mL x 3). The combined organic layers were washed with brine (5.00 mL x 2), dried over Na2SO4, filtered. The filtrate was concentrated to give a crude product. The crude was purified by flash silica gel chromatography (ISCO®; 4 g SepaFlash® Silica Flash Column, Eluent of 0~57% Ethyl acetate / Petroleum ether gradient @ 30 mL / min) to give (6-oxo-1-phenylpiperidin-3-yl)methyl 4- methylbenzenesulfonate (278 mg, 766 μmol, 71.4% yield, 99.0% purity) as a colorless oil. MS: product: m / z 360.4 (M+H)+.1H NMR (400 MHz, CHLOROFORM-d) δ = 7.70 (d, J = 8.4 Hz, 2H), 7.34 - 7.26 (m, 4H), 7.22 - 7.17 (m, 1H), 7.13 - 7.07 (m, 2H), 4.04 - 3.97 (m, 1H), 3.94 - 3.88 (m, 1H), 3.60 (ddd, J = 1.6, 4.8, 12.4 Hz, 1H), 3.42 - 3.34 (m, 1H), 2.42 - 2.26 (m, 5H), 1.96 - 1.86 (m, 1H), 1.52 - 1.66 (m, 2H). To a solution of (6-oxo-1-phenyl-3-piperidyl)methyl 4-methylbenzenesulfonate (275 mg, 765 μmol, 1.00 eq) in EtOH (3.00 mL) was added NH2NH2.H2O (940 mg, 15.9 mmol, 912 uL, 85.0% purity, 20.9 eq). The mixture was stirred at 20 °C for 2 h. The mixture was concentrated at 40 °C to give 1-(cyclohexa-1,3- dien-1-yl)-5-(hydrazineylmethyl)piperidin-2-one (161 mg, 734 μmol, 95.9% yield) as a colorless oil. MS: product: m / z 220.3 (M+H)+. To a solution of 1-(cyclohexa-1,3-dien-1-yl)-5-(hydrazineylmethyl)piperidin-2-one (109 mg, 497 μmol, 1.00 eq) in EtOH (2.00 mL) was added methyl 4-cyclopropyl-3-oxo-butanoate (77.6 mg, 497 μmol, 1.00 eq) at 20 °C. The mixture was stirred at 80 °C for 1 h. The reaction mixture was concentrated to give a residue. The residue was purified by flash silica gel chromatography (biotage®; 4 g SepaFlash® Silica Flash Column, Eluent of 0~50% Ethylacetate Petroleum ether gradient @ 30 mL / min) to give 5-((3- (cyclopropylmethyl)-5-hydroxy-1H-pyrazol-1-yl)methyl)-1-phenylpiperidin-2-one (95.0 mg, 195 μmol, 39.4% yield, 67.0% purity) as a black brown solid. MS: product: m / z 326.4 (M+H)+. To a solution of 5-((3-(cyclopropylmethyl)-5-hydroxy-1H-pyrazol-1-yl)methyl)-1-phenylpiperidin-2- one (95.0 mg, 292 μmol, 1.00 eq) in EtOH (1.00 mL) was added NaOH in water (2.50 M, 292 uL, 2.50 eq). The mixture was stirred at 20 °C for 0.5 h. The product of sodium 3-(cyclopropylmethyl)-1-((6-oxo-1- phenylpiperidin-3-yl)methyl)-1H-pyrazol-5-olate in EtOH / water as a yellow solution was used in next step without further purification. To a solution of 4,5-dimethylthiazol-2-amine (37.4 mg, 292 μmol, 1.00 eq) in HCl (401 mg, 3.85 mmol, 393 uL, 35.0% purity, 13.2 eq) was added a solution of NaNO2 (20.1 mg, 292 μmol, 1.00 eq) in H2O (0.50 mL) at 0 °C. The mixture was stirred at 0 °C for 0.5 h. The product of 4,5-dimethylthiazole-2- diazonium chloride in water as a yellow solution was used in next step without further purification. The solution of 4,5-dimethylthiazole-2-diazonium chloride (101 mg, 292 μmol, 1.00 eq, in water) was added to the solution of sodium 3-(cyclopropylmethyl)-1-((6-oxo-1-phenylpiperidin-3-yl)methyl)-1H- pyrazol-5-olate (51.3 mg, 292 μmol, 1.00 eq, in EtOH / H2O) at 0 °C. The resulting mixture was stirred at 20 °C for 1 h. The reaction mixture was extracted with DCM (5.00 mL x 3). The combined organic layers were washed with brine (5.00 mL x 2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Welch Ultimate C18150*25mm*5um;mobile phase: [water(FA)-ACN];B%: 56%-86%,10min) to give (Z)-5-((3- (cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-5-oxo-4,5-dihydro-1H-pyrazol-1- yl)methyl)-1-phenylpiperidin-2-one (1.20 mg, 2.45 μmol, 8.41e-1% yield, 95.0% purity) as a black brown solid. MS: product: m / z 326.4 (M+H)+.1H NMR (400 MHz, CHLOROFORM-d) δ = 7.44 - 7.35 (m, 2H), 7.27 - 7.22 (m, 3H), 3.82 (br d, J = 6.8 Hz, 2H), 3.66 - 3.59 (m, 1H), 3.58 - 3.51 (m, 1H), 2.73 - 2.66 (m, 1H), 2.63 - 2.55 (m, 2H), 2.48 (br d, J = 6.8 Hz, 2H), 2.32 (s, 3H), 2.25 (s, 3H), 2.08 - 2.03 (m, 1H), 1.79 - 1.72 (m, 1H), 1.08 - 1.00 (m, 1H), 0.58 - 0.49 (m, 2H), 0.27 (br d, J = 4.8 Hz, 2H). Example 36: Synthesis of Compound 36; (Z)-3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2- yl)hydrazono)-1-(4-(methylsulfonyl)benzyl)-1H-pyrazol-5(4H)-one To a solution of 1-(bromomethyl)-4-methylsulfonyl-benzene (2.00 g, 8.03 mmol, 1.00 eq) in EtOH (20.0 mL) was added NH2NH2.H2O (5.07 g, 86.1 mmol, 4.92 mL, 85% purity, 10.7 eq). The mixture was stirred at 80 °C for 1 h. The mixture was cooled to 25 °C, and concentrated at 40 °C to give a crude (4- (methylsulfonyl)benzyl)hydrazine (1.76 g, crude) as a light yellow oil. To a solution of (4-(methylsulfonyl)benzyl)hydrazine (500 mg, 2.50 mmol, 1.00 eq) in EtOH (5.00 mL) was added ethyl 4-cyclopropyl-3-oxobutanoate (425 mg, 2.50 mmol, 1.00 eq) at 25 °C. The mixture was stirred at 25 °C for 1 h. The mixture was concentrated to give a crude 3-(cyclopropylmethyl)-1-(4- (methylsulfonyl)benzyl)-1H-pyrazol-5-ol (631 mg, crude) as a brown oil. MS: product: m / z 306.9 (M+H)+. To a solution of 3-(cyclopropylmethyl)-1-(4-(methylsulfonyl)benzyl)-1H-pyrazol-5-ol (300 mg, 979 μmol, 1.00 eq) in EtOH (1.00 mL) was added a solution of NaOH in water (2.50 M, 979 uL, 2.50 eq) 25 °C. The mixture was stirred at 25 °C for 0.5 h. The product of sodium 3-(cyclopropylmethyl)-1-(4- (methylsulfonyl)benzyl)-1H-pyrazol-5-olate in EtOH / H2O as a brown solution was used in next step without further purification. To a solution of 4,5-dimethylthiazol-2-amine (126 mg, 979 μmol, 1.00 eq) in HCl (1.35 g, 12.9 mmol, 1.32 mL, 35% purity, 13.2 eq) was added a solution of NaNO2(67.6 mg, 979 μmol, 1.00 eq) in H2O (1.00 mL) at 0 °C. The mixture was stirred at 0 °C for 0.5 h. The product of 4,5-dimethylthiazole-2- diazonium chloride in water as a yellow solution was used in next step without further purification. The solution of 4,5-dimethylthiazole-2-diazonium chloride (172 mg, 979 μmol, 1.00 eq, in water) was added dropwise to the solution of sodium 3-(cyclopropylmethyl)-1-(4-(methylsulfonyl)benzyl)-1H- pyrazol-5-olate (322 mg, 979 μmol, 1.00 eq,in EtOH / H2O) at 0 °C. The resulting mixture was stirred at 25 °C for 1 h. The mixture was extracted with DCM (20.0 mL x 3). The combined organic was washed with brine (50.0 mL x 2), dried over Na2SO4, filtered. The filtrate was concentrated to give a residue. The residue was purified by prep-HPLC (column: Welch Ultimate C18150*25mm*5um;mobile phase: [water(FA)-ACN];B%: 48%-78%,10min) to give (4Z)-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2- yl)hydrazono]-2-[(4-methylsulfonylphenyl)methyl]pyrazol-3-one (17.1 mg, 35.4 μmol, 3.61% yield, 92.1% purity) as a red solid. MS: product: m / z 446.2 (M+H)+.1H NMR (400 MHz): CDCl3δ 7.92 (d, J = 8.4 Hz, 2H), 7.53 (d, J = 8.4 Hz, 2H), 5.02 (s, 2H), 3.04 (s, 3H), 2.50 (d, J = 7.2 Hz, 2H), 2.32 (s, 3H), 2.26 (s, 3H), 1.09 - 1.02 (m, 1H), 0.58 - 0.52 (m, 2H), 0.31 - 0.25 (m, 2H). Example 37: Synthesis of Compound 37; (Z)-5-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2- yl)hydrazineylidene)-2-(1-(4-(methylsulfonyl)benzoyl)pyrrolidin-3-yl)-2,4-dihydro-3H-pyrazol-3-one To a solution of (4Z)-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-2-pyrrolidin-3- yl-pyrazol-3-one (185 mg, 534 μmol, 1.00 eq), 4-methylsulfonylbenzoic acid (107 mg, 534 μmol, 1.00 eq) in DMF (2.00 mL) was added HATU (244 mg, 641 μmol, 1.20 eq) and DIEA (276 mg, 2.14 mmol, 372 uL, 4.00 eq). The mixture was stirred at 25 °C for 20 min. The reaction mixture was concentrated to dryness, and then purified by reversed-phase HPLC (0.05% FA condition) to give (4E)-5-(cyclopropylmethyl)-4- [(4,5-dimethylthiazol-2-yl)hydrazono]-2-[1-(4-methylsulfonylbenzoyl)pyrrolidin-3-yl]pyrazol-3-one (40.6 mg, 76.8 μmol, 12.8% yield) as a red solid. MS: m / z 529.3 (M+H)+.1H NMR (400 MHz): CDCl3 δ 8.03 - 7.98 (m, 2H), 7.73 - 7.70 (m, 2H), 5.01 - 4.83 (m, 1H), 3.99 - 3.43 (m, 4H), 3.06 (d, J = 9.2 Hz,3H), 2.51 - 2.46 (m, 3H), 2.32 - 2.25 (m, 7H), 1.06 - 1.02 (m, 1H), 0.58 - 0.54 (m, 2H), 0.29- 0.26 (m, 2H). Example 38: Synthesis of Compound 38; (Z)-5-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2- yl)hydrazineylidene)-2-(3-(2-hydroxyethoxy)phenethyl)-2,4-dihydro-3H-pyrazol-3-one (BKX-1003) To a solution of 3-(2-hydroxyethyl)phenol (2.00 g, 14.5 mmol, 1.85 mL, 1.00 eq) in MeCN (20.0 mL) was added K2CO3(3.00 g, 21.7 mmol, 1.50 eq) and ((2-bromoethoxy)methyl)benzene (3.74 g, 17.4 mmol, 2.75 mL, 1.20 eq). The mixture was stirred at 70 °C for 16 h. The mixture was cooled to 25 °C, and filtered. The filtrate was concentrated to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether / Ethyl acetate=10 / 1 to 3 / 1) to give a 2-(3-(2- (benzyloxy)ethoxy)phenyl)ethan-1-ol (1.94 g, 7.12 mmol, 49.2% yield, N / A purity) as a colorless oil. To a solution of 2-(3-(2-(benzyloxy)ethoxy)phenyl)ethan-1-ol (1.00 g, 3.67 mmol, 1.00 eq) in DCM (10.0 mL) was added TEA (743 mg, 7.34 mmol, 1.02 mL, 2.00 eq) and 4-methylbenzenesulfonyl chloride (1.05 g, 5.51 mmol, 1.50 eq). The mixture was stirred at 25 °C for 16 h. The mixture was concentrated to give a crude product. The crude product was purified by column chromatography (SiO2, Petroleum ether / Ethyl acetate = 10 / 1 to 5 / 1) to give 3-(2-(benzyloxy)ethoxy)phenethyl 4-methylbenzenesulfonate 1003.4 (1.32 g, 3.09 mmol, 84.3% yield, N / A purity) as a colorless oil.1H NMR (400 MHz): CDCl3 δ 7.63 - 7.61 (d, J = 8.4 Hz, 2H), 7.30 - 7.29 (m, 3H), 7.22 - 7.20 (m, 4H), 7.09 - 7.07 (m, 1H), 6.72 - 6.70 (m, 1H), 6.64 - 6.60 (m, 2H), 4.57 (s, 2H), 4.14 - 4.11 (m, 2H), 4.04 - 4.02 (m, 2H), 3.76 - 3.74 (m, 2H), 2.85 (t, J = 6.8 Hz, 2 H), 2.35 (s, 3H). To a solution of 3-(2-(benzyloxy)ethoxy)phenethyl 4-methylbenzenesulfonate (1.00 g, 2.34 mmol,1.00 eq) in EtOH (15.0 mL) was added NH2-NH2.H2O (1.42 g, 24.1 mmol, 1.38 mL, 85% purity, 10.3 eq).The mixture was stirred at 80 °C for 1 h. The mixture was concentrated at 40 °C under vacuum to give a crude (3-(2-(benzyloxy)ethoxy)phenethyl)hydrazine (1.03 g, crude) as a light yellow oil was used in the next step without further purification. To a solution of (3-(2-(benzyloxy)ethoxy)phenethyl)hydrazine (1.00 g, 3.49 mmol, 1.00 eq) in EtOH (10.0 mL) was added ethyl 4-cyclopropyl-3-oxobutanoate (594 mg, 3.49 mmol, 1.00 eq). The mixture was stirred at 80 °C for 1 h. The mixture was concentrated to give a crude 1-(3-(2- (benzyloxy)ethoxy)phenethyl)-3-(cyclopropylmethyl)-1H-pyrazol-5-ol (1.12 g, 1.46 mmol, 41.9% yield, 51.3% purity) as a light yellow oil. MS: product: m / z 393.1 (M+H)+.To a solution of 1-(3-(2-(benzyloxy)ethoxy)phenethyl)-3-(cyclopropylmethyl)-1H-pyrazol-5-ol (300 mg, 764 μmol, 1.00 eq) in MeOH (5.00 mL) was added Pd / C wet (100 mg, 10.0% purity) under N2 atmosphere. The suspension was degassed and purged with H2for 3 times. The mixture was stirred under H2(15 Psi) at 70 °C for 2 h. The mixture was filtered. The filtrate was concentrated to give a crude 3-(cyclopropylmethyl)-1-(3-(2-hydroxyethoxy)phenethyl)-1H-pyrazol-5-ol (251 mg, crude) as a light yellow oil was used in the next step without further purification. To a solution of 3-(cyclopropylmethyl)-1-(3-(2-hydroxyethoxy)phenethyl)-1H-pyrazol-5-ol (250 mg, 827 μmol, 1.00 eq) in EtOH (0.75 mL) was added a solution of NaOH in water (2.50 M, 827 uL, 2.50 eq) 25 °C. The mixture was stirred at 25 °C for 0.5 h. The product of sodium 3-(cyclopropylmethyl)-1-(3-(2- hydroxyethoxy)phenethyl)-1H-pyrazol-5-olate in water as a brown solution was used in the next step without further purification. To a solution of 4,5-dimethylthiazol-2-amine (106 mg, 827 μmol, 1.00 eq) in HCl (1.14 g, 10.9 mmol, 1.11 mL, 35% purity, 13.2 eq) was added a solution of NaNO2 (57.0 mg, 826.8 μmol, 1.00 eq) in H2O (0.80 mL) at 0 °C. The mixture was stirred at 0 °C for 0.5 h. The product of 4,5-dimethylthiazole-2- diazonium chloride in water as a yellow solution was used in the next step without further purification. The solution of 4,5-dimethylthiazole-2-diazonium chloride (145 mg, 827 μmol, 1.00 eq, in H2O) was added dropwise to the solution of sodium 3-(cyclobutylmethyl)-1-(5-(2-(2-methoxyethoxy)phenyl)- 1,3,4-thiadiazol-2-yl)-1H-pyrazol-5-olate (268 mg, 827 μmol, 1.00 eq, in EtOH / H2O) at 0 °C. The resulting mixture was stirred at 25°C for 1 h. The mixture was extracted with DCM (20.0 mL x 2). The combined organic was washed with brine (50.0 mL), dried over Na2SO4, filtered. The filtrate was concentrated to give a crude product. The crude product was purified by reversed-phase HPLC (C18, 20 - 45um, 100 A, 40.0 g, eluent of 5 ~ 80% MeCN in water with 0.1% FA condition) to give a (Z)-5-(cyclopropylmethyl)-4-(2- (4,5-dimethylthiazol-2-yl)hydrazineylidene)-2-(3-(2-hydroxyethoxy)phenethyl)-2,4-dihydro-3H-pyrazol-3- one (37.6 mg, 79.6 μmol, 9.63% yield, 93.5% purity) as a red solid. .MS: product: m / z 442.4 (M+H)+.1H NMR (400 MHz): CDCl3 δ 7.20 (t, J = 8.0 Hz, 1H), 6.83 - 6.82 (m, 2H), 6.79 - 6.76 (m, 1H), 4.10 - 4.08 (m, 2H), 4.02 - 4.00 (m, 2H), 3.98 - 3.95 (m, 2H), 3.02 (t, J = 7.6 Hz, 2H), 2.48 (d, J = 7.2 Hz, 2H), 2.31 (s, 3H), 2.27 (s, 3H), 1.07 - 1.04 (m, 1H), 0.58 - 0.55 (m, 2H), 0.29 - 0.27 (m, 4H). Example 39: Synthesis of Compound 39; (Z)-3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2- yl)hydrazono)-1-(3-(methylsulfonyl)benzyl)-1H-pyrazol-5(4H)-one To a solution of 3-(methylsulfonyl)benzaldehyde (1.00 g, 5.43 mmol, 1.00 eq) in MeOH (20.0 mL) was added tert-butyl N-aminocarbamate (789 mg, 5.97 mmol, 1.10 eq) at 25 °C. After stirring 1 h. NaBH3CN (1.02 g, 16.3 mmol, 3.00 eq) was added to the mixture at 25 °C. The resulting mixture was stirred at 25 °C - 75 °C for 64 h. The mixture was cooled to 25 °C, and quenched by water (50.0 mL), extracted with EtOAc (50.0 mL x 3). The combined organic was washed with brine (50.0 mL x 2), dried over Na2SO4, filtered. The filtrate was concentrated to give a crude tert-butyl 2-(3- (methylsulfonyl)benzylidene)hydrazinecarboxylate (1.73 g, crude) as a white solid. MS: product: m / z 242.7 (M+H)+. To a solution of tert-butyl 2-(3-(methylsulfonyl)benzylidene)hydrazinecarboxylate (1.50 g, 5.03 mmol, 1.00 eq) in THF (15.0 mL) was NaBH3CN (948 mg, 15.1 mmol, 3.00 eq) and acetic acid (8.33 g, 30.2 mmol, 6.00 eq) at 0 °C. The resulting mixture was stirred at 25 °C for 16 h. The mixture was adjusted pH to 7 by saturated NaHCO3at 25 °C, extracted with EtOAc (50.0 mL x 3). The combined organic was washed with brine (100 mL x 2), dried over Na2SO4, filtered. The filtrate was concentrated to give a crude tert-butyl 2-(3-(methylsulfonyl)benzyl)hydrazinecarboxylate (1.61 g, crude) as a yellow oil. MS: product: m / z 244.8 (M+H)+.1H NMR (400 MHz): DMSO-d6 δ 8.29 (s, 1H), 7.90 (s, 1H), 7.78 (d, J = 7.6 Hz, 1H), 7.68 - 7.64 (m, 1H), 7.61 - 7.55 (m, 1H), 5.02 (d, J = 2.8 Hz, 1H), 3.97 (s, 2H), 3.19 (s, 3H), 1.43 - 1.37 (m, 9H) To a solution of tert-butyl 2-(3-(methylsulfonyl)benzyl)hydrazinecarboxylate (1.60 g, 5.33 mmol, 1.00 eq) in DCM (16.0 mL) was added TFA (8.00 mL) at 25 °C. The resulting mixture was stirred at 25 °C for 1 h. The mixture was concentrated to give a residue. The residue was diluted with water (20.0 mL) and DCM (20.0 mL) and adjusted pH to 7 by saturated NaHCO3at 25 °C, extracted with DCM (20.0 mL x 3). The aqueous phase was concentrated to give a residue. The residue was washed with MeOH / DCM (5.00 mL / 50.0 mL), and filtered. The filtrate was concentrated to give a crude (3- (methylsulfonyl)benzyl)hydrazine (1.21 g, crude) as a light yellow oil. The crude product was used in next step without further purification. MS: product: m / z N / A (M+H)+. To a solution of (3-(methylsulfonyl)benzyl)hydrazine (1.00 g, 4.99 mmol, 1.00 eq, in EtOH (10.0 mL) was added ethyl 4-cyclopropyl-3-oxo-butanoate (849.93 mg, 4.99 mmol, 1.00 eq). The mixture was stirred at 80 °C for 1 h. The mixture was concentrated to give a crude product. The crude product was purified by column chromatography (SiO2, Petroleum ether / Ethyl acetate=20 / 1 to 0 / 1) to give 3- (cyclopropylmethyl)-1-(3-(methylsulfonyl)benzyl)-1H-pyrazol-5-ol (602 mg, 1.96 mmol, 39.4% yield, N / A purity) as a brown oil. MS: product: m / z 306.8 (M+H)+. To a solution of 3-(cyclopropylmethyl)-1-(3-(methylsulfonyl)benzyl)-1H-pyrazol-5-ol (200 mg, 653 μmol, 1.00 eq) in EtOH (0.60 mL) was added a solution of NaOH in water (2.50 M, 653 uL, 2.50 eq) 25 °C. The mixture was stirred at 25 °C for 0.5 h. The product of sodium 3-(cyclopropylmethyl)-1-(3- (methylsulfonyl)benzyl)-1H-pyrazol-5-olate in EtOH / water as a brown solution was used in next step without further purification. To a solution of 4,5-dimethylthiazol-2-amine (83.7 mg, 653 μmol, 1.00 eq) in HCl (898 mg, 8.62 mmol, 880 uL, 35% purity, 13.2 eq) was added a solution of NaNO2(45.0 mg, 653 μmol, 1.00 eq) in H2O (0.80 mL) at 0 °C. The mixture was stirred at 0 °C for 0.5 h. The product of 4,5-dimethylthiazole-2- diazonium chloride in water as a yellow solution. It was used in next step without further purification. The solution of 4,5-dimethylthiazole-2-diazonium chloride (115 mg, 653 μmol, 1.00 eq) in water was added dropwise to the solution of sodium 3-(cyclopropylmethyl)-1-(3-(methylsulfonyl)benzyl)-1H-pyrazol-5-olate (214 mg, 653 μmol, 1.00 eq) in EtOH / H2O at 0 °C. The resulting mixture was stirred at25 °C for 1 h. The mixture was extracted with DCM (20.0 mL x 2). The combined organic was washed with brine (50.0 mL), dried over Na2SO4, filtered. The filtrate was concentrated to give a crude product. The crude product was purified by prep-HPLC (column: Welch Ultimate C18150*25mm*5um;mobile phase: [water(FA)-ACN]; B%: 52% - 82%,10min) to give (Z)-3-(cyclopropylmethyl)-4-(2-(4,5- dimethylthiazol-2-yl)hydrazono)-1-(3-(methylsulfonyl)benzyl)-1H-pyrazol-5(4H)-one (2.20 mg, 4.76 μmol, 4.24% yield, 96.4% purity) as a red solid. MS: product: m / z 446.2 (M+H)+.1H NMR (400 MHz): CDCl3 δ 7.92 (s, 1H), 7.88 (d, J = 7.6 Hz, 1H), 7.65 - 7.61 (m, 1H), 7.59 - 7.53 (m, 1H), 5.01 (s, 2H), 3.06 (s, 3H), 2.49 (d, J = 6.8 Hz, 2H), 2.32 (s, 3H), 2.26 (s, 3H), 1.08 - 1.02 (m, 1H), 0.57 - 0.52 (m, 2H), 0.30 - 0.26 (m, 2H). Example 40: Synthesis of Compound 40; (Z)-3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2- yl)hydrazono)-1-(4-(methylsulfonyl)phenethyl)-1H-pyrazol-5(4H)-one To a solution of 1-(2-bromoethyl)-4-(methylsulfonyl)benzene (500 mg, 1.90 mmol, 1.00 eq) in EtOH (5.00 mL) was added NH2-NH2.H2O (1.44 g, 24.4 mmol, 1.40 mL, 85% purity, 12.87 eq). The mixture was stirred at 80 °C for 1 h. The mixture was cooled to 25 °C, and concentrated at 40 °C to give a crude (4-(methylsulfonyl)phenethyl)hydrazine (461 mg, crude) as a light yellow oil. It was was used in next step without further purification. MS: product: m / z 214.9 (M+H)+. To a solution of (4-(methylsulfonyl)phenethyl)hydrazine (400 mg, 1.87 mmol, 1.00 eq) in EtOH (4.00 mL) was added ethyl 4-cyclopropyl-3-oxo-butanoate (318 mg, 1.87 mmol, 1.00 eq). The mixture was stirred at 80 °C for 1 h. The mixture was concentrated to give a residue. The residue was purified by flash silica gel chromatography (eluent of 0 ~ 10% MeOH / DCM gradient) to give 3-(cyclopropylmethyl)-1- (4-(methylsulfonyl)phenethyl)-1H-pyrazol-5-ol (352 mg, 696 μmol, 37.3% yield, 63.4% purity) as a brown oil. MS: product: m / z 320.8 (M+H)+.1H NMR (400 MHz): CDCl3 δ 7.87 (d, J = 8.0 Hz, 2H), 7.47 - 7.41 (m, 2H), 7.37 - 7.30 (m, 1H), 3.96 - 3.90 (m, 2H), 3.12 (t, J = 7.2 Hz, 2H), 3.05 (s, 3H), 2.30 (d, J = 7.2 Hz, 2H), 1.27 - 1.26 (m, 1H), 0.91 - 0.84 (m, 2H), 0.62 - 0.58 (m, 2H). To a solution of 3-(cyclopropylmethyl)-1-(4-(methylsulfonyl)phenethyl)-1H-pyrazol-5-ol (150 mg, 468 μmol, 1.00 eq) in EtOH (0.45 mL) was added a solution of NaOH in water (2.50 M, 468 uL, 2.50 eq) 25 °C. The mixture was stirred at 25 °C for 0.5 h. The product of sodium 3-(cyclopropylmethyl)-1-(4- (methylsulfonyl)phenethyl)-1H-pyrazol-5-olate in EtOH / H2O as a brown solution was used in next step without further purification. To a solution of 4,5-dimethylthiazol-2-amine (60.0 mg, 468 μmol, 1.00 eq) in HCl (644 mg, 6.18 mmol, 631 uL, 35% purity, 13.2 eq) was added a solution of NaNO2 (32.3 mg, 468 μmol, 1.00 eq) in H2O (0.40 mL) at 0 °C. The mixture was stirred at 0 °C for 0.5 h. The product of 4,5-dimethylthiazole-2- diazonium chloride in water as a yellow solution was used in next step without further purification. The solution of 4,5-dimethylthiazole-2-diazonium chloride (82.2 mg, 468 μmol, 1.00 eq, in water) was added dropwise to the solution of sodium 3-(cyclopropylmethyl)-1-(4-(methylsulfonyl)phenethyl)-1H- pyrazol-5-olate (160 mg, 468 μmol, 1.00 eq, in EtOH / H2O) at 0 °C. The resulting mixture was stirred at 25 °C for 1 h. The mixture was extracted with DCM (20.0 mL x 3). The combined organic was washed with brine (50.0 mL x 2), dried over Na2SO4, filtered. The filtrate was concentrated to give a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18150*25mm* 10um;mobile phase: [water(FA)-ACN]; B%: 51% - 81%,10min) to give (Z)-3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2- yl)hydrazono)-1-(4-(methylsulfonyl)phenethyl)-1H-pyrazol-5(4H)-one (25.5 mg, 53.7 μmol, 11.5% yield, 96.8% purity) as a red solid. MS: product: m / z 460.0 (M+H)+.1H NMR (400 MHz): CDCl3 δ 7.86 (d, J = 8.0 Hz, 2H), 7.43 (d, J = 8.0 Hz, 2H), 4.03 (t, J = 7.2 Hz, 2H), 3.16 (t, J = 7.2 Hz, 2H), 3.04 (s, 3H), 2.49 (d, J = 7.2 Hz, 2H), 2.32 (s, 3H), 2.25 (s, 3H), 1.09 - 1.02 (m, 1H), 0.60 - 0.53 (m, 2H), 0.30 - 0.26 (m, 2H). Example 41: Synthesis of Compound 41; (Z)-1-(1-(1H-pyrazole-3-carbonyl)pyrrolidin-3-yl)-3- (cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazono)-1H-pyrazol-5(4H)-one To a solution of (4Z)-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-2-pyrrolidin-3- yl-pyrazol-3-one (200 mg, 577 μmol, 1.00 eq) and 1H-pyrazole-3-carboxylic acid (64.7 mg, 577 μmol, 1.00 eq) in DMF (3.00 mL) was added HATU (263 mg, 693 μmol, 1.20 eq) and DIPEA (448 mg, 3.46 mmol, 603 uL, 6.00 eq). The mixture was stirred at 25 °C for 30 min. The mixture was diluted with DCM (30.0 mL). The mixture was washed with water (50.0 mL x2 ) and concentrated to give a residue. The residue was purified by prep-HPLC (0.05% FA condition) to give (Z)-1-(1-(1H-pyrazole-3- carbonyl)pyrrolidin-3-yl)-3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazono)-1H-pyrazol- 5(4H)-one (22.5 mg, 51.0 μmol, 8.84% yield, 99.9% purity) as a red solid. MS: product: m / z 441.1 (M+H)+.1H NMR (400 MHz): CDCl3 δ 7.42 (d, J=12.40 Hz, 1 H), 6.47 (s, 1 H), 4.75 - 4.73 (m, 1 H), 3.97 – 3.84 (m, 1 H), 3.81 - 3.72 (m, 2 H), 3.56 - 3.54 (m, 1 H), 2.25 - 2.15 ( m, 2 H), 2.22 - 2.15 (m, 1 H), 2.08 (s, 3 H), 2.02 (s, 4 H), 0.80 - 0.77 (m, 1 H), 0.31 - 0.26 (m, 2 H), 0.05 - 0.01 (m, 2 H). Example 42: Synthesis of Compound 42; (4Z)-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2- yl)hydrazono]-2-[[4-(2-hydroxyethoxy)phenyl]methyl]pyrazol-3-one To a solution of 4-hydroxybenzaldehyde (1.00 g, 8.19 mmol, 1.00 eq) in DMF (5.00 mL), K2CO3(2.26 g, 16.4 mmol, 2.00 eq) and 2-bromoethanol (1.74 g, 13.9 mmol, 988 uL, 1.70 eq) were added at 15~25°C under N2. The reaction mixture was stirred at 100°C for 12 h. H2O (40.0 mL) was added, and the mixture was stirred for 0.5 h at 15~25°C. The mixture was extracted with EA (30.0 mL x 3). The organic layer was washed with brine (50.0 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give 4-(2-hydroxyethoxy)benzaldehyde (1.10 g, 6.31 mmol, 77.1% yield, 95.4% purity) as a yellow oil. MS: product: m / z 166.8 (M+H)+. To a solution of 4-(2-hydroxyethoxy)benzaldehyde (500 mg, 3.01 mmol, 1.00 eq) in THF (5.00 mL) was added tert-butyl N-aminocarbamate (398 mg, 3.01 mmol, 1.00 eq) at 15~25°C under N2. The mixture was stirred at 15~25°C for 4 h. Then, AcOH (3.00 mL) and NaBH3CN (416 mg, 6.62 mmol, 2.20 eq) were added. The resulting mixture was stirred at 15~25°C for 12 h.1 M NaOH (50.0 mL, aqueous) was added dropwise (the pH was 9-10). The mixture was extracted with EA (30.0 mL x 3). The organic layer was washed with brine (50.0 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give tert-butyl N-[[4-(2-hydroxyethoxy)phenyl]methylamino]carbamate (900 mg, crude) as a yellow oil. The crude product was used into the next step without further purification. MS: product: m / z 304.9 (M+Na)+. To a tert-butyl N-[[4-(2-hydroxyethoxy)phenyl]methylamino]carbamate (900 mg, 3.19 mmol, 1.00 eq) was added TFA (5.00 mL) at 15~25°C. The mixture was stirred at 15~25°C for 1.5 h. The reaction mixture was concentrated under reduced pressure to give 2-[4-(hydrazinomethyl)phenoxy]ethanol (2.20 g, crude) as a yellow oil. MS: product: m / z 246.8 (M+MeCN+Na)+. The crude product was used into the next step without further purification. To a solution of 2-[4-(hydrazinomethyl)phenoxy]ethanol (1.00 g, 1.81 mmol, 33.0% purity, 1.00 eq) in EtOH (5.00 mL) was added ethyl 4-cyclopropyl-3-oxo-butanoate (401 mg, 2.35 mmol, 1.30 eq) at 15~25°C. The mixture was stirred at 80°C for 1 h. The reaction mixture was concentrated under reduced pressure and purified by Prep-HPLC (column: Xtimate C18150*40mm*5um;mobile phase: [water(HCl)- ACN];B%: 5%-35%,10min) to give 5-(cyclopropylmethyl)-2-[[4-(2-hydroxyethoxy)phenyl]methyl]pyrazol-3- ol (130 mg, 438 μmol, 24.2% yield, 97.1% purity) as a colourless oil. MS: product: m / z 289.1 (M+H)+.1H NMR (400 MHz, MeOD-d4) δ ppm 7.25 (d, J=8.4 Hz, 2H), 6.99 (d, J=8.8 Hz, 2H), 5.90 (s, 1H), 5.23 (s, 2H), 4.06 - 4.02 (m, 2H), 3.88 - 3.84 (m, 2H), 2.56 (d, J=7.2 Hz, 2H), 1.05 - 0.99 (m, 1H), 0.65 - 0.54 (m, 2H), 0.30 - 0.19 (m, 2H). To the mixture of 5-(cyclopropylmethyl)-2-[[4-(2-hydroxyethoxy)phenyl]methyl]pyrazol-3-ol (130 mg, 451 μmol, 1.00 eq) in EtOH (1.00 mL) was added NaOH in H2O (2.50 M, 451 uL, 2.50 eq) at 15~25°C, and the mixture was stirred for 0.5 h at 15~25°C to give a clear solution of [5- (cyclopropylmethyl)-2-[[4-(2-hydroxyethoxy)phenyl]methyl]pyrazol-3-yl]oxysodium in EtOH / H2O. The mixture of 4,5-dimethylthiazol-2-amine (87.0 mg, 679 μmol, 1.00 eq) in HCl (915 uL, 8.96 mmol, 35.0% purity, 13.2 eq) was cooled to -10~-5°C. The solution of NaNO2(46.8 mg, 679 μmol, 1.00 eq) in H2O (0.50 mL) was added dropwise at -10~-5°C. The mixture was stirred for 0.5 h at -10~-5°C to give a solution of 4,5-dimethyl-2-[BLAH(nitrido)-λ5-azanyl]thiazole in H2O. The mixture of [5-(cyclopropylmethyl)-2-[[4-(2-hydroxyethoxy)phenyl]methyl]pyrazol-3- yl]oxysodium (140 mg, 451 μmol, 1.00 eq, in EtOH / H2O) was added dropwise to the solution of 4,5- dimethyl-2-[BLAH(nitrido)-λ5-azanyl]thiazole (119 mg, 676 μmol, 1.50 eq, in H2O) at -10~-5°C. After complete addition, the mixture was stirred for 3 h at 15~25°C. H2O (20.0 mL) was added. The mixture was extracted with DCM (20.0 mL x 3). The organic layer was washed with brine (50.0 mL), dried over Na2SO4, filtered, concentrated under reduced pressure and purified by Prep-HPLC (column: Welch Xtimate C18100*40mm*3um;mobile phase: [water(HCl)-ACN];B%: 35%-65%,8min) to give (4Z)-5- (cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-2-[[4-(2-hydroxyethoxy)phenyl]methyl]pyrazol- 3-one (15.4 mg, 36.0 μmol, 7.99% yield, 100% purity) as a yellow solid. MS: product: m / z 428.3 (M+H)+.1H NMR (400 MHz, CDCl3-d) δ ppm 7.29 (d, J=8.4 Hz, 2H), 6.87 (d, J=8.8 Hz, 2H), 4.85 (s, 2H), 4.09 - 4.03 (m, 2H), 3.98 - 3.91 (m, 2H), 2.46 (d, J=7.2 Hz, 2H), 2.31 (s, 3H), 2.27 (s, 3H), 1.06 - 0.98 (m, 1H), 0.57 - 0.47 (m, 2H), 0.30 - 0.21 (m, 2H). Example 43: Synthesis of Compound 43; (Z)-2-(5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl)-5- (cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-2,4-dihydro-3H-pyrazol-3-one To the mixture of 4-methoxy-1,5-dihydro-2H-pyrrol-2-one (1.00 g, 8.84 mmol, 2.00 eq), iodobenzene (902 mg, 4.42 mmol, 493 μL, 1.00 eq), K2CO3 (1.22 g, 8.84 mmol, 2.00 eq), CuI (421 mg, 2.21 mmol, 0.500 eq) in 1,4-dioxane (5.00 mL) was added DMEDA (390 mg, 4.42 mmol, 476 μL, 1.00 eq) dropwise under N2. The mixture was stirred at 100 °C for 2 hr under N2 atmosphere. The reaction mixture was diluted with H2O (50.0 mL), extracted with EA (100 mL). The combined organic phase was washed with H2O (100 mL x 2), brine (200 mL), dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether / Ethyl acetate=1 / 0 to 1 / 1) to give 4-methoxy-1-phenyl-1,5-dihydro- 2H-pyrrol-2-one (394 mg, 2.08 mmol, 47.1% yield, N / A purity) as a white solid.1H NMR (400 MHz): CDCl3δ 7.65 (d, J = 8.0 Hz, 2H), 7.36 (td, J = 8.4, 8.0 Hz, 2H), 7.13 - 7.05 (m, 1H), 5.20 (s, 1H), 4.30 (s, 2H), 3.87 (s, 3H) A mixture of 4-methoxy-1-phenyl-1,5-dihydro-2H-pyrrol-2-one (294 mg, 1.55 mmol, 1.00 eq) in i- PrOH (2.00 mL) and HCl (12.0 M, 882 μL, 6.81 eq) was stirred at 50 °C for 16 hr under N2atmosphere. The reaction mixture was concentrated under reduced pressure to remove i-PrOH (2.00 mL) to give a residue. The residue was triturated with concentrated HCl (2.00 mL) at 50 °C for 2 hr. And then the solid was collected by filtration, washed with HCl (5.00 mL x 3 ), dried in vacuum to give 4-hydroxy-1-phenyl- 1,5-dihydro-2H-pyrrol-2-one (350 mg, 2.00 mmol, 64.3% yield, N / A purity) as a yellow solid.1H NMR (400 MHz): CDCl3 δ 7.66 (d, J = 7.6 Hz, 2H), 7.32 - 7.28 (m, 2H), 7.02 - 6.97 (m, 1H), 4.97 (s, 1H), 4.36 (s, 2H). To a solution of 4-hydroxy-1-phenyl-1,5-dihydro-2H-pyrrol-2-one (300 mg, 1.71 mmol, 1.00 eq) in EtOH (5.00 mL) was added NH2NH2.H2O (2.02 g, 34.3 mmol, 1.95 mL, 85.0% purity, 20.0 eq) at 25 °C .The mixture was stirred at 80 °C for 2 hr. The reaction mixture was concentrated under reduced pressure to give a residue. The residue 4-hydrazineyl-1-phenyl-1,5-dihydro-2H-pyrrol-2-one (300 mg, crude) as a white solid was used into the next step without further purification. A mixture of 4-hydrazineyl-1-phenyl-1,5-dihydro-2H-pyrrol-2-one (300 mg, 1.59 mmol, 1.00 eq) and ethyl 4-cyclopropyl-3-oxo-butanoate (405 mg, 2.38 mmol, 1.50 eq) in EtOH (5.00 mL) was stirred at 80 °C for 1 hr. The reaction mixture was diluted with H2O (50.0 mL) and extracted with EA (100 mL x 3). The combined organic layers were washed with aqueous NaCl (100 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue 1-cyclohexyl-4-(3- (cyclopropylmethyl)-5-hydroxy-1H-pyrazol-1-yl)-1,5-dihydro-2H-pyrrol-2-one (337 mg, crude) as a yellow solid was used into the next step without further purification. To the mixture of 1-cyclohexyl-4-(3-(cyclopropylmethyl)-5-hydroxy-1H-pyrazol-1-yl)-1,5-dihydro- 2H-pyrrol-2-one (300 mg, 1.02 mmol, 1.00 eq) in EtOH (3.00 mL) was added NaOH in H2O (2.50 M, 1.02 mL, 2.50 eq). The mixture was stirred at 25 °C for 0.5 h. The product of sodium 1-(1-cyclohexyl-5-oxo-2,5- dihydro-1H-pyrrol-3-yl)-3-(cyclopropylmethyl)-1H-pyrazol-5-olate in EtOH / H2O as a light yellow liquid was used in the next step without further purification. To a solution of 4,5-dimethylthiazol-2-amine (150 mg, 1.17 mmol, 1.00 eq) in HCl (1.61 g, 15.5 mmol, 1.58 mL, 35.0% purity, 13.2 eq) was added NaNO2 (80.7 mg, 1.17 mmol, 1.00 eq) in H2O (2.00 mL) at 0 °C. The mixture was stirred for 0.5 hr at 0 °C. The product of 4,5-dimethylthiazole-2-diazonium chloride in H2O as a yellow suspension was used in the next step without further purification. A solution of 4,5-dimethylthiazole-2-diazonium chloride (166 mg, 945 μmol, 1.00 eq, in H2O) was added dropwise to the solution of sodium 1-(1-cyclohexyl-5-oxo-2,5-dihydro-1H-pyrrol-3-yl)-3- (cyclopropylmethyl)-1H-pyrazol-5-olate (300 mg, 945 μmol, 1.00 eq, in EtOH / H2O) at 0 °C. The resulting mixture was stirred at 25°C for 1 hr. The reaction mixture was filtered to give a solid. The solid was purified by column chromatography (SiO2, DCM : MeOH =1 / 0 to 30 / 1) to give (4Z)-5-(cyclopropylmethyl)- 4-[(4,5-dimethylthiazol-2-yl)hydrazono]-2-(5-oxo-1-phenyl-2H-pyrrol-3-yl)pyrazol-3-one (43.5 mg, 91.3 μmol, 9.66% yield, 91.24% purity) as a red solid. MS: product: m / z 435.2 (M+H)+.1H NMR (400 MHz): CDCl3 δ 7.76 (d, J = 8.0 Hz, 2H), 7.43 - 7.34 (m, 2H), 7.15 - 7.10 (m, 1H), 6.31 (s, 1H), 4.97 - 4.78 (m, 2H), 2.62 - 2.56 (m, 2H), 2.35 (s, 3H), 2.30 (s, 3H), 1.13 - 1.07 (m, 1H), 0.68 - 0.51 (m, 2H), 0.44 - 0.20 (m, 2H) Example 44: Synthesis of Compound 44; 4-[4-[(4Z)-3-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2- yl)hydrazono]-5-oxo-pyrazol-1-yl]-2-oxo-pyrrolidin-1-yl]benzoic acid To a solution of 2-cyclopropylacetic acid (1.00 g, 9.99 mmol, 1.00 eq) in THF (10.0 mL) was added CDI (1.94 g, 11.9 mmol, 1.20 eq) at 20 °C. The mixture was stirred at 20 °C for 1 h. Then MgCl2 (1.14 g, 11.9 mmol, 491 uL, 1.20 eq) and (3-ethoxy-3-oxo-propanoyl)oxypotassium (2.55 g, 14.9 mmol, 1.50 eq) were added to the mixture at 20 °C. The resulting mixture was stirred at 20 °C for 16 h. The reaction mixture was quenched by water (20.0 mL), extracted with ethyl acetate (20 mL x 3). The combined organic was washed with brine (20.0 mL), dried over Na2SO4and filtered. The filtrate was concentrated under reduce pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0 ~ 5% Ethyl acetate / Petroleum ethergradient @ 30 mL / min) to give ethyl 4-cyclopropyl-3-oxo-butanoate (523 mg, 3.07 mmol, 30.7% yield) as a colorless oil.1H NMR (400 MHz): CDCl3δ: 4.10 - 4.23 (m, 2H), 3.39 - 3.53 (m, 2H), 2.33 - 2.46 (m, 2H), 1.15 - 1.35 (m, 4H), 0.43 - 0.63 (m, 2H), 0.10 (d, J = 2.5 Hz, 2H) A mixture of ethyl 4-cyclopropyl-3-oxo-butanoate (300 mg, 1.76 mmol, 1.00 eq) and methyl 4-(4- hydrazino-2-oxo-pyrrolidin-1-yl)benzoate (440 mg, 1.77 mmol, 1.00 eq) in MeOH (10.0 mL) was degassed and purged with N2for 3 times. Then the mixture was stirred at 65 °C for 2 hr under N2atmosphere. The mixture was filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was triturated with MeOH (20.0 mL) at 20 ~ 25 °C for 0.5 hr and filtered. The filtrate was concentrated under reduced pressure to give methyl 4-[4-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol- 1-yl]-2-oxo-pyrrolidin-1-yl]benzoate (518 mg, 1.21 mmol, 68.3% yield, 82.6% purity) as a yellow solid. MS:product: m / z 355.9 (M+H)+.To a solution of 4,5-dimethylthiazol-2-amine (145 mg, 1.13 mmol, 1.00 eq) in HCl (1.50 mL, 14.7 mmol, 35.0% purity) was added dropwise a solution of NaNO2 (79.0 mg, 1.14 mmol, 1.01 eq) in H2O (1.00 mL) at 0 ~ 5 °C. The resulting mixture was stirred at 0 ~ 5 °C for 0.5 hr. The mixture of 4,5-dimethyl- 2-[BLAH(nitrido)-λ5-azanyl]thiazole in H2O was used directly as theory amount in next step without work- up. Two batches were set-up in same scale. To a mixture of methyl 4-[4-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]-2-oxo-pyrrolidin-1- yl]benzoate (400 mg, 1.13 mmol, 1.00 eq) and EtOH (1.00 mL) was added NaOH in H2O (2.50 M, 1.13 mL, 2.50 eq). The mixture was stirred at 15 ~ 25 °C for 5 min. The mixture of [5-(cyclopropylmethyl)-2-[1- (4-methoxycarbonylphenyl)-5-oxo-pyrrolidin-3-yl]pyrazol-3-yl]oxysodium in EtOH / H2O was used as theory amount in next step without work-up. The solution of 4,5-dimethyl-2-[BLAH(nitrido)-λ5-azanyl]thiazole (198 mg, 1.13 mmol, 1.00 eq, in H2O) was added dropwise to the solution of [5-(cyclopropylmethyl)-2-[1-(4-methoxycarbonylphenyl)-5- oxo-pyrrolidin-3-yl]pyrazol-3-yl]oxysodium (426 mg, 1.13 mmol, 1.00 eq, in EtOH / H2O) at 0 ~ 5 °C. After complete addition, the mixture was stirred for 0.5 hr at 15~25 °C. And then to the mixture was added dropwise another batches of 4,5-dimethyl-2-[BLAH(nitrido)-λ5-azanyl]thiazole (198 mg, 1.13 mmol, 1.00 eq, in H2O) at 0 ~ 5 °C for 16 hr. The mixture was filtered and the wet cake was washed with H2O (10.0 mL x 2). The wet cake was triturated with MeOH / DCM = 4 mL / 0.5 mL at 20 ~ 25 °C for 0.5 hr and filtered. The wet cake was triturated with isopropanol (3.00 mL) at 20 ~ 25 °C for 0.5 hr and filtered. The filtrate was concentrated under reduced pressure to give a residue. The residue was purified by prep- HPLC (column: Phenomenex luna C18150 * 25mm * 10um; mobile phase: [water(HCl) - ACN]; B%: 28% - 58%, 10 min) to give a crude product. The crude product was purified by prep-HPLC (column: Welch Xtimate C18150 * 25mm * 5um; mobile phase: [water (HCl) - ACN]; B%: 31% - 61%, 8 min) to give 4-[4- [(4Z)-3-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-5-oxo-pyrazol-1-yl]-2-oxo-pyrrolidin-1- yl]benzoic acid (12.0 mg, 23.1 μmol, 26.4% yield, 92.6% purity) as a red solid. MS: product: m / z 480.3 (M+H)+;1H NMR (400 MHz): CDCl3δ: 7.86 (d, J=8.4 Hz, 2H), 7.76 (d, J=8.8 Hz, 2H), 5.13 - 5.25 (m, 1H), 4.05 - 4.26 (m, 2H), 2.96 - 3.16 (m, 2H), 2.51 (d, J = 7.0 Hz, 2H), 2.35 (s, 3H), 2.31 (s, 3H), 0.99 - 1.09 (m, 1H), 0.52 - 0.61 (q, J = 4.8 Hz, 2H), 0.28 (q, J = 4.8 Hz, 2H). Example 45: Synthesis of Compound 45; (4Z)-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2- yl)hydrazono]-2-[[3-(2-hydroxyethoxy)phenyl]methyl]pyrazol-3-one To a solution of 3-hydroxybenzaldehyde (1.00 g, 8.19 mmol, 1.00 eq) in DMF (20.0 mL) was added Cs2CO3 (4.00 g, 12.3 mmol, 1.50 eq) and 2-bromoethanol (1.02 g, 8.19 mmol, 581 uL, 1.00 eq). The mixture was stirred at 60 °C for 12 h. The reaction mixture was poured into H2O (30.0 mL), extracted with EtOAc (50.0 mLx3). The combined organic layers were washed with H2O (30.0 mLx4) and brine (20.0 mLx2), dried over Na2SO4, filtered and concentrated under vacuum to give a residue. The residue was purified by flash silica gel chromatography (Eluent of 0~12% Ethyl acetate / Dichloromethane) to give compound 3-(2-hydroxyethoxy)benzaldehyde (330 mg, 1.99 mmol, 24.3% yield) as a yellow oil.1H NMR (400MHz, CHLOROFORM-d) δ = 7.47 - 7.39 (m, 2H), 7.38 - 7.36 (m, 1H), 7.21 - 7.15 (m, 1H), 4.15 - 4.09 (m, 2H), 4.00 - 3.95 (m, 2H). To a solution of 3-(2-hydroxyethoxy)benzaldehyde (300 mg, 1.81 mmol, 1.00 eq) and tert-butyl N- aminocarbamate (286 mg, 2.17 mmol, 1.20 eq) in DCM (6.00 mL) was added Acetic acid (498 mg, 1.81 mmol, 1.00 eq). The mixture was stirred at 25 °C for 2h, NaBH3CN (363 mg, 5.78 mmol, 3.20 eq) was added. The mixture was stirred at 25 °C for 4 h. The reaction mixture was quenched with 1 M aqueous NaOH (30.0 mL), extracted with DCM (40.0 mLx3). The combined organic layers were washed with brine (30.0 mLx2), dried over Na2SO4, filtered and concentrated under vacuum to give compound tert-butyl N- [[3-(2-hydroxyethoxy)phenyl]methylamino]carbamate (500 mg, crude) as a yellow oil. To a solution of tert-butyl N-[[3-(2-hydroxyethoxy)phenyl]methylamino]carbamate (0.50 g, 1.77 mmol, 1.00 eq) in DCM (5.00 mL) was added TFA (4.62 g, 40.5 mmol, 3.00 mL, 22.9 eq). The mixture was stirred at 25 °C for 1 h. The reaction mixture was concentrated under vacuum to give a 2-[3- (hydrazinomethyl)phenoxy]ethanol (500 mg, crude) as a yellow oil. A mixture of 2-[3-(hydrazinomethyl)phenoxy]ethanol (400 mg, 2.20 mmol, 1.00 eq) and ethyl 4- cyclopropyl-3-oxo-butanoate (448 mg, 2.63 mmol, 1.20 eq) was dissolved in EtOH (6.00 mL). The mixture was stirred at 80 °C for 1 h. The reaction mixture was concentrated in vacuum to give a residue. The residue was purified by prep-HPLC (column: Phenomenex C18150*40mm*5um;mobile phase: [water(HCl)-ACN];B%: 5%-35%,10min) to give 5-(cyclopropylmethyl)-2-[[3-(2- hydroxyethoxy)phenyl]methyl]pyrazol-3-ol (140 mg, 476 μmol, 21.7% yield, 98% purity) as a yellow oil. To a mixture of 4,5-dimethylthiazol-2-amine (110 mg, 858 μmol, 1.00 eq) in HCl (1.14 g, 11.6 mmol, 1.12 mL, 37% purity, 13.5 eq) was dropwise added a solution of NaNO2 (88.8 mg, 1.29 mmol, 1.50 eq) in H2O (1.50 mL) at -5°C. The mixture was stirred at -5°C for 0.5 h. The product of 2-BLAH-4,5- dimethyl-thiazole in H2O as a yellow liquid was used into the next step without further purification. To a solution of 5-(cyclopropylmethyl)-2-[[3-(2-hydroxyethoxy)phenyl]methyl]pyrazol-3-ol (140 mg, 486 μmol, 1.00 eq) in EtOH (1.50 mL) was dropwise added NaOH in H2O (2.50 M, 194 uL, 1.00 eq). The mixture was stirred at 25 °C for 0.5 h. The product of [5-(cyclopropylmethyl)-2-[[3-(2- hydroxyethoxy)phenyl]methyl]pyrazol-3-yl]oxysodium in EtOH / H2O as a yellow liquid was used into the next step without further purification. To a mixture of 2-BLAH-4,5-dimethyl-thiazole (119 mg, 677 μmol, 1.50 eq, in H2O) was dropwise added a solution of [5-(cyclopropylmethyl)-2-[[3-(2-hydroxyethoxy)phenyl]methyl]pyrazol-3-yl]oxysodium (140 mg, 451 μmol, 1.00 eq, in EtOH / H2O) at -5°C. The mixture was stirred at 25 °C for 0.5 h. The reaction mixture was quenched with H2O (10.0 mL), extracted with DCM (30.0 mLx2). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered and concentrated under vacuum to give the red solid. The red solid was purified by prep-HPLC (column: Xtimate C18 150*40mm*5um;mobile phase: [water(HCl)-ACN];B%: 45%-75%,10min) to give compound (4Z)-5- (cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-2-[[3-(2-hydroxyethoxy)phenyl]methyl]pyrazol- 3-one (19.0 mg, 44.4 μmol, 9.85% yield, 100% purity) as a red solid.MS: product: m / z 428.2(M+H)+.1H NMR (400MHz, CHLOROFORM-d) δ = 7.25 - 7.20 (m, 1H), 6.99 - 6.91 (m, 2H), 6.84 (d, J=7.80 Hz, 1H), 4.90 - 4.86 (m, 2H), 4.17 - 4.04 (m, 2H), 4.02 - 3.90 (m, 2H), 2.46 (s, 2H), 2.39 (s, 3H), 2.35 (s, 3H), 1.09 - 0.95 (m, 1H), 0.59 - 0.51 (m, 2H), 0.27 - 0.20 (m, 2H). Example 46: Synthesis of Compound 46; 8-[(4Z)-3-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2- yl)hydrazono]-5-oxo-pyrazol-1-yl]-2-azaspiro[4.5]decan-3-one 9,12-dioxa-3-azadispiro[4.2.48.25]tetradecan-2-one (0.25 g, 1.18 mmol, 1.00 eq) was dissolved in HCl in H2O (2.00 M, 592 uL, 1.00 eq). The mixture was stirred at 25 °C for 2 h. The reaction mixture was concentrated under vacuum to give a residue. The residue was diluted with H2O (10.0 mL), extracted with EtOAc (15.0 mLx3). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered and concentrated under vacuum to give a residue. The residue was purified by prep- HPLC (column: Welch Xtimate C18100*40mm*3um;mobile phase: [water(HCl)-ACN];B%: 0%-30%,8min) to give compound 2-azaspiro[4.5]decane-3,8-dione (130 mg, 777 μmol, 65.7% yield, N / A purity) as a yellow oil. To a stirred solution of 2-azaspiro[4.5]decane-3,8-dione (130 mg, 777μmol, 1.00 eq) in Acetic acid (2.00 mL) was added tert-butyl N-aminocarbamate (123mg, 933 μmol, 1.20 eq) at 25°C. After 0.5 h,NaBH3CN (48.9 mg, 777 μmol, 1.00 eq) was added. The mixture was stirred at 25 °C for 0.5 h. Thereaction mixture was adjusted to pH=8-9 with aqueous 5 M NaOH, extracted with DCM (20.0 mLx3). The combined organic layers were washed with brine (15.0 mL), dried over Na2SO4, filtered and concentrated under vacuum to give tert-butyl N-[(3-oxo-2-azaspiro[4.5]decan-8-yl)amino]carbamate (0.30 g, crude) as a yellow oil. To a solution of tert-butyl N-[(3-oxo-2-azaspiro[4.5]decan-8-yl)amino]carbamate (180 mg, 635 μmol, 1.00 eq) in DCM (5.00 mL) was added TFA (1.45 g, 12.7 mmol, 941 uL, 20.0 eq). The mixture was stirred at 25 °C for 1 h. The reaction mixture was concentrated under vacuum to give 8-hydrazino-2- azaspiro[4.5]decan-3-one (200 mg, crude) as a yellow oil. To a solution of 8-hydrazino-2-azaspiro[4.5]decan-3-one (200 mg, 1.09 mmol, 1.00 eq) in EtOH (4.00 mL) was added ethyl 4-cyclopropyl-3-oxo-butanoate (223 mg, 1.31 mmol, 1.20 eq). The mixture was stirred at 80 °C for 1 h. The reaction mixture was concentrated under vacuum to give a residue. The residue was purified by prep-HPLC (column: Welch Xtimate C18100*40mm*3um;mobile phase: [water(HCl)-ACN];B%: 0%-30%,8min) to give 8-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]-2- azaspiro[4.5]decan-3-one (60.0 mg, 196 μmol, 18.0% yield, 94.6% purity) as a yellow oil. MS: product: m / z 290.0 (M+H)+To a mixture of 4,5-dimethylthiazol-2-amine (51.0 mg, 398 μmol, 1.00 eq) in HCl (529 mg, 5.37 mmol, 519 uL, 37% purity, 13.5 eq) was dropwise added a solution of NaNO2 (41.17 mg, 596.75 μmol, 1.5 eq) in H2O (0.7 mL) at -5°C. The mixture was stirred at -5°C for 0.5 h. The product of 2-BLAH-4,5- dimethyl-thiazole in H2O as a yellow liquid was used into the next step without further purification. To a solution of 8-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]-2-azaspiro[4.5]decan-3-one (60.0 mg, 207 μmol, 1.00 eq) in EtOH (1.00 mL) was added NaOH in H2O (2.50 M, 207 uL, 2.50 eq). The mixture was stirred at 25 °C for 0.5 h. The product of [5-(cyclopropylmethyl)-2-(3-oxo-2- azaspiro[4.5]decan-8-yl)pyrazol-3-yl]oxysodium in EtOH / H2O as a yellow liquid was used into the next step without further purification. To a mixture of 2-BLAH-4,5-dimethyl-thiazole (50.8 mg, 289 μmol, 1.50 eq) was dropwise added a solution of [5-(cyclopropylmethyl)-2-(3-oxo-2-azaspiro[4.5]decan-8-yl)pyrazol-3-yl]oxysodium (60.0 mg, 193 μmol, 1.00 eq) in EtOH (1.00 mL) at -5 °C. The mixture was stirred at 25°C for 0.5 h. The reaction mixture was quenched with H2O (20.0 mL), extracted with DCM (30.0 mLx3). The combined organic layers were washed with brine (10.0 mL), dried over Na2SO4, filtered and concentrated under vacuum to give a residue. The residue was purified by prep-HPLC (column: Welch Xtimate C18 100*40mm*3um;mobile phase: [water(HCl)-ACN];B%: 33%-63%,8min) to give 8-[(4Z)-3- (cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-5-oxo-pyrazol-1-yl]-2-azaspiro[4.5]decan-3- one (2.80 mg, 6.53 μmol, 3.39% yield, 100% purity) as a red solid.MS: product: m / z 429.2(M+H)+.1H NMR (400MHz, CHLOROFORM-d) δ = 4.12 (s, 1H), 3.35 (s, 1H), 3.16 (s, 1H), 2.48 (d, J=6.80 Hz, 2H), 2.36 - 2.33 (m, 1H), 2.31 (s, 3H), 2.28 (s, 3H), 2.19 (s, 1H), 1.96-1.85 (m, 4H), 1.83 - 1.72 (m, 2H), 1.62 - 1.48 (m, 2H), 1.03 (s, 1H), 0.54 (d, J=7.20 Hz, 2H), 0.27 (d, J=4.80 Hz, 2H). Example 47: Synthesis of Compound 47; (Z)-3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2- yl)hydrazono)-1-(1-(4-(methylsulfonyl)phenyl)-2-oxopyrrolidin-3-yl)-1H-pyrazol-5(4H)-one To a solution of 1-(4-bromophenyl)pyrrolidin-2-one (1.00 g, 4.16 mmol, 1.00 eq) and tert-butyl (NE)- N-tert-butoxycarbonyliminocarbamate (1.34 g, 5.83 mmol, 1.40 eq) in THF (30.0 mL) was added dropwise NaHMDS in THF (1.00 M, 4.98 mL, 1.20 eq) at -70 °C over 30 min. After addition, the mixture was stirred at this temperature for 1 h. The reaction mixture was quenched by aqueous solution of NH4Cl (10.0 mL) at -78 °C, and then diluted with H2O (40.0 mL) and extracted with EA (50.0 mL x 2). The combined organic layers were washed with brine (40.0 mL ), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (eluent of 10 ~ 60% EA in PE gradient) to give tert-butyl N-[1-(4-bromophenyl)-2-oxo-pyrrolidin-3-yl]-N- (tert-butoxycarbonylamino)carbamate (1.71 g, 3.60 mmol, 86.42% yield, 99% purity) as a white solid. MS: product: m / z 471.9 (M+H)+. A mixture of tert-butyl N-[1-(4-bromophenyl)-2-oxo-pyrrolidin-3-yl]-N-(tert- butoxycarbonylamino)carbamate (800 mg, 1.70 mmol, 1.00 eq), methylsulfinyloxysodium (260 mg, 2.55 mmol, 1.50 eq), CuI (32.3 mg, 170 μmol, 0.100 eq) and L-proline (39.2 mg, 340 μmol, 0.200 eq) in DMSO (8.00 mL) was degassed and purged with N2 for 3 times. The mixture was stirred at 120 °C for 16 h under N2atmosphere. The reaction mixture was diluted with H2O (50.0 mL) and extracted with EA (25.0 mLx2). The combined organic layers were washed with brine (25.0 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 40g SepaFlash® Silica Flash Column, Eluent of 0~100% PE / EA @ 30mL / min) to give tert-butyl N-(tert-butoxycarbonylamino)-N-[1-(4-methylsulfonylphenyl)-2-oxo-pyrrolidin-3-yl] carbamate (230 mg, 490 μmol, 28.8% yield) was obtained as a yellow oil. MS: product: m / z 470.0(M+H)+. A mixture of tert-butyl N-(tert-butoxycarbonylamino)-N-[1-(4-methylsulfonylphenyl)-2-oxo-pyrrolidin- 3-yl]carbamate (460 mg, 980 μmol, 1.00 eq) in 4 mol / L HCl / dioxane (10.0 mL), and then the mixture was stirred at 50 °C for 5 h. The mixture was concentrated to give 3-hydrazino-1-(4-methylsulfonylphenyl) pyrrolidin-2-one (265 mg, crude) was obtained as a light yellow solid. MS: product: m / z 269.8 (M+H)+. A mixture of 3-hydrazino-1-(4-methylsulfonylphenyl) pyrrolidin-2-one (165 mg, 613 μmol, 1.00 eq) and ethyl 4-cyclopropyl-3-oxo-butanoate (115 mg, 674 μmol, 1.10 eq) in AcOH (4.00 mL) was degassed and purged with N2for 3 times, and then the mixture was stirred at 100 °C for 2 h under N2 atmosphere. The reaction mixture was concentrated to dryness to give a residue. The residue was purified by reversed-phase HPLC (0.0500% TFA condition) to give 5-(cyclopropylmethyl)-2-[1-(4- methylsulfonylphenyl)-2-oxo-pyrrolidin-3-yl]-4H-pyrazol-3-one 972.6 (202 mg, 511 μmol, 83.4% yield, 95.0% purity) was obtained as a light yellow solid. MS: product: m / z 375.9 (M+H)+. To the mixture of 5-(cyclopropylmethyl)-2-[1-(4-methylsulfonylphenyl)-2-oxo-pyrrolidin-3-yl]-4H- pyrazol-3-one 972.6 (202 mg, 538 μmol, 1.00 eq) in EtOH (3.00 mL) was added NaOH in H2O (2.50 M, 1.08 mL, 5.00 eq) at 25 °C, and the mixture was stirred for 0.5 h at 25 °C to give a clear solution. The product of sodium 3-(cyclopropylmethyl)-1-(1-(4-(methylsulfonyl)phenyl)-2-oxopyrrolidin-3-yl)-1H-pyrazol- 5-olate 972.7 in EtOH / H2O as a light yellow liquid was used into the next step without further purification. To a mixture of 4,5-dimethylthiazol-2-amine 972.8A (83.0 mg, 647 μmol, 1.00 eq) in HCl (337 mg, 3.24 mmol, 331 uL, 35.0% purity, 5.00 eq)was added a solution of NaNO2(44.7 mg, 647 μmol, 1.00 eq) in H2O (1.00 mL) at 0 °C, and then the mixture was stirred for 1 h at 0 °C. The product of 4,5- dimethylthiazole-2-diazonium chloride 972.8 in H2O as a yellow liquid was used into the next step without further purification. A solution of 4,5-dimethylthiazole-2-diazonium chloride (113 mg, 643 μmol, 1.20 eq, in H2O) was added dropwise to the solution of sodium 3-(cyclopropylmethyl)-1-(1-(4-(methylsulfonyl)phenyl)-2- oxopyrrolidin-3-yl)-1H-pyrazol-5-olate (213 mg, 536 μmol, 1.00 eq, in EtOH / H2O) at 0°C. After complete addition, the mixture was stirred for 1 h at 25°C. The reaction mixture was partitioned between DCM (30.0 mL) and H2O (10.0 mL). The organic phase was separated, and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (0.05% FA condition) to give(Z)-3- (cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazono)-1-(1-(4-(methylsulfonyl)phenyl)-2- oxopyrrolidin-3-yl)-1H-pyrazol-5(4H)-one (13.5mg, 24.7 μmol, 4.61% yield, 93.9% purity) was obtained as a red solid. MS: product: m / z 515.0(M+H)+.1H NMR (400 MHz): CDCl3δ 7.97 - 7.90 (m, 4H), 5.22 (t, J = 9.6 Hz, 1H), 4.07 - 4.00 (m, 1H), 3.96 - 3.90 (m, 1H), 3.05 (s, 3H), 2.65 - 2.60 (m, 2H), 2.52 - 2.49 (m, 2H), 2.31 (s, 3H), 2.24 (s, 3H), 1.08 - 1.03 (m, 1H), 0.55 - 0.52 (m, 2H), 0.30 - 0.26 (m, 2H).

[0020] Example 48: Synthesis of Compound 48; sodium (Z)-3-(4-(3-(cyclopropylmethyl)-4-(2-(4,5- dimethylthiazol-2-yl)hydrazineylidene)-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)-2-oxopyrrolidin-1- yl)benzoate To a solution of methyl 3-aminobenzoate (2.00 g, 13.2 mmol, 1.00 eq) in H2O (20.0 mL) was added HCl (1.00 M, 13.2 mL, 1.00 eq) at 25 °C and pH = 1. The solution was kept at 40 °C and 2,5-dimethoxy- 2,5-dihydrofuran (1.72 g, 13.2 mmol, 1.00 eq) was added. The resulting mixture was stirred at 25 °C for 30 min. The reaction mixture was cooled to 25 °C. The mixture was added DCM (10.0 mL) and slowly added saturated aqueous Na2HPO4 solution to pH = 7. The reaction mixture was extracted with DCM (30.0 mL). The combined organic phase was washed with H2O (20.0 mL x 2), brine (10.0 mL), dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure to give a crude. The crude was purified by column chromatography (SiO2, Petroleum ether / Ethyl acetate = 10 / 1 to 5 / 1) to give methyl 3- (2-oxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate (950 mg, 2.78 mmol, 24.1% yield, 63.5% purity) as a yellow oil. MS: product: m / z 218.2 (M+H)+. To a solution of methyl 3-(2-oxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate (950 mg, 4.37 mmol, 467 uL, 1.00 eq) in EtOH (10.0 mL) was added NH2NH2.H2O (5.15 g, 87.4 mmol, 5.00 mL, 85% purity, 20.0 eq) at 25 °C. The mixture was stirred at 80 °C for 2 hr. The mixture was concentrated at 40 °C to give methyl 3- (4-hydrazineyl-2-oxopyrrolidin-1-yl)benzoate (1.00 g, 4.01 mmol, 91.7% yield) as yellow solid. The solution of methyl 3-(4-hydrazineyl-2-oxopyrrolidin-1-yl)benzoate (900 mg, 3.61 mmol, 1.00 eq) and ethyl 4-cyclopropyl-3-oxobutanoate (614 mg, 3.61 mmol, 1.00 eq) in EtOH (10.0 mL) was stirred at 25 °C. The mixture was stirred at 25 °C for 2 hr. The reaction mixture was poured into water (20.0 mL) and extracted with dichloromethane (20.0 mL x 2). The combined organic phase was washed with brine (20.0 mL), dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, Petroleum ether / Ethyl acetate=10 / 1 to 3 / 1) to give methyl 3-(4-(3-(cyclopropylmethyl)-5-hydroxy-1H-pyrazol-1-yl)-2-oxopyrrolidin-1-yl)benzoate (700 mg, 1.62 mmol, 44.7% yield, 82.1% purity) as a yellow solid. MS: product: m / z 355.8 (M)+.1H NMR (400 MHz, CHLOROFORM-d) δ ppm 9.38 - 9.01 (m, 1H), 8.21 (s, 1H), 7.68 (d, J = 7.6 Hz, 1H), 7.57 (br s, 1H), 7.45 (br s, 1H), 5.54 - 5.24 (m, 1H), 5.13 - 5.03 (m, 1H), 4.22 - 3.95 (m, 3H), 3.35 (s, 2H), 2.97 (br d, J = 7.2 Hz, 2H), 2.28 (br d, J = 7.2 Hz, 2H), 0.89 - 0.80 (m, 1H), 0.56 (br d, J = 6.0 Hz, 2H), 0.16 (br d, J = 4.4 Hz, 2H) To the mixture of methyl 3-(4-(3-(cyclopropylmethyl)-5-hydroxy-1H-pyrazol-1-yl)-2-oxopyrrolidin-1- yl)benzoate (200 mg, 562 μmol, 1.00 eq) in EtOH (1.00 mL) was added aqueous NaOH (2.50 M, 562 uL, 2.50 eq) at 25 °C. The reaction mixture was stirred for 0.5 h at 25 °C to give a sodium 1-(1-(3- carboxyphenyl)-5-oxopyrrolidin-3-yl)-3-(cyclopropylmethyl)-1H-pyrazol-5-olate as clear solution. The clear solution was directly used as theory amount in next step without work-up. The solution of 4,5-dimethylthiazol-2-amine (73.0 mg, 569 μmol, 1.00 eq) in HCl (0.77 mL, 7.52mmol, 35.0% purity) was cooled to 0 °C. The solution of NaNO2(39.3 mg, 569 μmol, 1.00 eq) in H2O(0.70 mL) was added dropwise to the above mixture at 0 °C. The mixture was stirred for 0.5 hr at 0 °C to give 4,5-dimethylthiazole-2-diazonium chloride as turbid liquid. The mixture was directly used as theory amount in next step without work-up. The reaction mixture of sodium 1-(1-(3-carboxyphenyl)-5-oxopyrrolidin-3-yl)-3-(cyclopropylmethyl)- 1H-pyrazol-5-olate (216 mg, 560 μmol, 1.00 eq, in EtOH / H2O) was added dropwise to the solution of 4,5-dimethylthiazole-2-diazonium chloride (98.5 mg, 560 μmol, 1.00 eq, in H2O). The resulting mixture was stirred at 0~25 °C for 0.5 hr. The mixture was filtered. The wet cake was washed with H2O (4.00 mL), dried under vacuo to give the crude. The crude was washed with water (20.0 mL ), dried under reduced pressure to give the solid. The solid was purified by prep-HPLC(column: Welch Ultimate C18150*25 mm*5 um;mobile phase: [water(TFA)-ACN];B%: 40%-70%,10 min) to give (Z)-3-(4-(3- (cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)-2- oxopyrrolidin-1-yl)benzoic acid (14.8 mg, 28.2 μmol, 5.03% yield, 91.5% purity) as a red solid. MS: product: m / z 480.8 (M+H)+. To a solution of (Z)-3-(4-(3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-5- oxo-4,5-dihydro-1H-pyrazol-1-yl)-2-oxopyrrolidin-1-yl)benzoic acid (14.8 mg, 30.8 μmol, 1.00 eq) in MeCN (0.50 mL) was added NaOH (1.23 mg, 30.8 μmol, 16.8 uL, 1.00 eq) and H2O (2.00 mL). The mixture was stirred at 25 °C for 10 min. The mixture was lyophilized to give sodium (Z)-3-(4-(3-(cyclopropylmethyl)-4- (2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)-2-oxopyrrolidin-1- yl)benzoate (6.0 mg, 11.9 μmol, 38.7% yield) as a red solid. MS: product: m / z 480.9 (M-Na)+.1H NMR (400 MHz, METHANOL - d4) δ ppm 8.18 (br s, 1H), 7.89 - 7.81 (m, 2H), 7.46 (t, J = 8.0 Hz, 1H), 5.16 (br s, 1H), 4.35 - 4.26 (m, 1H), 4.05 (dd, J = 4.4, 10.2 Hz, 1H), 3.08 - 2.91 (m, 2H), 2.52 (br s, 2H), 2.29 (s, 3H), 2.20 (s, 3H), 1.08 (br s, 1H), 0.46 (br d, J = 7.2 Hz, 2H), 0.23 (br d, J = 4.4 Hz, 2H) Example 49: Synthesis of Compound 49; (Z)-5-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2- yl)hydrazineylidene)-2-(1-(tetrahydrofuran-3-carbonyl)pyrrolidin-3-yl)-2,4-dihydro-3H-pyrazol-3-one To a solution of (4Z)-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-2-pyrrolidin-3- yl-pyrazol-3-one (150 mg, 433 μmol, 1.00 eq) and tetrahydrofuran-3-carboxylic acid (50.3 mg, 433 μmol, 41.6 uL, 1.00 eq) in DMF (2 mL) was added HATU (198 mg, 520 μmol, 1.20 eq) and DIEA (224 mg, 1.73 mmol, 302 uL, 4.00 eq). The mixture was stirred at 25 °C for 20 min. The mixture was concentrated to give a residue. The crude product was purified by prep-HPLC (0.05% NH3.H2O) to give (4Z)-5- (cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-2-[1-(tetrahydrofuran-3-carbonyl)pyrrolidin-3- yl]pyrazol-3-one (5.90 mg, 13.2 μmol, 3.04% yield, 99.2% purity) as a red solid. MS: m / z 445.3 (M+H)+.1H NMR (400 MHz): CDCl3δ 4.96 - 4.88 (m, 1H), 4.03 - 3.89 (m, 1H), 3.88 - 3.85 (m, 6H), 3.84 - 3.76 (m, 1H), 3.25 - 3.06 (m, 1H), 2.46 (t, J = 7.2 Hz 2H), 2.32 - 2.30 (m, 1H), 2.26 (s, 3H), 2.25 - 2.24 (m, 1H), 2.22 (m, 3H), 2.20 - 2.11 (m, 1H), 2.09 (d, J = 8.0 Hz 1H) , 1.06 - 1.00 (m, 1H) , 0.56 - 0.52 (m, 2H) , 0.27 - 0.25 (m, 2H). Example 50: Synthesis of Compound 50; (Z)-3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2- yl)hydrazono)-1-(1-(1-(methylsulfonyl)piperidin-4-yl)-5-oxopyrrolidin-3-yl)-1H-pyrazol-5(4H)-one To a solution of 1-methylsulfonylpiperidin-4-amine (2.00 g, 11.2 mmol, 1.00 eq) in HCl (1.00 M, 16.0 mL, 1.43 eq) was added 2,5-dimethoxy-2,5-dihydrofuran (1.61 g, 12.3 mmol, 1.10 eq) at 40 °C. The mixture was stirred at 40 °C for 0.5 h. The mixture was adjusted to pH=8 with saturated sodium bicarbonate solution. Then the mixture was extracted with EA (100 mL x 3). The combed organic layers were washed with brine (100 mL), dried over Na2SO4and concentrated to dryness. The residue was purified by flash silica gel chromatography (eluent of 0 ~ 10% MeOH in DCM gradient) to give 1-(1- methylsulfonyl-4-piperidyl)-2H-pyrrol-5-one (1.33 g, 4.09 mmol, 36.4% yield, 75.0% purity) as a red solid. MS: product: m / z 244.7 (M+H)+. To a solution of 1-(1-methylsulfonyl-4-piperidyl)-2H-pyrrol-5-one (1.32 g, 5.41 mmol, 1 eq) in EtOH (15.0 mL) was added NH2NH2.H2O (0.640 g, 10.8 mmol, 621 uL, 85.0% purity, 2.01 eq). The mixture was stirred at 80 °C for 4 h. The mixture was concentrated under reduced pressure to give 4-hydrazino-1-(1- methylsulfonyl-4-piperidyl)pyrrolidin-2-one (1.42 g, crude) as a yellow solid. A mixture of 4-hydrazino-1-(1-methylsulfonyl-4-piperidyl)pyrrolidin-2-one (600 mg, 2.17 mmol, 1.00 eq), methyl 4-cyclopropyl-3-oxo-butanoate (339 mg, 2.17 mmol, 1.00 eq) and AcOH (13.0 mg, 217 μmol, 12.4 uL, 0.10 eq) in Dioxane (12.0 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 100 °C for 1 h under N2atmosphere. The reaction mixture was concentrated to dryness. The residue was purified by flash silica gel chromatography (eluent of 0~10% MeOH in DCM gradient) to give 4-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]-1-(1-methylsulfonyl-4- piperidyl)pyrrolidin-2-one (151 mg, 343 μmol, 15.8% yield, 86.9% purity) as a light yellow solid. MS: product: m / z 383.0 (M+H)+. To a mixture of 4-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]-1-(1-methylsulfonyl-4- piperidyl)pyrrolidin-2-one (151 mg, 395 μmol, 1.00 eq) in EtOH (3.00 mL) was added NaOH in H2O (2.50 M, 395 uL, 2.50 eq) at 20 °C, and the mixture was stirred for 0.5 h at 20 °C. The product of [5- (cyclopropylmethyl)-2-[1-(1-methylsulfonyl-4-piperidyl)-5-oxo-pyrrolidin-3-yl]pyrazol-3-yl]oxysodium in EtOH / H2O as a light yellow liquid was used into the next step without further purification. To a the mixture of 4,5-dimethylthiazol-2-amine (70.0 mg, 546 μmol, 1.00 eq) in HCl (569 mg, 5.46 mmol, 558 uL, 35.0% purity, 10.0 eq) was added NaNO2 (37.7 mg, 546 μmol, 1.00 eq) in H2O (1.00 mL) at 0 °C, and then the mixture was stirred for 1 h at 0 °C. The product of 4,5-dimethylthiazole-2- diazonium chloride in H2O as a yellow liquid was used into the next step without further purification. A solution of 4,5-dimethylthiazole-2-diazonium chloride (83.2 mg, 474 μmol, 1.20 eq) in H2O was added dropwise to the solution of [5-(cyclopropylmethyl)-2-[1-(1-methylsulfonyl-4-piperidyl)-5-oxo- pyrrolidin-3-yl]pyrazol-3-yl]oxysodium (160 mg, 395 μmol, 1.00 eq) in EtOH / H2O at 0 °C. After complete addition, the mixture was stirred for 1 h at 0°C. The reaction mixture was partitioned between DCM (15.0 mL) and H2O (10.0 mL). The organic phase was separated, dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reversed-phase HPLC (0.05% FA condition) to give (4Z)-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2- yl)hydrazono]-2-[1-(1-methylsulfonyl-4-piperidyl)-5-oxo-pyrrolidin-3-yl]pyrazol-3-one (37.9 mg, 71.2 μmol, 18.0% yield, 97.8% purity) as a red solid. MS: product: m / z 522.4 (M+H)+.1H NMR (400 MHz): CDCl3δ 5.04 - 4.99 (m, 1H), 4.19 - 4.12 (m, 1H), 3.91 - 3.88 (m, 2H), 3.65 (t, J = 9.6 Hz, 1H), 3.53-3.51 (m, 1H), 2.79 - 2.73 (m, 7H), 2.46 (d, J = 6.8 Hz, 2H), 2.31 (s, 3H), 2.24 (s, 3H), 1.81 - 1.76 (m, 4H), 1.03 - 0.99 (m, 1H), 0.55 - 0.50 (m, 2H), 0.27 - 0.23 (m, 2H). Example 51: Synthesis of Compound 51; (Z)-3-(cyclopropylmethyl)-1-(2-(4,4-difluoropiperidin-1-yl)- 2-oxoethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazono)-1H-pyrazol-5(4H)-one A mixture of ethyl 2-hydrazinoacetate (800 mg, 5.17 mmol, 1.00 eq, HCl) and methyl 4- cyclopropyl-3-oxo-butanoate (970 mg, 6.21 mmol, 1.20 eq) in AcOH (10.0 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 100 °C for 1 h under N2 atmosphere. The reaction mixture was concentrated to dryness to give a residue. The residue was purified by flash silica gel chromatography (eluent of 30 ~ 80% EA in PE gradient) to give ethyl 2-[3-(cyclopropylmethyl)-5-hydroxy- pyrazol-1-yl]acetate (531 mg, 2.30 mmol, 44.4% yield, 98.5% purity) as a light yellow solid. MS: product: m / z 225.2 (M+H)+. To a solution of ethyl 2-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]acetate (590 mg, 2.63 mmol, 1.00 eq) in EtOH (9.00 mL) was added NaOH (552 mg, 13.8 mmol, 5.25 eq) and H2O (3.00 mL). The mixture was stirred at 25 °C for 1 h. The reaction mixture was acidified with 1N HCl to pH=3 and extracted with DCM (15.0 mLx5). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was used into the next step without any purification.2-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]acetic acid (625 mg, crude) was obtained as yellow oil. MS: product: m / z 197.0 (M+H)+. To a solution of 2-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]acetic acid (525 mg, 2.68 mmol, 1.00 eq) and 4,4-difluoropiperidine (422 mg, 2.68 mmol, 1.00 eq, HCl) in DMF (10.0 mL) was added HATU (1.12 g, 2.94 mmol, 1.10 eq) and DIPEA (1.04 g, 8.03 mmol, 1.40 mL, 3.00 eq). The mixture was stirred at 25 °C for 1 h. The reaction mixture was poured into water (60.0 mL) and extracted with EA (50.0 mLx2). The combined organic phase was washed with brine (40.0 mL), dried over Na2SO4, filtered and concentrated to give a residue. The residue was purified by flash silica gel chromatography (eluent of 0 ~ 10% MeOH in DCM gradient) to give 2-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]-1-(4,4-difluoro- 1-piperidyl)ethanone (792 mg, 2.01 mmol, 75.2% yield, 76.2% purity) as a yellow solid. MS: product: m / z 300.1 (M+H)+. To a solution of 2-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]-1-(4,4-difluoro-1- piperidyl)ethanone (690 mg, 2.31 mmol, 1.00 eq) in EtOH (7.00 mL) was added a solution of NaOH in water (2.50 M, 2.31 mL, 2.50 eq) at 25 °C. The mixture was stirred at 25 °C for 0.5 h. The product of sodium 3-(cyclopropylmethyl)-1-(2-(4,4-difluoropiperidin-1-yl)-2-oxoethyl)-1H-pyrazol-5-olate in EtOH / H2O as a light yellow liquid was used into the next step without further purification. To a solution of 4,5-dimethylthiazol-2-amine (380 mg, 2.96 mmol, 1.00 eq) in HCl (1.54 g, 14.8 mmol, 1.51 mL, 35% purity, 5.00 eq) was added a solution of NaNO2(205 mg, 2.96 mmol, 1.00 eq) in H2O (5.00 mL) dropwise at 0 °C. The mixture was stirred at 0 °C for 0.5 h. The product of 4,5- dimethylthiazole-2-diazonium chloride in H2O as a yellow liquid was used into the next step without further purification. The solution of 4,5-dimethylthiazole-2-diazonium chloride (485 mg, 2.76 mmol, 1.20 eq, in water) was added to the solution of sodium 3-(cyclopropylmethyl)-1-(2-(4,4-difluoropiperidin-1-yl)-2-oxoethyl)- 1H-pyrazol-5-olate (740 mg, 2.30 mmol, 1.00 eq) dropwise at 0 °C. The resulting mixture was stirred at 25 °C for 1 h. The reaction mixture was partitioned between DCM (100 mL) and H2O (80.0 mL). The organic phase was separated, dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0~70% ACN / H2O(0.05%FA)@ 35 mL / min) to give (Z)-3-(cyclopropylmethyl)-1-(2-(4,4- difluoropiperidin-1-yl)-2-oxoethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazono)-1H-pyrazol-5(4H)-one (107 mg, 244 μmol, 10.5% yield, 98.9% purity) as a red solid. MS: product: m / z 439.5 (M+H)+.1H NMR (400 MHz): CDCl3δ 4.63 (s, 2H), 3.75 (t, J = 4.8 Hz, 2H), 3.59 (t, J = 5.2 Hz, 2H), 2.52 (d, J = 6.8 Hz, 2H), 2.32 (s, 3H), 2.25 (s, 3H), 2.10 - 1.92 (m, 4H), 1.11 - 1.00 (m, 1H), 0.60 - 0.50 (m, 2H), 0.29 (q, J = 4.8 Hz, 2H).19H NMR (400 MHz): CDCl3 δ -98.13. Example 52: Synthesis of Compound 52; (Z)-5-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2- yl)hydrazineylidene)-2-((1S,2S)-2-hydroxycyclohexyl)-2,4-dihydro-3H-pyrazol-3-one The solution of 7-oxabicyclo[4.1.0]heptane (1.00 g, 10.2 mmol, 1.03 mL, 1.00 eq) in NH2NH2.H2O (6.00 g, 102 mmol, 5.81 mL, 85.0% purity, 10.0 eq) was degassed and purged with N2for 3 times, and then the mixture was stirred at 100 °C for 3 hr under N2atmosphere. The mixture was cooled to room temperature and concentrated in vacuo to give a residue. The residue was used in the next step without any purification.2-hydrazineylcyclohexan-1-ol (1.18 g, crude) was obtained as white soild. MS: m / z 131.2(M+H)+HNMR(400MHz, CDCl3-d): δ ppm 3.64 - 3.41 (m,4H), 2.46 - 2.38 (m,1H), 1.99 - 1.91 (m,1H), 1.83 - 1.60 (m,4H), 1.36 - 1.13 (m,3H), 1.12 - 0.97 (m,1H). To a solution of 2-hydrazineylcyclohexan-1-ol (300 mg, 2.30 mmol, 1.00 eq) in EtOH (5.00 mL) was added ethyl 4-cyclopropyl-3-oxo-butanoate (431 mg, 2.53 mmol, 1.10 eq), and then degassed and purged with N2for 3 times, and then the mixture was stirred at 80 °C for 1 hr under N2atmosphere. The mixture was cooled to room temperature and concentrated in vacuo to give a residue. The residue was used in the next step without any purification.3-(cyclopropylmethyl)-1-(2-hydroxycyclohexyl)-1H- pyrazol-5-ol (591 mg, crude) was obtained as a brown oil. MS:m / s 237.1(M+H)+To a solution of 5-(cyclopropylmethyl)-2-(2-hydroxycyclohexyl)pyrazol-3-ol (408 mg, 1.73 mmol, 1.00 eq) in EtOH (4.00 mL) was added aqueous NaOH (2.50 M, 1.73 mL, 2.50 eq) under N2atmosphere. The suspension was degassed and purged with N2 for 3 times. The mixture was stirred at 25 °C for 0.5 hr. The product of [5-(cyclopropylmethyl)-2-(2-hydroxycyclohexyl) pyrazol-3-yl]oxysodium in EtOH / H2O as a yellow liquid was used into the next step without further purification. To a solution of 4, 5-dimethylthiazol-2-amine (230 mg, 1.79 mmol, 1.00 eq) and HCl (1.87 g, 17.9 mmol, 1.83 mL, 35.0% purity, 10.0 eq) was added NaNO2 (124 mg, 1.79 mmol, 1.00 eq) in H2O (2.00 mL). The mixture was stirred at 0-25 °C for 1 hr. The product of 4, 5-dimethylthiazole-2-diazonium;chloride in H2O as a yellow liquid was used into the next step without further purification. A solution of [5-(cyclopropylmethyl)-2-(2-hydroxycyclohexyl)pyrazol-3-yl]oxysodium (446 mg, 1.73 mmol, 1.00 eq, in EtOH / H2O) was added dropwise to the solution of 4,5-dimethylthiazole-2- diazonium;chloride (315 mg, 1.65 mmol, 1.00 eq, in H2O) under N2atmosphere. The mixture was stirred at 0 °C for 1 hr. The mixture was added water (10mL), and then extracted with dichloromethane (25 mL × 3). The combined organic phase was dried over anhydrous sodium sulfate, filtered and concentrated to give a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18150*25mm* 10um;mobile phase: [water(FA)-ACN];gradient:55%-85% B over 11 min) and separated by SFC(EC13228-18-P1) (column: DAICEL CHIRALCEL OD(250mm*30mm,10um);mobile phase: [CO2- MeOH(0.1%NH3H2O)];25% B isocratic elution mode) to give (4Z)-5-(cyclopropylmethyl)-4-[(4,5- dimethylthiazol-2-yl)hydrazono]-2-[(1S,2S)-2-hydroxycyclohexyl]pyrazol-3-one (20.4 mg, 54.33 μmol, 3.15% yield) and (4Z)-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-2-[(1S,2R)-2- hydroxycyclohexyl]pyrazol-3-one (16.53 mg, 44.02 μmol, 2.55% yield) both as red solid. MS: product: m / z 547.9 (M+H)+ 1H NMR (400MHz, CDCl3-d) δ ppm 3.95-3.85 (m, 2H), 2.49(d, J=7.2 Hz, 2H), 2.30(s, 3H), 2.24(s, 3H), 2.14(d, J=10.4, 1H), 1.93(d, J=13.2, 1H), 1.84-1.67 (m,5H), 1.41-1.37 (m, 3H), 1.10-1.03 (m, 1H), 0.57-0.51 (m, 2H), 0.26-0.33 (m, 2H). MS: product: m / z 547.9 (M+H)+ 1H NMR (400MHz, CDCl3-d) δ ppm 3.92 (s, 2H), 2.49 (d, J=5.6, 2H), 2.30 (s, 3H), 2.24 (s, 3H), 2.14 (d, J=8.8, 1H), 1.93 (d, J=12, 1H), 1.83-1.72 (m, 5H), 1.42 - 1.31 (m, 4H), 1.04 (s, 1H), 0.54 (d, J=6.8, 2H), 0.33 - 0.24 (m, 2H). Example 53: Synthesis of Compound 53; (Z)-2-(3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2- yl)hydrazono)-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)-N-methyl-N-(4-(methylsulfonyl)phenyl)acetamide 2-[(4Z)-3-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-5-oxo-pyrazol-1-yl]acetic acid (200 mg, 596 μmol, 1.00 eq) was placed in a round bottom flask. Place in an ice water bath for 5 min. Then SOCl2 (4.00 mL) was added dropwise, and the reaction was stirred at 60 °C for 1 hr. The reaction mixture was concentrated under reduce pressure to give 2-[(4Z)-3-(cyclopropylmethyl)-4-[(4,5- dimethylthiazol-2-yl)hydrazono]-5-oxo-pyrazol-1-yl]acetyl chloride (231 mg, crude) as a red solid. To a solution of N-methyl-4-methylsulfonyl-aniline (150 mg, 678 μmol, 1.20 eq, HCl) in pyridine (2.00 mL) was added dropwise 2-[(4Z)-3-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-5- oxo-pyrazol-1-yl]acetyl chloride (200 mg, 565 μmol, 1.00 eq) in DCM (1.00 mL) at 0°C. The resulting mixture was stirred at 25°C for 1 h. The reaction mixture was concentrated under reduce pressure to give a residue which was purified by prep-HPLC (C18; 40 g SepaFlash® Silica Flash Column, Eluent of 0~70% CAN / H2O (0.05%FA)@ 35 mL / min) to give (Z)-2-(3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol- 2-yl)hydrazono)-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)-N-methyl-N-(4-(methylsulfonyl)phenyl)acetamide (8.0 mg, 15.3 μmol, 2.71% yield, 96.3% purity) as a red solid. MS: product: m / z 503.2 (M+H)+.1H NMR (400 MHz): CDCl3 δ 8.06 (d, J = 8.4 Hz, 2H), 7.56 (d, J = 8.4 Hz, 2H), 4.42 (s, 2H), 3.37 (s, 3H), 3.10 (s, 3H), 2.51 (d, J = 6.8 Hz, 2H), 2.33 (s, 3H), 2.26 (s, 3H), 1.08 - 1.05 (m, 1H), 0.59 - 0.54 (m, 2H), 0.31 - 0.28 (m, 2H). Example 54: Synthesis of Compound 54; (Z)-4-(4-(3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol- 2-yl)hydrazineylidene)-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)-2-oxopyrrolidin-1-yl)cyclohexane-1- carboxamide To a solution of 4-aminocyclohexane-1-carboxylic acid (2.00 g, 13.9 mmol, 1.00 eq) in MeOH (20.0 mL) was added SOCl2(1.66 g, 13.9 mmol, 1.01 mL, 1.00 eq). The mixture was stirred at 60 °C for 2 hr. The reaction mixture was concentrated under reduced pressure to give methyl 4-aminocyclohexane-1- carboxylate as white solid.1H NMR (400 MHz, CHLOROFORM) δ ppm 8.23 (br s, 2H), 3.70 (s, 3H), 2.56 (br t, J = 4.4 Hz, 1H), 2.23 - 2.11 (m, 2H), 2.03 - 1.91 (m, 2H), 1.85 - 1.74 (m, 2H), 1.71 - 1.61 (m, 2H), 1.57 - 1.41 (m, 1H) To a solution of methyl 4-aminocyclohexane-1-carboxylate (2.20 g, 13.9 mmol, 1.00 eq) in H2O (20.0 mL) was added HCl (1.00 M, 13.9 mL, 1.00 eq) at 25 °C and pH = 1. The solution was kept at 40 °C and 2,5-dimethoxy-2,5-dihydrofuran (1.82 g, 13.9 mmol, 1.00 eq) was added. The resulting mixture was stirred at 25 °C for 30 min. The reaction mixture was cooled to 25 °C. The mixture was added DCM (10.0 mL) and slowly added saturated aqueous Na2HPO4solution to pH = 7. The reaction mixture was extracted with DCM (20.0 mL). The combined organic phase was washed with H2O (20.0 mL x 2), brine (10.0 mL), dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure to give methyl 4-(2-oxo-2,5-dihydro-1H-pyrrol-1-yl)cyclohexane-1-carboxylate (0.80 g, crude) as a yellow oil.1H NMR (400 MHz, CHLOROFORM) δ ppm 7.05 (d, J = 6.0 Hz, 1H), 6.15 (d, J = 6.0 Hz, 1H), 3.70 (s, 3H), 3.61 (s, 1H), 2.67 (s, 2H), 2.30 - 2.17 (m, 4H), 2.04 (s, 1H), 1.71 - 1.65 (m, 4H) To a solution of methyl 4-(2-oxo-2,5-dihydro-1H-pyrrol-1-yl)cyclohexane-1-carboxylate (0.80 g, 3.58 mmol, 467 uL, 1.00 eq) in EtOH (10.0 mL) was added NH2NH2.H2O (4.22 g, 71.7 mmol, 4.10 mL, 85% purity, 20.0 eq) at 25 °C. The mixture was stirred at 80 °C for 1 hr. The mixture was concentrated at 40 °C to give methyl 4-(4-hydrazineyl-2-oxopyrrolidin-1-yl)cyclohexane-1-carboxylate (700 mg, crude) as a yellow solid. To a solution of methyl 4-(4-hydrazineyl-2-oxopyrrolidin-1-yl)cyclohexane-1-carboxylate (600 mg, 2.35 mmol, 1.00 eq) and ethyl 4-cyclopropyl-3-oxobutanoate (399 mg, 2.35 mmol, 1.00 eq) in EtOH (10.0 mL) was stirred at 25 °C. The mixture was stirred at 25 °C for 16 hr. The reaction mixture was poured into water (20.0 mL) and extracted with dichloromethane (20.0 mL x 2). The combined organic phase was washed with brine (20.0 mL), dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give methyl 4-(4-(3-(cyclopropylmethyl)-5-hydroxy-1H-pyrazol-1-yl)-2-oxopyrrolidin-1- yl)cyclohexane-1-carboxylate (600 mg, crude) as yellow solid. MS: product: m / z 362.2 (M+H)+. To the mixture of 4-(4-(3-(cyclopropylmethyl)-5-hydroxy-1H-pyrazol-1-yl)-2-oxopyrrolidin-1- yl)cyclohexane-1-carboxylate (400 mg, 1.11 mmol, 1.00 eq) in EtOH (2.00 mL) was added aqueous NaOH (2.50 M, 442 uL, 1.00 eq) at 25 °C. The reaction mixture was stirred for 0.5 hr at 25 °C to give a sodium 4-(4-(3-(cyclopropylmethyl)-5-oxido-1H-pyrazol-1-yl)-2-oxopyrrolidin-1-yl)cyclohexane-1- carboxylate as clear solution. The clear solution was used directly as theory amount in next step without work-up. The solution of 4,5-dimethylthiazol-2-amine (150 mg, 1.17 mmol, 1.00 eq) in HCl (1.58 mL, 15.4 mmol, 35% purity) was cooled to 0 °C. The solution of NaNO2 (80.7 mg, 1.17 mmol, 1.00 eq) in H2O (1.50 mL) was added dropwise to the above mixture at 0 °C. The mixture was stirred for 0.5 hr at 0 °C to give 4,5-dimethylthiazole-2-diazonium chloride as turbid liquid. The mixture was directly used as theory amount in next step without work-up. The reaction mixture of sodium 4-(4-(3-(cyclopropylmethyl)-5-oxido-1H-pyrazol-1-yl)-2-oxopyrrolidin- 1-yl)cyclohexane-1-carboxylate (433 mg, 1.11 mmol, 1.00 eq, in EtOH / H2O) was added dropwise to the solution of 4,5-dimethylthiazole-2-diazonium chloride (194 mg, 1.11 μmol, 1.00 eq, in H2O). The resulting mixture was stirred at 0~25 °C for 0.5 hr. The solid was precipitated out and collected by filtration. And the solid was washed with water (20.0 mL × 2), dried under reduced pressure to give the crude product. The crude product was purified by reversed-phase HPLC(0.1% FA condition) to give (Z)-4-(4-(3- (cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)-2- oxopyrrolidin-1-yl)cyclohexane-1-carboxylic acid (30 mg, crude) as a red solid. MS: product: m / z 487.2 (M+H)+. To the solution of (Z)-4-(4-(3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-5- oxo-4,5-dihydro-1H-pyrazol-1-yl)-2-oxopyrrolidin-1-yl)cyclohexane-1-carboxylic acid (14.0 mg, 28.8 μmol, 1.00 eq) in THF (1.00 mL) was added CDI (14.0 mg, 86.3 μmol, 3.00 eq) at 25 °C. After stirred at 25 °C for 1 hr, NH3.H2O (4.03 mg, 28.7 μmol, 4.43 uL, 25% purity, 1.00 eq) was added in the mixture. The mixture was stirred at 25 °C for 3 hr. The mixture was added HCl solution to pH = 6. The mixture was filtered and the wet cake was washed with H2O (4.00 mL), the wet cake was dried under vacuo to give the crude. The solid was washed with water (20.0 mL), dried under reduced pressure to give the crude product. The solid was purified by prep-HPLC(column: Phenomenex luna C18150*25mm* 10um; mobile phase: [water(FA)-ACN];B%: 29%-59%, 0 min) to give (Z)-4-(4-(3-(cyclopropylmethyl)-4-(2-(4,5- dimethylthiazol-2-yl)hydrazineylidene)-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)-2-oxopyrrolidin-1- yl)cyclohexane-1-carboxamide (7.00 mg, 13.7 μmol, 47.8% yield, 95.4% purity) as a red solid. MS: product: m / z 486.0 (M+H)+.1H NMR (400 MHz, CHLOROFORM) δ ppm 5.68 - 5.32 (m, 2H), 5.02 - 4.90 (m, 1H), 4.13 - 4.01 (m, 1H), 3.70 - 3.60 (m, 1H), 3.51 (dd, J = 5.2, 10.0 Hz, 1H), 2.82 - 2.70 (m, 2H), 2.52 (s, 1H), 2.46 (d, J = 6.8 Hz, 2H), 2.30 (s, 3H), 2.23 (s, 3H), 2.10 (d, J = 10.8 Hz, 2H), 1.79 - 1.59 (m, 6H), 1.07 - 0.97 (m, 1H), 0.54-0.50 (m, 2H), 0.28-0.22 (m, 2H). Example 55: Synthesis of Compound 55; (Z)-1-(2-acetyl-2-azaspiro[3.3]heptan-6-yl)-3- (cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazono)-1H-pyrazol-5(4H)-one To a solution of tert-butyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylate (2.00 g, 9.47 mmol, 1.00 eq) in DCM (30.0 mL) was added TFA (9.24 g, 81.0 mmol, 6.00 mL, 8.56 eq). The mixture was stirred at 25 °C for 2 h. The mixture was concentrated to give a crude 2-azaspiro[3.3]heptan-6-one (2.23 g, crude, TFA) as a light yellow oil. To a solution of 2-azaspiro[3.3]heptan-6-one (2.20 g, 9.77 mmol, 1.00 eq, TFA) in DCM (30.0 mL) was added TEA (4.94 g, 48.8 mmol, 6.80 mL, 5.00 eq) and Ac2O (1.50 g, 14.7 mmol, 1.38 mL, 1.50 eq). The mixture was stirred at 25 °C for 16 h. The mixture was concentrated to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 5 / 1 to 0 / 1) to give a 2- acetyl-2-azaspiro[3.3]heptan-6-one (1.32 g, 3.09 mmol, 84.3% yield, N / A purity) as a colorless oil. The crude product was used in next step without further purification.1H NMR (400 MHz): CDCl3 δ 4.27 (d, J = 54.0 Hz, 4H), 3.32 (s, 4H), 2.05 (s, 3H) To a solution of 2-acetyl-2-azaspiro[3.3]heptan-6-one (1.40 g, 9.14 mmol, 1.00 eq) in MeOH (20.0 mL) was added tert-butyl N-aminocarbamate (1.45 g, 11.0 mmol, 1.20 eq). The mixture was stirred at 25 °C for 1 h. AcOH (1.65 g, 27.4 mmol, 1.57 mL, 3.00 eq) and NaBH3CN (1.72 g, 27.4 mmol, 3.00 eq) was added to the mixture. The resulting mixture was stirred at 25 °C for 16 h. The mixture was adjusted pH ~ 7 by saturated aqueous NaHCO3, extracted with DCM (20.0 mL x 3). The combined organic was washed with brine (20.0 x 2), dried over Na2SO4, filtered. The filtrate was concentrated to give a residue. The residue was purified by column chromatography (SiO2, DCM : MeOH = 20:1) to give a tert-butyl 2-(2- acetyl-2-azaspiro[3.3]heptan-6-yl)hydrazinecarboxylate (1.93 g, 7.17 mmol, 78.4% yield, N / A purity) as a colorless oil. The crude product was used in next step without further purification.1H NMR (400 MHz): CDCl3δ 4.08 - 3.88 (m, 4H), 3.51 - 3.47 (m, 1H), 3.39 - 3.34 (m, 1H), 2.36 - 2.27 (m, 2H), 2.05 - 1.98 (m, 2H), 1.81 (s, 3H), 1.44 (s, 9H). To a solution of tert-butyl 2-(2-acetyl-2-azaspiro[3.3]heptan-6-yl)hydrazinecarboxylate (500 mg, 1.86 mmol, 1.00 eq) in DCM (5.00 mL) was added TFA (3.08 g, 27.0 mmol, 2.00 mL, 14.6 eq). The mixture was stirred at 25 °C for 16 h. The mixture was concentrated to give a crude 1-(6-hydrazinyl-2- azaspiro[3.3]heptan-2-yl)ethanone (541 mg, crude, TFA) as a colorless oil. To a solution of 1-(6-hydrazinyl-2-azaspiro[3.3]heptan-2-yl)ethanone (500 mg, 1.77 mmol, 1.00 eq, TFA) in EtOH (5.00 mL) was added ethyl 4-cyclopropyl-3-oxo-butanoate (300.45 mg, 1.77 mmol, 1 eq). The mixture was stirred at 80 °C for 1 h. The mixture was concentrated to give a crude 1-(6-(3- (cyclopropylmethyl)-5-hydroxy-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)ethanone (491 mg, crude) as a light yellow oil. It was used in next step without further purification. MS: product: m / z 276.1 (M+H)+. To a solution of 1-(6-(3-(cyclopropylmethyl)-5-hydroxy-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2- yl)ethanone (490 mg, 1.78 mmol, 1.00 eq) in EtOH (1.50 mL) was added a solution of NaOH in water (2.50 M, 1.78 mL, 2.50 eq) 25 °C. The mixture was stirred at 25 °C for 0.5 h. The product of sodium 1-(2- acetyl-2-azaspiro[3.3]heptan-6-yl)-3-(cyclopropylmethyl)-1H-pyrazol-5-olate in EtOH / water as a brown solution was used in next step without further purification. To a solution of 4,5-dimethylthiazol-2-amine (228.19 mg, 1.78 mmol, 1.00 eq) in HCl (2.45 g, 23.50 mmol, 2.40 mL, 35% purity, 13.2 eq) was added a solution of NaNO2(122.82 mg, 1.78 mmol, 1.00 eq) in H2O (1.50 mL) at 0 °C. The mixture was stirred at 0 °C for 0.5 h. The product of 4,5- dimethylthiazole-2-diazonium chloride in water as a yellow solution was used in next step without further purification. The solution of 4,5-dimethylthiazole-2-diazonium chloride (313 mg, 1.78 mmol, 1.00 eq, in water) was added dropwise to the solution of sodium 1-(2-acetyl-2-azaspiro[3.3]heptan-6-yl)-3- (cyclopropylmethyl)-1H-pyrazol-5-olate (529 mg, 1.78 mmol, 1.00 eq, in EtOH / H2O) at 0 °C. The resulting mixture was stirred at 25 °C for 1 h. The mixture was extracted with DCM (20.0 mL x 2). The combined organic was washed with brine (50.0 mL), dried over Na2SO4, filtered. The filtrate was concentrated to give a crude product. The crude product was purified by reversed-phase HPLC (C18, 20-45um, 100 A, 40.0 g, eluent of 5 ~ 50% MeCN in water with 0.1% FA condition) to give (Z)-1-(2-acetyl-2- azaspiro[3.3]heptan-6-yl)-3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazono)-1H-pyrazol- 5(4H)-one (35.7 mg, 78.9 μmol, 4.43% yield, 91.6% purity) as a red solid. MS: product: m / z 415.1 (M+H)+.1H NMR (400 MHz): CDCl3δ 4.77 - 4.66 (m, 1H), 4.17 (d, J = 17.2 Hz, 2H), 4.05 (d, J = 17.2 Hz, 2H), 2.75 - 2.69 (m, 2H), 2.59 - 2.53 (m, 2H), 2.51 (d, J = 6.8 Hz, 2H), 2.32 (s, 3H), 2.25 (s, 3H), 1.87 (d, J = 4.0 Hz, 3H), 1.09 - 1.02 (m, 1H), 0.59 - 0.52 (m, 2H), 0.35 - 0.25 (m, 2H) Example 56: Synthesis of Compound 56 and Compound 58 (R,Z)-3-(cyclopropylmethyl)-4-(2-(4,5- dimethylthiazol-2-yl)hydrazono)-1-(1-(4-(methylsulfonyl)piperidin-1-yl)-1-oxopropan-2-yl)-1H- pyrazol-5(4H)-one; (S,Z)-3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazono)-1-(1-(4- (methylsulfonyl)piperidin-1-yl)-1-oxopropan-2-yl)-1H-pyrazol-5(4H)-one To a solution of 2-[(4Z)-3-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-5-oxo-pyrazol- 1-yl]propanoic acid (150 mg, 429 μmol, 1.00 eq) and 4-methylsulfonylpiperidine (84.1 mg, 515 μmol, 1.20 eq) in DMF (2.00 mL) was added DIPEA (277 mg, 2.15 mmol, 374 uL, 5.00 eq) and HATU (196 mg, 515 μmol, 1.20 eq). The mixture was stirred at 25 °C for1 h. The reaction mixture was poured into water (20.0 mL) and extracted with EA (30.0 mL x 2). The combined organic phase was washed with brine (20.0 mL), dried over Na2SO4, filtered and concentrated to give a residue. The residue was separated by SFC (column: DAICEL CHIRALPAK AD (250mm*30mm,10um);mobile phase: [0.1%NH3H2O EtOH];B%: 30%-30%,C7.2;80min). Compound (R,Z)-3-(cyclopropylmethyl)-4-(2-(4,5- dimethylthiazol-2-yl)hydrazono)-1-(1-(4-(methylsulfonyl)piperidin-1-yl)-1-oxopropan-2-yl)-1H-pyrazol- 5(4H)-one (21.3 mg, 39.9 μmol, 9.31% yield, 95.6% purity) was obtained as a red solid. MS: product: m / z 495.1 (M+H)+.1H NMR (400 MHz): CDCl3 δ 5.14 (q, J = 13.2 Hz, 1H), 4.84 - 4.73 (m, 1H), 4.12 - 4.03 (m, 1H), 3.04 - 2.98 (m, 2H), 2.85 - 2.65 (m, 4H), 2.50 (d, J = 6.8 Hz, 2H), 2.31 (s, 3H), 2.24 (s, 3H), 2.16 – 2.09 (m, 2H), 1.78 - 1.75 (m, 2H), 1.56 (s, 3H), 1.06 - 1.02 (m, 1H), 0.53 - 0.51 (m, 2H), 0.28 - 0.25 (m, 2H). Compound (R,Z)-3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazono)-1-(1-(4- (methylsulfonyl)piperidin-1-yl)-1-oxopropan-2-yl)-1H-pyrazol-5(4H)-one (17.2 mg, 33.2 μmol, 7.74% yield, 92.9% purity) was obtained as a red solid. MS: product: m / z 495.1 (M+H)+.5.14 (q, J = 13.2 Hz, 1H), 4.84 - 4.73 (m, 1H), 4.09 - 4.06 (m, 1H), 3.04 – 3.01 (m, 2H), 2.85 - 2.65 (m, 4H), 2.50 (d, J = 6.8 Hz, 2H), 2.31 (s, 3H), 2.24 (s, 3H), 2.17 – 2.08 (m, 2H), 1.79 - 1.71 (m, 2H), 1.56 (s, 3H), 1.06 - 1.02 (m, 1H), 0.54 - 0.51 (m, 2H), 0.28 - 0.25 (m, 2H). Example 57: Synthesis of Compound 57; (Z)-1-(1-(1-acetylpiperidin-4-yl)-5-oxopyrrolidin-3-yl)-3- (cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazono)-1H-pyrazol-5(4H)-one To a solution of tert-butyl piperidin-4-ylcarbamate (5.00 g, 25.0 mmol, 1.00 eq) in DCM (50.0 mL) was added TEA (3.79 g, 37.5 mmol, 5.21 mL, 1.50 eq) and acetyl chloride (2.16 g, 27.5 mmol, 1.96 mL, 1.10 eq) dropwise at 25 °C. The mixture was stirred at 25 °C for 16 h. The mixture was diluted with water (50.0 mL) and DCM (50.0 mL), and extracted with DCM (50.0 mL x 2). The combined organic was washed with brine (100 mL x 2), dried over Na2SO4, filtered. The filtrate was concentrated to give a crude tert-butyl N-(1-acetyl-4-piperidyl)carbamate (6.32 g, crude) as a light yellow oil. It was used in the next step without further purification.1H NMR (400 MHz): CDCl3δ 4.60 - 4.50 (m, 1H), 4.50 - 4.42 (m, 1H), 3.80 - 3.70 (m, 1H), 3.70 - 3.59 (m, 1H), 3.17 - 3.08 (m, 1H), 2.78 - 2.66 (m, 1H), 2.07 (s, 3H), 2.02 - 1.97 (m, 1H), 1.96 - 1.88 (m, 1H), 1.43 (s, 9H), 1.31 - 1.28 (m, 1H) To a solution of tert-butyl N-(1-acetyl-4-piperidyl)carbamate (6.20 g, 25.6 mmol, 1.00 eq) in DCM (60.0 mL) was added TFA (15.0 mL) at 25 °C. The mixture was stirred at 25 °C for 4 h. The mixture was adjusted to pH ~ 7 by saturated aqueous NaHCO3. The mixture was concentrated to give a crude product 1-(4-aminopiperidin-1-yl)ethanone (4.11 g, crude) as a yellow oil. To a solution of 1-(4-aminopiperidin-1-yl)ethanone (2.00 g, 14.1 mmol, 1.00 eq) in HCl (1.00 M, 10.0 mL) was added 2,5-dimethoxy-2,5-dihydrofuran (2.01 g, 15.5 mmol, 1.10 eq) at 40 °C. The mixture was stirred at 40 °C for 0.5 h. The mixture was adjusted to pH ~ 6 by saturated aqueous NaH2PO4, extracted with DCM (20.0 mL x 2). The combined organic was washed with brine (50.0 mL x 2), dried over Na2SO4, filtered. The filtrate was concentrated to give a crude 1-(1-acetylpiperidin-4-yl)-1H-pyrrol- 2(5H)-one (932 mg, crude) as a yellow oil. The crude product was used in next step without further purification. MS: product: m / z 208.9 (M+H)+. To a solution of 1-(1-acetylpiperidin-4-yl)-1H-pyrrol-2(5H)-one (920 mg, 4.42 mmol, 1.00 eq) in EtOH (10.0 mL) was added NH2NH2.H2O (2.97 g, 50.4 mmol, 2.88 mL, 85% purity, 11.4 eq). The mixture was stirred at 80 °C for 17 h. The mixture was cooled to 25 °C, and concentrated at 40 °C to give a crude 1-(1-acetylpiperidin-4-yl)-4-hydrazinylpyrrolidin-2-one (1.24 g, crude) as a brown oil. MS: product: m / z N / A (M+H)+. To a solution of 1-(1-acetylpiperidin-4-yl)-4-hydrazinylpyrrolidin-2-one (500 mg, 2.08 mmol, 1.00 eq) in EtOH (5.00 mL) was added ethyl 4-cyclopropyl-3-oxo-butanoate (354 mg, 2.08 mmol, 1.00 eq). The mixture was stirred at 80 °C for 1 h. The mixture was concentrated to give a residue. The residue was purified by flash silica gel chromatography (eluent of 0 ~ 10% MeOH / DCM) to give a 1-(1- acetylpiperidin-4-yl)-4-(3-(cyclopropylmethyl)-5-hydroxy-1H-pyrazol-1-yl)pyrrolidin-2-one (361 mg, 852 μmol, 41.0% yield, 81.8% purity) as a brown oil. MS: product: m / z 346.9 (M+H)+.1H NMR (400 MHz): CDCl3δ 5.02 - 4.84 (m, 1H), 4.74 ( d, J = 13.2 Hz, 1H), 4.34 - 4.18 (m, 1H), 3.92 - 3.85 (m, 1H), 3.67 - 3.55 (m, 1H), 3.46 - 3.38 (m, 1H), 3.29 - 3.11 (m, 2H), 2.64 - 2.53 (m, 2H), 2.28 (d, J = 7.2 Hz, 2H), 2.11 (s, 3H), 1.80 - 1.69 (m, 2H), 1.59 - 1.50 (m, 2H), 0.89 - 0.84 (m, 1H), 0.58 - 0.54 (m, 2H), 0.27 - 0.13 (m, 2H). To a solution of 1-(1-acetylpiperidin-4-yl)-4-(3-(cyclopropylmethyl)-5-hydroxy-1H-pyrazol-1- yl)pyrrolidin-2-one (150 mg, 433 μmol, 1.00 eq) in EtOH (0.45 mL) was added a solution of NaOH in water (2.50 M, 433 uL, 2.50 eq) 25 °C. The mixture was stirred at 25 °C for 0.5 h. The product of sodium 1-(1-(1-acetylpiperidin-4-yl)-5-oxopyrrolidin-3-yl)-3-(cyclopropylmethyl)-1H-pyrazol-5-olate in EtOH / H2O as a brown solution. It was used in next step without further purification. To a solution of 4,5-dimethylthiazol-2-amine (55.5 mg, 433 μmol, 1.00 eq) in HCl (595 mg, 5.72 mmol, 584 uL, 35% purity, 13.2 eq) was added a solution of NaNO2 (29.9 mg, 433 μmol, 1.00 eq) in H2O (0.30 mL) at 0 °C. The mixture was stirred at 0 °C for 0.5 h. The product of 4,5-dimethylthiazole-2- diazonium chloridein water as a yellow solution. It was used in next step without further purification. The solution of 4,5-dimethylthiazole-2-diazonium chloride (76.0 mg, 433 μmol, 1.00 eq, in water) was added to the solution of sodium 1-(1-(1-acetylpiperidin-4-yl)-5-oxopyrrolidin-3-yl)-3- (cyclopropylmethyl)-1H-pyrazol-5-olate (160 mg, 433 μmol, 1.00 eq, in EtOH / H2O) at 0 °C. The mixture was stirred at 25 °C for 1 h. The mixture was extracted with DCM (20.0 mL x 3). The combined organic was washed with brine (50.0 mL x 2), dried over Na2SO4, filtered. The filtrate was concentrated to give a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18150*25mm* 10um;mobile phase: [water(FA)-ACN];B%: 30%-60%,10min) to give (Z)-1-(1-(1-acetylpiperidin-4-yl)-5- oxopyrrolidin-3-yl)-3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazono)-1H-pyrazol-5(4H)-one (18.3 mg, 36.03 μmol, 8.32% yield, 95.6% purity) as a red solid. MS: product: m / z 486.4 (M+H)+.1H NMR (400 MHz): CDCl3 δ 5.10 - 4.95 (m, 1H), 4.81 - 4.70 (m, 1H), 4.38 - 4.23 (m, 1H), 3.95 - 3.83 (m, 1H), 3.71 - 3.58 (m, 1H), 3.52 - 3.47 (m, 1H), 3.25 - 3.08 (m, 1H), 2.84 - 2.73 (m, 2H), 2.64 - 2.56 (m, 1H), 2.48 (d, J = 7.2 Hz, 2H), 2.32 (s, 3H), 2.25 (s, 3H), 2.10 (s, 3H), 1.88 - 1.74 (m, 2H), 1.61 - 1.51 (m, 2H), 1.08 - 0.97 (m, 1H), 0.61 - 0.49 (m, 2H), 0.27 (d, J = 4.4 Hz, 2H) Example 58: Synthesis of Compound 59; (Z)-5-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2- yl)hydrazineylidene)-2-(1-(1-methylpiperidin-4-yl)-5-oxopyrrolidin-3-yl)-2,4-dihydro-3H-pyrazol-3- one To a solution of 1-methylpiperidin-4-amine (100 mg, 876 μmol, 1.00 eq) in H2O (3.00 mL) was added HCl (91.2 mg, 876 μmol, 89.4 μL, 35.0% purity, 1.00 eq) at 25 °C and pH = 1. The solution was kept at 40 °C and 2,5-dimethoxy-2,5-dihydrofuran (137 mg, 1.05 mmol, 1.20 eq) was added. The resulting mixture was stirred at 40 °C for 0.5 h. The reaction mixture was cooled to 25 °C. The mixture was added DCM (10.0 mL) and slowly added NaHCO3 to pH = 7. The reaction mixture was extracted with DCM (10.0 mL x 3). The combined organic phase was washed brine (10.0 mL x 2), dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure to give 1-(1-methylpiperidin-4- yl)-1,5-dihydro-2H-pyrrol-2-one (215 mg, crude) as a black brown solid.1H NMR (400 MHz, CHLOROFORM-d) δ = 7.07 (br d, J = 6.0 Hz, 1H), 6.16 (br d, J = 6.0 Hz, 1H), 4.10 - 4.03 (m, 1H), 3.95 (s, 2H), 2.92 (br d, J = 11.6 Hz, 4H), 2.29 (s, 3H), 2.11 (dt, J = 3.6, 11.6 Hz, 4H). To a solution of 1-(1-methylpiperidin-4-yl)-1,5-dihydro-2H-pyrrol-2-one (200 mg, 1.11 mmol, 1.00 eq) in EtOH (5.00 mL) was added NH2NH2.H2O (1.19 g, 20.2 mmol, 1.15 mL, 85.0% purity, 18.2 eq). The mixture was stirred at 80 °C for 2 h. The mixture was concentrated at 40 °C to give 4-hydrazineyl-1-(1- methylpiperidin-4-yl)pyrrolidin-2-one (231 mg, crude) as a brown solid. MS: product: m / z 213.1 (M+H)+. To a solution of 4-hydrazineyl-1-(1-methylpiperidin-4-yl)pyrrolidin-2-one (230 mg, 1.08 mmol, 1.00 eq) in EtOH (5.00 mL) was added ethyl 4-cyclopropyl-3-oxobutanoate (221 mg, 1.30 mmol, 1.20 eq). The mixture was stirred at 80 °C for 1 h. The reaction mixture was concentrated directly to give 4-(3- (cyclopropylmethyl)-5-hydroxy-1H-pyrazol-1-yl)-1-(1-methylpiperidin-4-yl)pyrrolidin-2-one (303 mg, crude) as a brown solid. MS: product: m / z 319.1 (M+H)+. To a solution of 4-(3-(cyclopropylmethyl)-5-hydroxy-1H-pyrazol-1-yl)-1-(1-methylpiperidin-4- yl)pyrrolidin-2-one (300 mg, 942 μmol, 1.00 eq) in EtOH (5.00 mL) was added NaOH in water (2.50 M, 942 μL, 2.50 eq). The mixture was stirred at 25 °C for 0.5 h. The product of sodium 3- (cyclopropylmethyl)-1-(1-(1-methylpiperidin-4-yl)-5-oxopyrrolidin-3-yl)-1H-pyrazol-5-olate in EtOH / water as a yellow solution was used in next step without further purification. To a solution of 4,5-dimethylthiazol-2-amine (121 mg, 942 μmol, 1.00 eq) in HCl (1.26 g, 12.4 mmol, 1.23 mL, 36.0% purity, 13.2 eq) was added a solution of NaNO2(65.0 mg, 942 μmol, 1.00 eq) in H2O (0.50 mL) at 0 °C. The mixture was stirred at 0 °C for 0.5 h. The product of 4,5-dimethylthiazole-2- diazonium chloride in water as a yellow solution was used in next step without further purification. The solution of 4,5-dimethylthiazole-2-diazonium chloride (165 mg, 942 μmol, 1.00 eq, in water) was added to the solution of sodium 3-(cyclopropylmethyl)-1-(1-(1-methylpiperidin-4-yl)-5-oxopyrrolidin-3- yl)-1H-pyrazol-5-olate (320 mg, 942 μmol, 1.00 eq, in water / EtOH) at 0 °C. The mixture was stirred at 25 °C for 1 h. The reaction mixture was adjusted to pH~7 by aqueous NaHCO3. The resulting mixture was extracted with DCM (10.0 mL x 3). The combined organic phase was washed with brine (20.0 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reversed-phase HPLC (column: Welch Ultimate C18150*25mm*5um;mobile phase: [water(FA)-ACN];gradient:13%-43% B over 10 min) to give solid. Then the solid was stirred with HCl (5.00 ml) at 25 °C for 30 min and lyophilized to give (Z)-5-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2- yl)hydrazineylidene)-2-(1-(1-methylpiperidin-4-yl)-5-oxopyrrolidin-3-yl)-2,4-dihydro-3H-pyrazol-3-one (6.40 mg, 12.7 μmol, 1.35% yield, 98.5% purity, HCl) as a red solid. MS: product: m / z 458.1 (M+H)+.1H NMR (400 MHz, D2O) δ = 5.00 (br s, 1H), 4.25 - 4.15 (m, 1H), 3.88 (br dd, J = 8.0, 10.4 Hz, 1H), 3.65 - 3.50 (m, 3H), 3.16 (br t, J = 11.2 Hz, 2H), 2.98 - 2.91 (m, 1H), 2.86 (s, 3H), 2.73 - 2.65 (m, 1H), 2.39 (br dd, J = 4.0, 7.2 Hz, 2H), 2.20 - 2.10 (m, 6H), 2.07 - 1.91 (m, 4H), 0.98 (br d, J = 3.2 Hz, 1H), 0.43 (br s, 2H), 0.15 (br s, 2H). Example 59: Synthesis of Compound 60; (Z)-3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2- yl)hydrazono)-1-(2-(4-(methylsulfonyl)piperidin-1-yl)-2-oxoethyl)-1H-pyrazol-5(4H)-one To a solution of 2-[(4Z)-3-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-5-oxo- pyrazol-1-yl]acetic acid (197 mg, 588 μmol, 1.20 eq) and 4-methylsulfonylpiperidine (80.0 mg, 490 μmol, 1.00 eq) in DMF (3.00 mL) was added HATU (242 mg, 637 μmol, 1.30 eq) and DIPEA (253 mg, 1.96 mmol, 341 uL, 4.00 eq). The mixture was stirred at 25 °C for 1 h. The reaction mixture was concentrated to dryness to give a residue. The residue was purified by prep-HPLC (C18; 40 g SepaFlash® Silica Flash Column, Eluent of 0~70% CAN / H2O (0.05%FA)@ 35 mL / min) to give (Z)-3-(cyclopropylmethyl)-4-(2-(4,5- dimethylthiazol-2-yl)hydrazono)-1-(2-(4-(methylsulfonyl)piperidin-1-yl)-2-oxoethyl)-1H-pyrazol-5(4H)-one (17.3 mg, 34.2 μmol, 6.97% yield, 96.6% purity) as a red solid. MS: product: m / z 481.2 (M+H)+.1H NMR (400 MHz): CDCl3 δ 4.75 (d, J = 5.6 Hz, 1H), 4.61 (s, 2H), 4.02 (dd, J = 1.6, 13.6 Hz, 1H), 3.23 - 3.13 (m, 1H), 3.11 - 3.01 (m, 1H), 2.87 (s, 3H), 2.79 - 2.63 (m, 1H), 2.52 (d, J = 7.2 Hz, 2H), 2.32 (s, 3H), 2.25 (s, 4H), 2.23 - 2.15 (m, 2H), 1.90 - 1.72 (m, 3H), 1.12 - 1.01 (m, 1H), 0.59 - 0.51 (m, 2H), 0.33 - 0.25 (m, 2H). Example 60: Synthesis of Compound 61 and Compound 63; (S,Z)-3-(cyclopropylmethyl)-4-(2-(4,5- dimethylthiazol-2-yl)hydrazono)-1-(1-(4-(methylsulfonyl)piperazin-1-yl)-1-oxopropan-2-yl)-1H- pyrazol-5(4H)-one; (R,Z)-3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazono)-1-(1-(4- (methylsulfonyl)piperazin-1-yl)-1-oxopropan-2-yl)-1H-pyrazol-5(4H)-one To a solution of 2-[(4Z)-3-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-5-oxo- pyrazol-1-yl]propanoic acid (150 mg, 429 μmol, 1.00 eq) and 1-methylsulfonylpiperazine (84.6 mg, 515 μmol, 1.20 eq) in DMF (2.00 mL) was added DIPEA (277 mg, 2.15 mmol, 374 uL, 5.00 eq) and HATU (196 mg, 515 μmol, 1.20 eq). The mixture was stirred at 25 °C for1 h. The reaction mixture was poured into water (60.0 mL) and extracted with ethyl acetate (50.0 mL x 2). The combined organic phase was washed with brine (40.0 mL), dried over Na2SO4, filtered and concentrated to give a residue. The residue was separated by Pre-SFC (column: DAICEL CHIRALPAK AD(250mm*30mm,10um);mobile phase: [0.1%NH3H2O EtOH];B%: 30%-30%,C7.2;80min). Compound (R,Z)-3-(cyclopropylmethyl)-4-(2-(4,5- dimethylthiazol-2-yl)hydrazono)-1-(1-(4-(methylsulfonyl)piperazin-1-yl)-1-oxopropan-2-yl)-1H-pyrazol- 5(4H)-one (25.9 mg, 52.0 μmol, 12.1% yield, 99.5% purity) was obtained as a red solid. MS: product: m / z 496.0 (M+H)+.1H NMR (400 MHz): CDCl3δ 4.90 (q, J=14.0 Hz, 1 H), 3.67 - 3.64 (m, 1H), 3.41 - 3.35 (m, 3H), 3.03 (br s, 2H), 2.93 (br s, 1H), 2.81 (br s, 1 H), 2.55 (s, 3H), 2.30 - 2.27 (m, 2 H), 2.09 (s, 3H), 2.02 (s, 3H), 1.34 (d, J=6.8 Hz, 3 H), 0.84-0.78 (m, 1 H), 0.31-0.29 (m, 2 H), 0.06 - 0.03 (m, 2H). Compound (R,Z)-3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazono)-1-(1-(4-(methylsulfonyl)piperazin-1- yl)-1-oxopropan-2-yl)-1H-pyrazol-5(4H)-one (25.9 mg, 52.0 μmol, 12.1% yield, 99.5% purity) was obtained as a red solid. MS: product: m / z 496.0 (M+H)+.1H NMR (400 MHz): CDCl3δ 5.13 (q, J=13.6 Hz, 1H), 3.87 - 3.85 (m, 1H), 3.64 - 3.57 (m, 3H), 3.26 (br s, 2H), 3.16 (br s, 1H), 3.04 (br s, 1H), 2.77 (s, 3H), 2.52 - 2.50 (m, 2H), 2.10 (s, 3H), 2.02 (s, 3H), 1.57 (d, J=6.8 Hz, 3H), 1.07-1.01 (m, 1H), 0.53-0.51 (m, 2H), 0.29-0.25 (m, 2H). Example 61: Synthesis of Compound 63; (4Z)-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2- yl)hydrazono]-2-(2-methylsulfonyl-2-azaspiro[3.3]heptan-6-yl)pyrazol-3-one To a solution of tert-butyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylate (4.00 g, 18.9 mmol, 1.00 eq) in DCM (6.00 mL) was added TFA (8.64 g, 75.7 mmol, 5.61 mL, 4.00 eq). The mixture was stirred at 40 °C for 16 h. The reaction mixture was concentrated under reduced pressure to give 2- azaspiro[3.3]heptan-6-one (2.10 g, crude) as a colorless oil. To a solution of 2-azaspiro[3.3]heptan-6-one (2.10 g, 18.8 mmol, 1.00 eq) in DCM (20.0 mL) was added TEA (5.96 g, 58.9 mmol, 8.20 mL, 3.12 eq) and MsCl (5.29 g, 46.1 mmol, 3.57 mL, 2.44 eq). The mixture was stirred at 0 °C for 0.5 h and then 25 °C for 16 h. The reaction mixture was quenched with H2O (200 mL), and extracted with DCM (200 x 3). The combined organic layers were washed with brine (200 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give 2-methylsulfonyl- 2-azaspiro[3.3]heptan-6-one (3.10 g, crude) as a yellow oil.1H NMR (400 MHz): DMSO δ 3.37 (s, 4H), 3.11 - 3.08 (m, 7H) To a solution of 2-methylsulfonyl-2-azaspiro[3.3]heptan-6-one (1.00 g, 5.28 mmol, 1.00 eq) in MeOH (10.0 mL) was added AcOH (634 mg, 10.5 mmol, 604 uL, 2.00 eq) and tert-butyl N- aminocarbamate (1.05 g, 7.93 mmol, 1.50 eq). The mixture was stirred at 25 °C for 4 h. Then NaBH3CN (664 mg, 10.5 mmol, 2.00 eq) was added and the mixture was stirred at 25 °C for 16 h. The reaction mixture was quenched with H2O (100 mL), and extracted with EtOAc (100 x 3). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give tert-butyl N-[(2-methylsulfonyl-2-azaspiro[3.3]heptan-6-yl)amino]carbamate (1.46 g, crude) as a yellow oil.1H NMR (400 MHz): CDCl3 δ 5.89 (s, 1H), 4.09 (d, J = 3.2 Hz, 2H), 3.87 (d, J = 5.2 Hz, 2H), 3.16 - 3.11 (m, 3H), 2.82 (s, 1H), 2.37 - 2.34 (m, 2H), 2.08 - 2.02 (m, 3H), 1.46 (s, 9H) To a solution of tert-butyl N-[(2-methylsulfonyl-2-azaspiro[3.3]heptan-6-yl)amino]carbamate (1.46 g, 4.78 mmol, 1.00 eq) in DCM (2.00 mL) was added TFA (2.18 g, 19.1 mmol, 1.42 mL, 4.00 eq). The mixture was stirred at 40 °C for 16 h. The reaction mixture was concentrated under reduced pressure to give (2-methylsulfonyl-2-azaspiro[3.3]heptan-6-yl)hydrazine (980 mg, crude) as a yellow oil. To a solution of (2-methylsulfonyl-2-azaspiro[3.3]heptan-6-yl)hydrazine (980 mg, 4.77 mmol, 1.00 eq) in EtOH (10.0 mL) was added ethyl 4-cyclopropyl-3-oxo-butanoate (812 mg, 4.77 mmol, 1.00 eq). The mixture was stirred at 80 °C for 1 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by C18 reversed-phase column (FA condition; column: Welch Ultimate C18150*25mm*5um;mobile phase: [water(FA)-MeOH];B%: 40%-50%,10min) to give a 5- (cyclopropylmethyl)-2-(2-methylsulfonyl-2-azaspiro[3.3]heptan-6-yl)pyrazol-3-ol (100 mg, crude) as a brown solid. MS: product: m / z 311.7 (M+H)+. To a solution of 5-(cyclopropylmethyl)-2-(2-methylsulfonyl-2-azaspiro[3.3]heptan-6-yl)pyrazol-3-ol (100 mg, 321 μmol, 1.00 eq) in EtOH (1.00 mL) was added NaOH in H2O (2.50 M, 321 uL, 2.50 eq) at 25 °C. The mixture was stirred at 25 °C for 1 h to give a clear solution. The product of sodium [5- (cyclopropylmethyl)-2-(2-methylsulfonyl-2-azaspiro[3.3]heptan-6-yl)pyrazol-3-yl]oxysodium in EtOH / H2O to give a clear solution was used in the next step without further purification. A solution of 4,5-dimethylthiazol-2-amine (42.0 mg, 327 μmol, 1.00 eq) in HCl (438 mg, 4.32 mmol, 429 uL, 36% purity, 13.2 eq) was cooled to 0 °C. The solution of NaNO2 (22.6 mg, 327 μmol, 1.00 eq) in H2O (0.50 mL) was added dropwise to the mixture at 0 °C. The mixture was stirred at 0 °C for 0.5 h. The product of 4,5-dimethyl-2-[BLAH(nitrido)-λ5-azanyl]thiazole in H2O as a black suspension was used in the next step without further purification. To a solution of [5-(cyclopropylmethyl)-2-(2-methylsulfonyl-2-azaspiro[3.3]heptan-6-yl)pyrazol-3- yl]oxysodium (107 mg, 321 μmol, 1.00 eq, in EtOH and H2O) was added a solution of 4,5-dimethyl-2- [BLAH(nitrido)-λ5-azanyl]thiazole (56.4 mg, 321 μmol, 1.00 eq, in H2O) at 0 °C. The mixture was stirred at 0 °C for 1 h. The reaction mixture was diluted with H2O (20.0 mL) and extracted with DCM (20.0 mL x 3). The combined organic layers were washed with brine (20.0 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (FA condition; column: Welch Ultimate C18150*25mm*5um;mobile phase: [water(FA)-ACN];B%: 23%- 53%,10min) to give (4Z)-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-2-(2- methylsulfonyl-2-azaspiro[3.3]heptan-6-yl)pyrazol-3-one (5.00 mg, 9.54 μmol, 2.97% yield,) as a red solid. MS: product: m / z 451.0 (M+H)+.1H NMR (400 MHz): CDCl3 δ 4.85 (s, 1H), 4.28 (s, 1H), 3.42 (s, 2H), 3.03 (s, 3H), 2.82 (s, 2H), 2.74 (s, 2H), 2.48 (s, 3H), 2.40 - 2.31 (m, 7H), 0.88 - 0.86 (m, 1H), 0.55 (d, J = 6.8 Hz, 2H), 0.27 (d, J = 3.2 Hz, 2H). Example 62: Synthesis of Compound 64; (Z)-5-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2- yl)hydrazineylidene)-2-(3-(4-(methylsulfonyl)piperidin-1-yl)-3-oxopropyl)-2,4-dihydro-3H-pyrazol-3- one To a solution of 3-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]propanoic acid (400 mg, 1.90 mmol, 1.00 eq) in DMF (5.00 mL) and 4-methylsulfonylpiperidine (311 mg, 1.90 mmol, 1.00 eq) was added HATU (796 mg, 2.09 mmol, 1.10 eq) and DIPEA (984 mg, 7.61 mmol, 1.33 mL, 4.00 eq). The mixture was stirred at 25 °C for 1 hr. The reaction mixture was concentrated to dryness. The crude product was purified by reversed-phase HPLC (0.05% FA condition) to give 3-[3-(cyclopropylmethyl)-5- hydroxy-pyrazol-1-yl]-1-(4-methylsulfonyl-1-piperidyl)propan-1-one (145 mg, 407.93 μmol, 21.44% yield) as a yellow oil. MS: m / z 356.0 (M+H)+. To the mixture of 3-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]-1-(4-methylsulfonyl-1- piperidyl)propan-1-one (145 mg, 408 μmol, 1.00 eq) in EtOH (2.00 mL) was added a aqueous NaOH (2.50 M, 816 uL, 5.00 eq) at 20°C. The mixture was stirred for 0.5 h at 20°C to give a clear solution. The product of sodium 3-(cyclopropylmethyl)-1-(3-(4-(methylsulfonyl)piperidin-1-yl)-3-oxopropyl)-1H-pyrazol-5- olate in EtOH / H2O was used in next step without work-up. To a solution of 4-ethyl-5-methyl-thiazol-2-amine (65.0 mg, 507 μmol, 1.00 eq) in HCl (264 mg, 2.54 mmol, 259 uL, 35.0% purity, 5.00 eq) was added NaNO2 (35.0 mg, 507 μmol, 1.00 eq) in H2O (1.00 mL) at 0 °C. The mixture was stirred at 0 °C for 1hr. The product of 4-ethyl-5-methyl-thiazole-2- diazonium;chloride in H2O as a yellow liquid was used into the next step without work-up. A solution of 4,5-dimethylthiazol-2-amine (86.0 mg, 490 μmol, 1.20 eq, in H2O) was added dropwise to the solution of sodium 3-(cyclopropylmethyl)-1-(3-(4-(methylsulfonyl)piperidin-1-yl)-3- oxopropyl)-1H-pyrazol-5-olate (154 mg, 408 μmol, 1.00 eq, in EtOH / H2O) at 0 °C. The mixture was stirred for 1 h at 25°C. The mixture was extracted with DCM (30.0 mL x 2). The combined organic layers were washed with water (20.0 mL) and dried over Na2SO4, concentrated to give a residue. The residue product was purified by reversed-phase HPLC (0.05% FA condition) to give (Z)-5-(cyclopropylmethyl)-4-(2-(4,5- dimethylthiazol-2-yl)hydrazineylidene)-2-(3-(4-(methylsulfonyl)piperidin-1-yl)-3-oxopropyl)-2,4-dihydro-3H- pyrazol-3-one (11.2 mg, 22.1 μmol, 5.41% yield, 97.5% purity) as a red solid. MS: m / z 495.2 (M+H)+.1H NMR (400 MHz): CDCl3 δ 4.80 (d, J = 12.8 Hz, 1H), 4.11 - 4.02 (m, 3H), 3.09 - 3.04 (m, 2H), 2.85 (s, 3H), 2.81 - 2.78 (m, 2H), 2.67 - 2.54 (m, 1H), 2.48 (d, J= 6.8 Hz, 2H), 2.30 (s, 3H), 2.40 (s, 3H), 2.30 - 2.21 (m, 2H), 1.77 - 1.73 (m, 2H), 1.10 - 1.00 (m, 1H), 0.56 - 0.54 (m, 2H), 0.25 - 0.24 (m, 2H) . Example 63:Synthesis of Compound 65; (Z)-3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2- yl)hydrazono)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)-2-oxoethyl)-1H-pyrazol-5(4H)-one To a solution of 2-[(4Z)-3-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-5-oxo- pyrazol-1-yl]acetic acid (123 mg, 365 μmol, 1.20 eq) and 1-methylsulfonylpiperazine (50.0 mg, 304 μmol, 1.00 eq) in DMF (2.00 mL) was added HATU (150 mg, 396 μmol, 1.30 eq) and DIPEA (157 mg, 1.22 mmol, 212 uL, 4.00 eq). The mixture was stirred at 25 °C for 1 h. The reaction mixture was concentrated to dryness to give a residue. The residue was purified by prep-HPLC (C18; 40 g SepaFlash® Silica Flash Column, Eluent of 0~70% CAN / H2O (0.05%FA)@ 35 mL / min) to give (Z)-3-(cyclopropylmethyl)-4-(2-(4,5- dimethylthiazol-2-yl)hydrazono)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)-2-oxoethyl)-1H-pyrazol-5(4H)-one (52.4 mg, 104 μmol, 34.3% yield, 96.9% purity) as a red solid. MS: product: m / z 482.4 (M+H)+.1H NMR (400 MHz): CDCl3δ 4.62 (s, 2H), 3.77 (t, J = 4.4 Hz, 2H), 3.64 (t, J = 4.4 Hz, 2H), 3.32 (t, J = 4.4 Hz, 2H), 3.27 (t, J = 4.4 Hz, 2H), 2.82 (s, 3H), 2.52 (d, J = 6.8 Hz, 2H), 2.32 (s, 3H), 2.25 (s, 3H), 1.08 - 1.04 (m, 1H), 0.57 - 0.54 (m, 2H), 0.31 - 0.28 (m, 2H). Example 64: Synthesis of Compound 66; Sodium (Z)-1-(2-(3-(cyclopropylmethyl)-4-(2-(4,5- dimethylthiazol-2-yl)hydrazineylidene)-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)propanoyl)piperidine-4- carboxylate To a solution of methyl piperidine-4-carboxylate (41.0 mg, 286 μmol, 1.00 eq) and 2-[(4Z)-3- (cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-5-oxo-pyrazol-1-yl]propanoic acid (100 mg, 286 μmol, 1.00 eq) in DMF (1.00 mL) were added HATU (119 mg, 314 μmol, 1.10 eq) and DIPEA (148 mg, 1.14 mmol, 4.00 eq). The mixture was stirred at 25°C for1 hr. The reaction mixture was concentrated to give a residue, and purified by reversed-phase HPLC (0.05% FA condition) to give methyl (Z)-1-(2-(3- (cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-5-oxo-4,5-dihydro-1H-pyrazol-1- yl)propanoyl)piperidine-4-carboxylate (65.0 mg, 137 μmol, 47.8% yield) as a brown solid. MS: product: m / z 474.9 (M+H)+. To a mixture of methyl (Z)-1-(2-(3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2- yl)hydrazineylidene)-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)propanoyl)piperidine-4-carboxylate (65.0 mg, 137 μmol, 1 eq) in MeOH (2.0 mL) and H2O (0.50 mL) was added NaOH (27.4 mg, 685 μmol, 5.00 eq) at 20°C. The mixture was stirred at 20°C for 0.5 h. The reaction mixture was concentrated to give a residue that was purified by reversed-phase HPLC (0.05% FA condition) to give a residue. The residue was dissolved in ACN / H2O (10 mL / 10 mL), then NaOH in H2O (1 mg / mL, 4.065 mL) was added dropwise at 20°C. After addition, the mixture was stirred at 20°C for 2 hr. Then the resulting mixture was lyophilized to give sodium (Z)-1-(2-(3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol-2-yl)hydrazineylidene)-5-oxo-4,5- dihydro-1H-pyrazol-1-yl)propanoyl)piperidine-4-carboxylate (31.7 mg, 63.6 μmol, 46.4% yield) as a red solid. MS: product: m / z 461.1 (M+H)+.1H NMR (400 MHz, DMSO-d6) δ ppm 5.08-5.01 (m, 1H), 4.31 - 3.71 (m, 2H), 2.89 - 2.53 (m, 3H), 2.45 - 2.25 (m, 2H), 2.30 - 2.21 (m, 3H), 2.20 - 2.10 (m, 3H), 1.82 - 1.65 (m, 1H), 1.63 - 1.40 (m, 2H), 1.35 - 1.05 (m, 4H), 1.03- 0.85 (m, 1H), 0.40 - 0.23 (m, 2H), 0.20 - 0.05 (m, 2H). Example 65: Synthesis of Compound 67; (4Z)-5-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2- yl)hydrazono]-2-[2-(4-methylsulfonylanilino)ethyl]pyrazol-3-one To a solution of 4-methylsulfonylaniline (1.00 g, 5.84 mmol, 1.00 eq) in DCM (10.0 mL) was added DMAP (214 mg, 1.75 mmol, 0.30 eq) and 2-bromoacetyl chloride (1.15 g, 7.30 mmol, 608 uL, 1.25 eq) at 0°C under N2. The mixture was stirred at 0°C for 0.5 h. The mixture was stirred for an additional 4 h at 15~25°C. DCM (10.0 mL) was added. The organic phase was washed with 1 M HCl (5.00 mL) and saturated NaHCO3(5.00 mL). The mixture was extracted with DCM (30.0 mL x 3), washed with brine (50.0 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give 2- bromo-N-(4-methylsulfonylphenyl)acetamide (480 mg, 1.64 mmol, 28.1% yield, N / A purity) as a gray solid. The crude was used in next step without further purification.MS: product: m / z 293.7 (M+H)+. To a solution of 2-bromo-N-(4-methylsulfonylphenyl)acetamide (380 mg, 1.30 mmol, 1.00 eq) in THF (5.00 mL) was added dropwise BH3-Me2S in DMS (10.0 M, 325 uL, 2.50 eq) at 15~25°C under N2. The mixture was stirred at 70°C for 1 h. NH4Cl (20.0 mL) was added. The mixture was extracted with EA (30.0 mL x 3), washed with brine (50.0 mL), dried over anhydrous Na2SO4, filtered, concentrated under reduced pressure and purified by column chromatography (SiO2, PE / EA=0 to 40%) to give N-(2- bromoethyl)-4-methylsulfonyl-aniline (390 mg, 847 μmol, 51.7% yield, 60.4% purity) as an off-white solid. MS: product: m / z 280.2 (M+H)+. To a solution of N-(2-bromoethyl)-4-methylsulfonyl-aniline (390 mg, 1.40 mmol, 1.00 eq) in EtOH (1.00 mL) was added NH2NH2.H2O (1.04 mL, 18.2 mmol, 85.0% purity, 13.0 eq) at 15~25°C. The mixture was stirred at 80°C for 2 h. The mixture was concentrated under reduced pressure and purified by Prep- HPLC (column: Welch Xtimate C18100*40mm*3um;mobile phase: [water(HCl)-ACN];B%: 0%-30%,4min) to give N-(2-hydrazinoethyl)-4-methylsulfonyl-aniline (300 mg, 1.31 mmol, 93.3% yield, 100% purity) as an off-white solid. MS: product: m / z 230.0 (M+H)+. To a solution of N-(2-hydrazinoethyl)-4-methylsulfonyl-aniline (300 mg, 1.31 mmol, 1.00 eq) in EtOH (4.00 mL) was added ethyl 4-cyclopropyl-3-oxo-butanoate (289 mg, 1.70 mmol, 1.30 eq) at 15~25°C. The mixture was stirred at 80°C for 2 h. The reaction mixture was concentrated under reduced pressure and purified by Prep-HPLC (column: Welch Xtimate C18100*40mm*3um;mobile phase: [water(HCl)-ACN];B%: 0%-35%,8min) to give 5-(cyclopropylmethyl)-2-[2-(4- methylsulfonylanilino)ethyl]pyrazol-3-ol (200 mg, 587 μmol, 44.9% yield, 98.4% purity) as a yellow solid. MS: product: m / z 335.9 (M+H)+. To the mixture of 5-(cyclopropylmethyl)-2-[2-(4-methylsulfonylanilino)ethyl]pyrazol-3-ol (200 mg, 596 μmol, 1.00 eq) in EtOH (1.00 mL) was added NaOH in H2O (2.50 M, 596 uL, 2.50 eq) at 15~25°C, and the mixture was stirred for 0.5 h at 15~25°C to give a clear solution of [5-(cyclopropylmethyl)-2-[2-(4- methylsulfonylanilino)ethyl]pyrazol-3-yl]oxysodium in EtOH / H2O. The mixture of 4,5-dimethylthiazol-2-amine (115 mg, 897 μmol, 1.00 eq) in HCl (1.21 mL, 11.8 mmol, 35.0% purity, 13.2 eq) was cooled to -10~-5°C. The solution of NaNO2 (61.9 mg, 897 μmol, 1.00 eq) in H2O (0.50 mL) was added dropwise at -10~-5°C. The mixture was stirred for 0.5 h at -10~-5°C to give a solution of 4,5-dimethyl-2-[BLAH(nitrido)-λ5-azanyl]thiazole in H2O. The mixture of [5-(cyclopropylmethyl)-2-[2-(4-methylsulfonylanilino)ethyl]pyrazol-3-yl]oxysodium (213 mg, 596 μmol, 1.00 eq, in EtOH / H2O) was added dropwise to the solution of 4,5-dimethyl-2- [BLAH(nitrido)-λ5-azanyl]thiazole (157 mg, 894 μmol, 1.50 eq, in H2O) at -10~-5°C. After complete addition, the mixture was stirred for 2 h at 15~25°C. H2O (20.0 mL) was added. The mixture was extracted with DCM (30.0 mL x 3). The organic layer was washed with brine (50.0 mL), dried over Na2SO4, filtered, concentrated under reduced pressure and purified by Prep-HPLC (column: Phenomenex C1880*40mm*3um;mobile phase: [water(HCl)-ACN];B%: 18%-56%,8min) to give (4Z)-5- (cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-2-[2-(4-methylsulfonylanilino)ethyl]pyrazol-3- one 957 (117 mg, 247 μmol, 41.3% yield, 100% purity) as a yellow solid. MS: product: m / z 475.2 (M+H)+.1H NMR (400 MHz, DMSO-d6) δ ppm 7.92 - 7.83 (m, 2H), 7.43 (t, J=7.2 Hz, 2H), 5.23 (d, J=13.6 Hz, 1H), 4.67 - 4.60 (m, 2H), 4.30 - 4.23 (m, 2H), 3.19 (s, 3H), 2.53 - 2.52 (m, 2H), 2.35 (s, 3H), 2.27 (s, 3H), 0.90 - 0.80 (m, 1H), 0.44 - 0.39 (m, 2H), 0.13 - 0.07 (m, 2H). Example 66: Synthesis of Compound 69; (Z)-1-(3-(3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol- 2-yl)hydrazineylidene)-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)propanoyl)piperidine-4-carboxylic acid A solution of NH2NH2.H2O (1.86 g, 31.6 mmol, 1.81 mL, 85% purity, 2.02 eq) in EtOH (15.0 mL) was heated to reflux and tert-butyl prop-2-enoate (2.00 g, 15.6 mmol, 2.27 mL, 1.00 eq) was added dropwise. The mixture was stirred at 80 °C for 11 hr. The mixture was concentrated under reduced pressure to give tert-butyl 3-hydrazinopropanoate (1.92 g, crude) as a light yellow oil. The residue was used into next step without purification. To a solution of tert-butyl 3-hydrazinopropanoate (100 mg, 624 μmol, 1.00 eq) in CH3COOH (2.00 mL) was added methyl 4-cyclopropyl-3-oxo-butanoate (146 mg, 936 μmol, 1.50 eq).The mixture was stirred at 100 °C for 1 hr. The reaction mixture was concentrated to dryness to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0~10% DCM / MeOH @ 40 mL / min) to give tert-butyl 3-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1- yl]propanoate (120 mg, 451 μmol, 72.2% yield) as a light yellow oil. MS: m / z 266.9 (M+H)+. To a solution of tert-butyl 3-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]propanoate (100 mg, 375 μmol, 1.00 eq) in DCM (1.00 mL) was added TFA (1.54 g, 13.5 mmol, 1.00 mL, 36.0 eq). The mixture was stirred at 25 °C for 1 hr. The reaction mixture was concentrated to dryness to give 3-[3- (cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]propanoic acid (89.0 mg, crude) as a light yellow oil. MS: m / z 211.2 (M+H)+. To a solution of 3-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]propanoic acid (80.0 mg, 381 μmol, 1.00 eq) and methyl piperidine-4-carboxylate (54.5 mg, 381 μmol, 1.00 eq) in DMF (2.00 mL) was added HATU (159 mg, 419 μmol, 1.10 eq) and DIPEA (197 mg, 1.52 mmol, 265 uL, 4.00 eq). The mixture was stirred at 25 °C for 1 hr. The reaction mixture was concentrated to dryness. The crude product was purified by reversed-phase HPLC (0.05% FA condition) to give methyl 1-[3-[3-(cyclopropylmethyl)-5- hydroxy-pyrazol-1-yl]propanoyl]piperidine-4-carboxylate (114 mg, 340 μmol, 89.3% yield) as a yellow oil. MS: m / z 336.1 (M+H)+. To the mixture of methyl 1-[3-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]propanoyl]piperidine- 4-carboxylate (199 mg, 593 μmol, 1.00 eq) in EtOH (3.00 mL) was added a aqueous NaOH (2.50 M, 1.90 mL, 8.00 eq) at 25°C. The mixture was stirred for 0.5 h at 25°C to give a clear solution. The product of [5- (cyclopropylmethyl)-2-[3-oxo-3-[4-[[oxo(sodio)-λ4-oxidanyl]methyl]-1-piperidyl]propyl]pyrazol-3- yl]oxysodium in EtOH / H2O was used in next step without work-up. To a solution of 4-ethyl-5-methyl-thiazol-2-amine (100 mg, 780 μmol, 1.00 eq) in HCl (406 mg, 3.90 mmol, 398 uL, 35.0% purity, 5.00 eq) was added NaNO2 (53.8 mg, 780 μmol, 1.00 eq) in H2O (1.00 mL) at 0 °C. The mixture was stirred at 0 °C for 1hr. The product of 4-ethyl-5-methyl-thiazole-2- diazonium;chloride in H2O as a yellow liquid was used into the next step without work-up. A solution of 4,5-dimethylthiazol-2-amine (100 mg, 780 μmol, 1.00 eq, in H2O) was added dropwise to the solution of [5-(cyclopropylmethyl)-2-[3-oxo-3-[4-[[oxo(sodio)-λ4-oxidanyl]methyl]-1- piperidyl]propyl]pyrazol-3-yl]oxysodium (218 mg, 593 μmol, 1.00 eq, in EtOH / H2O) at 0 °C. The mixture was stirred for 1 h at 25°C. The mixture was extracted with DCM (30.0 mL x 2). The combined organic layers were washed with water (20.0 mL) and dried over Na2SO4, concentrated to give a residue. The residue was purified by reversed-phase HPLC (0.05% FA condition) to give 1-[3-[(4Z)-3- (cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-5-oxo-pyrazol-1-yl]propanoyl]piperidine-4- carboxylic acid (26.0 mg, 56.3 μmol, 9.49% yield, 99.7% purity) as a red solid. MS: m / z 461.1 (M+H)+.1H NMR (400 MHz): CDCl3 δ 4.42 (d, J = 13.2 Hz, 1H), 4.14 - 4.10 (m, 2H), 3.83 (d, J = 13.2 Hz, 1H), 3.16 (t, J = 10.8 Hz, 1H), 2.82 - 2.78 (m, 2H), 2.62 - 2.61 (m, 2H), 2.50 (d, J = 6.8 Hz, 2H), 2.32 (s, 3H), 2.26 (s, 3H), 2.00 - 1.97 (m, 2H), 1.75 - 1.70 (m, 2H), 1.08 - 1.06 (m, 1H), 0.58 - 0.54 (m, 2H), 0.32 - 0.28 (m, 2H). Example 67: Synthesis of Compound 71; (Z)-1-(2-(3-(cyclopropylmethyl)-4-(2-(4,5-dimethylthiazol- 2-yl)hydrazono)-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)acetyl)piperidine-4-carboxylic acid To a solution of 2-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]acetic acid (450 mg, 2.29 mmol, 1.00 eq) and methyl piperidine-4-carboxylate (328 mg, 2.29 mmol, 1.00 eq) in DMF (10.0 mL) was added HATU (1.05 g, 2.75 mmol, 1.20 eq) and DIPEA (889 mg, 6.88 mmol, 1.20 mL, 3.00 eq). The mixture was stirred at 25 °C for 1 hr. The reaction mixture was poured into water (60.0 mL) and extracted with EA (50.0 mL x 2). The combined organic phase was washed with brine (40.0 mL), dried over Na2SO4, filtered and concentrated to give a residue. The residue was purified by flash silica gel chromatography (eluent of 0 ~ 6% MeOH in DCM gradient) to give methyl 1-[2-[3-(cyclopropylmethyl)-5- hydroxy-pyrazol-1-yl]acetyl]piperidine-4-carboxylate (401 mg, 1.10 mmol, 47.9% yield, 88% purity) as a yellow solid. MS: product: m / z 321.9 (M+H)+. To a solution of methyl 1-[2-[3-(cyclopropylmethyl)-5-hydroxy-pyrazol-1-yl]acetyl]piperidine-4- carboxylate (300 mg, 934 μmol, 1.00 eq) in EtOH (3.00 mL) was added a solution of NaOH in water (2.5 M, 0.94 mL, 2.50 eq) at 25 °C. The mixture was stirred at 25 °C for 0.5 hr. The product of sodium 1-(2-(3-(cyclopropylmethyl)-5-oxido-1H-pyrazol-1-yl)acetyl)piperidine-4-carboxylate in EtOH / H2O as a lightyellow liquid was used into the next step without further purification. To a solution of 4,5-dimethylthiazol-2-amine (180 mg, 1.40 mmol, 1.00 eq) in HCl (731 mg, 7.02 mmol, 717 uL, 35% purity, 5.00 eq) was added a solution of NaNO2(97.0 mg, 1.40 mmol, 1.00 eq) in H2O (2.00 mL) dropwise at 0 °C. The mixture was stirred at 0 °C for 0.5 hr. The product of 4,5- dimethylthiazole-2-diazonium chloride in H2O as a yellow liquid was used into the next step without further purification. The solution of 4,5-dimethylthiazole-2-diazonium chloride (196 mg, 1.12 mmol, 1.20 eq, in water) was added to the solution of the product of sodium 1-(2-(3-(cyclopropylmethyl)-5-oxido-1H-pyrazol-1- yl)acetyl)piperidine-4-carboxylate (329 mg, 931 μmol, 1.00 eq, in EtOH / H2O) dropwise at 0 °C. The resulting mixture was stirred at 25 °C for 1 hr. The reaction mixture was partitioned between DCM (40.0 mL) and H2O (20.0 mL). The organic phase was separated, dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep- HPLC (C18; 40 g SepaFlash® Silica Flash Column, Eluent of 0~70% ACN / H2O (0.05%FA)@ 35 mL / min) to give 1-[2-[(4Z)-3-(cyclopropylmethyl)-4-[(4,5-dimethylthiazol-2-yl)hydrazono]-5-oxo-pyrazol-1- yl]acetyl]piperidine-4-carboxylic acid (168 mg, 364 μmol, 39.2% yield, 98.6% purity) as a red solid. MS: product: m / z 447.4 (M+H)+.1H NMR (400 MHz): CDCl3δ 4.77 (d, J = 16.4 Hz, 1H), 4.61 (d, J = 15.6 Hz, 1H), 4.36 (d, J = 13.6 Hz, 1H), 3.81 (d, J = 13.6 Hz, 1H), 3.21 (t, J = 11.2 Hz, 1H), 2.95 (t, J = 10.8 Hz, 1H), 2.67 - 2.58 (m, 1H), 2.53 (d, J = 7.2 Hz, 2H), 2.33 (s, 3H), 2.26 (s, 3H), 2.07 - 1.94 (m, 2H), 1.91 - 1.68 (m, 2H), 1.12- 1.03 (m, 1H), 0.60 - 0.53 (m, 2H), 0.34 - 0.27 (m, 2H). Example 68: Binding of Compounds to BAX Protein Recombinant human BAX protein expression and purification The gene sequence encoding H. sapiens BAX was custom-synthesized and cloned into pTYB1 vector (New England Biolabs Inc.) using NdeI and SapI restriction sites to create plasmid pL-001 (reference 1). The final construct was confirmed by sequencing, and the protein matched that of human BAX protein (Uniprot accession number Q07812). The plasmid was transformed into E. coli BL21(DE3). A single colony of BL21(DE3) / pL-001 was inoculated into a 200 ml culture of Luria Broth (LB) containing 100 µg / mL ampicillin and grown overnight at 37 °C. The overnight culture was diluted to OD600=0.1 in 10 x 1-liter of LB containing 100 μg / mL ampicillin and grown at 30 °C with aeration to OD600 = 0.8. IPTG was then added to a final concentration of 1 mM. After 4 hours at 30 °C, the cells were harvested by centrifugation at 5,000 x g for 15 min at 25 °C. Cell pastes were stored at -20 °C. The frozen cell paste from 10 L of cell culture was suspended in 300 ml of Buffer A consisting of 20 mM Tris / HCl, pH 7.2, 250 mM NaCl, 5% (v / v) glycerol, supplemented with 6 EDTA-free protease inhibitor cocktail tablets (Roche Molecular Biochemical). Cells were disrupted by high pressure homogenizer at 4 ºC, and the crude extract was centrifuged at 16,000 rpm for 60 min at 4 ºC. The supernatant was applied to 5 ml chitin beads (New England Biolabs Inc.) pre-equilibrated with buffer A and then washed with buffer A, and BAX protein was cleaved by overnight incubation with 50 mM DTT in Buffer A. The cleaved BAX protein was concentrated by Amicon®Ultracel-10K (Millipore) and loaded onto a Superdex 7510 / 300 GL column (Cytiva) pre-equilibrated with 20 mM HEPES, pH 7.2, 150 mM KCl, 1 mM TCEP, 10% glycerol. The fractions containing BAX protein were pooled and concentrated by Amicon®Ultracel-10K (Millipore) to about 1 mg / ml. Fluorescence polarization assay A fluorescence polarization (FP) assay was used to assess the binding affinity of Compounds 1- 11, 14, 16, 31-35, 42, 47, and 50 to BAX protein. The competitive fluorescence polarization assay was developed based on the interaction between human recombinant BAX protein and fluorescein isothiocyanate (FITC) labelled at N-terminus of stabilized α-helix of BCL-2 domain (SAHB) as FITC-bAla- EIWIA...

Claims

What is claimed is: CLAIMS 1. A compound of formula (A-I):or a pharmaceutically acceptable salt thereof, wherein G is CH or N; R1is optionally substituted aryl or optionally substituted heteroaryl; X is an optionally substituted alkyl or heteroalkyl; R2is selected from optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted heterobicycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; R3ais selected from optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroalkyl, optionally substituted heterocycloalkyl, or CHR4(CR5aR5b)0-4R6; wherein R4, R5a, and R5bare independently selected from H, optionally substituted alkyl, and R6is selected from CONR7R8, SO2NR7R8, NR7COR7, NR7SO2R8; wherein R7and R8are independently selected from H, optionally substituted alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or R7and R8together with the atoms to which they are attached form a optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted heterobicycloalkyl; R3bis optionally substituted alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl; Y is selected from O, NR9, S, (CHR9)1-4, CO, or SO2; each R9is independently selected from H or optionally substituted alkyl; p is 0 or 1; and q is 0 or 1.

2. The compound of claim 1, wherein G is N.

3. The compound of claim 1 or claim 2, wherein p is 1 and X is -CH2-.

4. The compound of claim 3, wherein R2is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

5. The compound of any one of claims 1-4, wherein q is 0.

6. The compound of any one of claims 1-5, wherein R1is:wherein R1aand R1bare independently selected from H, optionally substituted alkyl, or optionally substituted cycloalkyl.

7. The compound of claim 6, wherein R1aand R1bare independently -CH3, -CH2CH3, - CH(CH3)2, -C(CH3)3, cyclopropyl, or -CF3.

8. The compound of claim 6 or claim 7, wherein R1aand R1bare both methyl.

9. The compound of any one of claims 1-8, wherein R2-(X)p- forms a moiety selected from:

10. The compound of any one of claims 1 to 9, wherein R3ais an optionally substituted heterocycloalkyl, acyl, amido, sulfonyl, alkyl, or heterobicycloalkyl.

11. The compound of any one of claims 1-10 wherein R3ais an optionally substituted heterocycloalkyl.

12. The compound of claim 11, wherein R3ais optionally substituted pyrrolidonyl, optionally substituted pyrrolidenonyl, optionally substituted pyrrolinyl, optionally substituted piperidinyl, optionally substituted 2-sultamyl, optionally substituted piperidonyl, optionally substituted pyrazolinonyl, or optionally substituted tetrahydrofuranyl.

13. The compound of any one of claims 1 to 10, wherein R3ais acyl, amido, or sulfonyl.

14. The compound of any one of claims 1 to 10, wherein R3ais alkyl.

15. The compound of claim 14, wherein R3ais methyl, ethyl, or isopropyl.

16. The compound of any one of claims 1 to 10, wherein R3ais cycloalkyl.

17. The compound of claim 16, wherein R3ais optionally substituted cyclopropanyl, optionally substituted cyclobutanyl, or optionally substituted cyclohexyl.

18. The compound of any one of claims 1 to 10, wherein R3ais a heterobicycloalkyl.

19. The compound of claim 18, wherein R3ais optionally substituted spiro[4,5]decanyl, optionally substituted spiro[5,5]undecanyl, optionally substituted spiro[3,3]heptanyl, optionally substituted azaspiro[3,3]heptane, optionally substituted azaspiro[4,5]decane.

20. The compound of any one of claims 1-19, wherein R3bis optionally substituted heterocycloalkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl.

21. The compound of any one of claims 1 to 19, wherein R3bis optionally substituted aryl.

22. The compound of claim 21, wherein R3biswherein R10a, R10b, R10c, R10c, R10d, and R10eare independently H, halo, sulfonyl, carboxyl, optionally substituted alkyl, hydroxy, or alkoxy.

23. The compound of any one of claims 1 to 10, wherein R3a-(Y)q-R3bform a moiety selected from:

24. The compound of claim 1, wherein the compound is a compound from Table 1, or a pharmaceutically acceptable salt thereof 25. A pharmaceutical composition comprising a compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

26. A method of treating cancer, comprising administering to a subject in need thereof an effective amount of a compound of any one of claims 1-24, or a pharmaceutically acceptable salt thereof.

27. The method of claim 26, wherein the compound is administered in combination with is an inhibitor of B cell lymphoma 2 (BCL-2), B-cell lymphoma-extra large protein (BCL-XL), B cell lymphoma 2-like protein (BCL-w), BCL-2-related protein A1 (BFL-1), myeloid cell leukemia 1 (MCL-1), or a combination thereof.

28. The method of claim 26 or claim 27, wherein the cancer is a solid tumor.

29. The method of any one of claims 26 to 28, wherein the cancer is breast cancer, skin cancer, central nervous system cancer, head and neck cancer, bladder cancer, kidney cancer, cancer of the gastrointestinal tract, lung cancer, eye cancer, genitourinary cancer, gynecologic cancer, endocrine cancer, soft tissue sarcoma, hematopoietic cancer, or neuroendocrine cancer.

30. The method of any one of claims 26 to 29, wherein the cancer is hematopoietic cancer.

31. The method of any one of claims 26 to 30, wherein the cancer is leukemia.

32. The method of any one of claims 26 to 31, wherein the cancer is acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, or chronic myeloid leukemia.

33. The method of any one of claims 26 to 32, wherein the cancer is lymphoma.

34. A method of treating a disorder associated with cancer, comprising administering to a subject in need thereof an effective amount of a compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, wherein the disorder is malignant hypercalcemia or cervical hyperplasia.

35. A method of inducing apoptosis in a cancer cell in a subject, comprising contacting the cancer cell with an effective amount of a compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof.

36. The method of claim 35, wherein the cancer cell is a leukemia cell.

37. The method of claim 35 or claim 36, wherein the cancer cell is selected from acute lymphoblastic leukemia cells, acute myeloid leukemia cells, chronic lymphocytic leukemia cells, or chronic myeloid leukemia cells.

38. The method of any one of claims 35 to 37, wherein the cancer cell is a solid tumor cell.

39. A method of inducing apoptosis in a leukemic stem cell in a subject, comprising contacting the leukemic stem cell with an effective amount of a compound of any one of claims 1-24 or a pharmaceutically acceptable salt thereof.

40. The method of any one of claims 26-39, wherein the method does not induce apoptosis in healthy tissue.

41. The method of any one of claims 26-40, wherein the subject is a human.